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Neuropsychiatric manifestations of HCV treatment 
 
Summary  
Hepatitis C (HCV) infection is associated with high rates of mortality and morbidity. 
Interferon alpha based treatment for HCV offers a good rate of viral clearance, however 
the associated neuropsychiatric side effects increase the risk of treatment interruption 
and disease progression. The HIV/HCV coinfection is of particular interest due to 
association with higher rates of HCV treatment side effects and earlier treatment 
discontinuation when compared with HCV mono-infection. Therefore, the aim of the 
thesis was to further explore the effect of coinfection on mood and cognition and how 
HCV interferon based treatment influences neuropsychiatric side effects in mono and 
co-infected samples. Firstly a meta-analysis was performed to explore cognitive 
impairment and depression in HIV HCV co-infection. The results suggested that there 
was consistent literature indicating that the coinfected group were more cognitively 
impaired and more likely to be depressed than the HCV and HIV monoinfected groups. 
Secondly empirical studies were conducted to analyse the profile of depression during 
interferon-based treatment, and explore potential risk factors, such as gender and 
immune profile. Co-infected patients appeared less vulnerable to the emergence of 
depressive symptoms during HCV treatment than HCV mono-infected patients. 
Additionally, neither female gender nor immune response were associated with 
increased vulnerability to depression. Finally, a longitudinal study investigating 
cognitive performance during interferon-based treatment was conducted. A significant 
effect of treatment on information processing speed level of executive function was 
observed. Overall the research reported in this thesis further clarifies the nature of 
interferon induced depression and cognitive effects differences between mono and 
coinfected groups. Having identified a neurovegetative symptom profile and speed of 
processing impairment of executive function during HCV treatment, the discussion 
considers the potential of targeted interventions via psychotropic medication and 
cognitive interventions to minimise the impact of these treatment effects and optimise 
outcomes in this clinical group.  
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1. Introduction 
 
1.1. General Introduction 
Infection with Hepatitis C virus (HCV) is a major health burden in England as 
evidenced by the Department of Health initiated Hepatitis C strategy and Action Plan 
(Public Health England [PHE], 2015). Estimates on the prevalence of HCV worldwide 
indicate that three to four million are newly infected per year and approximately 180 
million people are believed to be currently chronically HCV infected (Mohd et al., 
2013). However, according to a World Health Organisation report (2017) 1.75 million 
new infected HCV cases were reported in 2015, representing a global incidence rate of 
23.7 per 10.000. Chronic hepatitis C is the leading cause of end-stage liver disease, 
hepatocellular carcinoma and liver related deaths (Westbrook & Dusheilo, 2014). HCV 
infection is associated with high fatality rates (Mohd et al., 2013). The evolution of 
better treatment for HCV in the form of Direct Acting Antivirals mean that at last 
eradication of hepatitis C may be possible but only if all with HCV are treated. 
An estimated 2.3 million people living with HIV are coinfected with hepatitis C 
virus (HCV) globally (Platt et al., 2016). Of these, more than half, or 1.3 million, are 
people who inject drugs (PWID). The study also found that HIV-infected people are on 
average 6 times more likely than HIV-uninfected people to have HCV infection, 
pointing to a need to improve integrated HIV/HCV services (Platt et al., 2016). Since 
2000, the incidence of HCV infection among HIV-positive men who have sex with men 
(MSM) population has dramatically increased in Europe, USA and Australia (Fox et al., 
2008; Martin et al., 2013; Van de Laar et al., 2011). More specifically, in the UK 
HIV/HCV co-infection in MSM enhanced from 0% in 1999 to 4% in 2006 (Fox et al., 
2008). A significant change in the epidemiology of HIV HCV coinfection has definitely 
occurred. In particular, acute HCV infection in HIV-positive MSM is an emerging 
problem. Additionally, several studies have reported a high risk of reinfection in HIV-
positive MSM in both treated and those who spontaneously cleared the virus (Stellbrink 
et al., 2010; Martin et al, 2013).  
HIV and HCV viruses share common routes of infection, but they have differences 
regarding types of exposure and disease progression. HIV is a chronic disease 
manageable with treatment (antiretroviral therapy-ART). The medication redefined the 
concept of quality of life improving health and prolongs life (Deeks, Lewin & Havlir, 
2013). HCV infection is characterized by an acute stage that is typically mild and 
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undiagnosed (Westbrook & Dusheiko, 2014). After six months of persistent HCV RNA, 
the possibility of spontaneous clearance is significantly reduced and the infection is 
defined as chronic. However, treatments now exist with 95% response rates for HCV so 
the chance of cure in chronic HCV is high. In coinfection there is an accelerated liver 
disease that has been associated with immune activation and dysregulation causing 
complications such as bone disorders, metabolic disorders, kidney disease, 
cardiovascular disease, and neurologic disease (Operskalski & Kovacs, 2011). Overall, 
the burden of HCV indicates that treatment could be a strategy to prevent progression of 
disease, eliminate infection and improve quality of life (Bernstein et al., 2002; Fried et 
al., 2002; Jacobson et al., 201; Poordad et al., 2001).  
 
1.2. Psychopathology of Inflammation  
Evidence has emerged to suggest that inflammation is a response involving cytokine 
activation and changes in both adaptive and innate immunity (Irwin, 2011; Haapakoski 
et al., 2016). The relationship between inflammatory immune response and 
neuropsychiatric changes has been noted (McNamara & Lotrich, 2012), establishing 
that inflammatory reactions and neuro-immune changes have an effect on behaviour. 
These inflammatory processes seem to regulate mood, which affects alteration in 
serotonin levels (Lotrich et al., 2013; Wichers & Maes, 2004), activation of microglia 
(Fenn et al., 2014) and local invasion of circulating immune cells (Nathan, 2002).  
The cytokines are divided into pro-inflammatory and anti-inflammatory cytokines. 
For the purpose of this thesis we will focus on the role of pro-inflammatory cytokines, 
in particular interferon alpha (), which is involved in facilitating an inflammatory 
response associated with depressive mood, anhedonia, sleep changes, fatigue, anorexia 
and cognitive impairment (Anisman & Merali, 2002; Capuron et al., 2000, 2002; Whale 
et al., 2015).  
 
1.2.1. The inflammatory Paradigm   
Cytokine induced sickness behaviour was proposed by Hart (1988), as an adaptive 
response to infection. Increasing evidence suggest that activation of pro-inflammatory 
cytokines leads to a behavioural repertoire that is associated with the pathophysiology 
of psychiatric disorders (Dantzer et al., 2008; Haapakoski et al., 2016; Miller et al., 
2009).  
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Pro-inflammatory cytokines production has been implicated in influencing 
behaviour, due to penetration of the central nervous system (CNS), inducing sleep 
changes, anhedonia, cognitive disturbances, psychomotor retardation and depressive 
mood (Harrison et al., 2009; Maes et al., 1993). These symptoms are known as sickness 
behaviour and some symptoms overlap with major depressive disorders symptoms 
(Dantzer, 2001, Dantzer & Kelley, 2007).  
The blood brain barrier (BBB) controls the exchanges between the blood and the 
brain in order to prevent diseases. Failing to control this dynamic communication causes 
neuroinflammatory events that have been associated with the emergence of diseases 
(Banks, 2015; Banks & Erickson, 2010). Neuroinflammation is the result of 
transmitting inflammatory signals to the brain that may lead to depression. Peripherally 
administered cytokines can penetrate the brain by directly crossing the blood-brain 
barrier (BBB) (Banks, 2015), interaction with circumventricular organs (Blatteis et al., 
1983), immune cell trafficking (Wetzel et al., 2000) or induction of release from BBB 
cells (Verma et al., 2006).  
Microglia, a type of glial cell, which resides within CNS, has an important role 
regulating neuronal activities and immune functions (Fenn et al., 2014). When the brain 
presents changes as a result of an infection, microglia boost pro-inflammatory cytokine 
release (Lehnardt, 2010) in order to restore the neural integrity. Persistent  activation of 
microglia may induce a behaviour state of depressive disorder via this cytokine release. 
(Hanisch & Kettenman, 2007; Maes, 2011). According to recent evidence, microglia 
has an important implication in depression-like behaviour due to a direct effect of 
interferon- (Zheng et al., 2015). In particular, in the hippocampus it seems that the 
density of microglia was increased and significantly associated with depression 
(Belzung et al., 2014; Zheng et al., 2015).  
 
1.2.2. Inflammation and Cognitive Impairment 
In the context of chronic inflammation such as HIV and HCV infections, the viruses 
can contribute to the disturbance of CNS function. HIV crosses the BBB through 
infected immune cell migration, which induces neuropathology (Hong & Banks for 
review, 2015). These processes are aggravated by pro-inflammatory reactions mediated 
by the HIV itself (Alonso et al., 1997). The severe impact on behaviour - in particular in 
neurocognitive performance - is facilitated by the difficulty to suppress HIV replication 
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on the CNS due to compartmentalisation of virus within the CNS and differing CNS 
penetration of antiretroviral drugs.  In fact it seems that the CNS is a potential reservoir 
for HIV causing a systemic inflammation (Hayashi et al., 2006).  
It has been suggested that HCV also crosses the BBB and microglia cells may be the 
reservoir of HCV infection (Aloisi, 2001). There is evidence for HCV affecting the 
cerebral function with significant correlation between cognitive impairment and 
changes in cerebral metabolism (Forton et al., 2008).  
In HIV HCV co-infection, having both viruses insulting the CNS, a significant 
inflammatory response is expected, as confirmed by changes in microglia and a 
significant association with neuroinflammation that may be causing cognitive 
performance impairment (Garvey et al., 2012). Additionally under interferon- external 
exposure, measured by interferon-based treatments, the likelihood of inflammatory 
activation is high, increasing the risk of cognitive impairment.  
 
1.2.3. Inflammation and Depression in clinical settings  
An increased prevalence of mood symptoms was found in several inflammatory 
conditions, such as cardiovascular diseases, diabetes, obesity, autoimmune diseases, 
HCV and metabolic syndrome (Walker et al., 2011, Whale et al., 2015). The immune 
reaction activates cellular responses that have a toxic effect on cells identified as 
harmful and release cytokines to recruit additional immune cells - such as macrophages 
- lymphocytes and neutrophils, to induce a response against pathogens (Abbas et al., 
2012).  
The association between inflammation and depression has been supported by the 
key idea that inflammation causes immune changes and those alterations have an impact 
in the pathophysiology of depression (Kim & Maes, 2003, Reyes-Vasquez, 2012). 
There are several lines of research that explore this model. Inducing a pro-inflammatory 
response in healthy and non-healthy populations seems to increase pro-inflammatory 
cytokines levels that have been significantly associated with mood disorders (Capuron 
et al., 2000; Capuron & Miller, 2004, 2011; Harrison et al., 2009; Wichers et al., 2007). 
Previous studies reported that the levels of pro-inflammatory cytokines were 
significantly higher in depressed patients (Dowlati et al., 2010; Kim et al., 2007). 
Conversely, high levels of inflammation were associated with resistance to treatment 
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with anti-depressant medication (Strawbridge et al., 2015). Peripheral levels of 
inflammatory markers were associated with MDD (Felger & Lotrich 2013).  
In studies with exogenous pro-inflammatory exposure, there was a significant 
association with depression (Liang & Ghany, 2013, Whale et al., 2015). Furthermore, 
meta-analytic data reported that emotional stress was associated with high levels of 
inflammatory markers such as IL-6, IL-1, TNF-, and CRP (Steptoe et al., 2007). The 
idea that psychological or physical stress can trigger an inflammatory response has also 
been documented (Miller et al., 2013; Abbas et al., 2012). Overall, it seems that the 
relationship between inflammation and mood disorders is bidirectional.  
The mechanisms of interferon-induced depression includes upregulation of the 
central serotonin transporter molecule (Zhu et al., 2006), alteration in T cell activation 
(Felger & Lotrich, 2013; Maes et al., 2001a), changes in tryptophan metabolism 
including activation of indoleamine-2,3-dioxygenase - IDO (Christmas et al., 2011), 
changes in glutamate metabolism (Taylor et al., 2013) and activation of the 
hypothalamic-pituitary-adrenal axis (Eccles et al., 2012). Despite the complexity of 
these pathways that trigger immune and inflammatory reactions, the common result is 
depressive associated  behaviour.  
Peripheral inflammation, such as exogenous administration of interferon-, has 
been associated with changes in cortical and sub-cortical structures. The areas more 
sensitive to behavioural change include the ventral striatum regions (Capuron et al., 
2012; Harrison et al., 2015), and hippocampus (Harrison et al., 2015). In HCV patients 
receiving interferon- based treatment changes were found in the whole brain 
functional network architecture within 4 hours after interferon- administration, which 
was correlated with mood and cognitive changes (Dispaquale et al., 2015).  A study by 
Dowell and colleagues (2015) showed in HCV patients that peripheral administration of 
interferon- rapidly changed striatal regions that were significantly associated with 
interferon induced fatigue at week 4 of treatment.  
Overall it seems clear that interferon- affects the brain resulting in behavioural 
changes including depression, fatigue, motivation and cognitive impairment (Capuron et 
al., 2002; Dantzer et al., 2008). What is unclear are the specific brain areas involved in 
these neuropsychiatric manifestations, the underlying mechanisms and the nature of the 
mood and cognitive alterations.  
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1.3.Hepatitis C Treatment 
Until 2015 the standard of care (SoC) for chronic hepatitis C treatment was a 
combination of pegylated interferon- (INF-) and ribavirin for 24 to 48 weeks, 
depending on HCV genotype and treatment response (Vogel & Rockstroh, 2009). HCV 
viral load is normally measured at week 4, 12 and week 24. These time points are used 
to compare response in HCV RNA to baseline levels in order to assess the type of 
response. If negative HCV viral load is achieved at week 4, a rapid virological response 
is considered, if negative at week 12 it is defined as early virological response, if 
negative at week 24 it is a delayed virological response.   
The therapy goal is to clear the virus at the end of treatment (ETR) leading to a 
sustained virological response (SVR) defined as negative HCV viral load 6 months after 
treatment exposure. Historically HCV genotypes 2 and 3 present higher rates of positive 
treatment response than genotype 1 and 4 to treatment with INF- and ribavirin (Antaki 
et al., 2010).  
In special groups such as HIV/HCV co-infected patients, early HCV treatment is 
recommended due to the accelerated progression of liver disease. The indications for 
HCV treatment are similar to HCV mono-infection.  However, if the immune profile is 
poor, with CD4 cell count <200 cells/l, it is recommended to improve CD4 cell count 
based on HIV therapy (cART) (EASL, 2011). cART has been significantly associated 
with controlling HIV viral load (Maartens et al., 2014). As result the patients present 
high CD4 counts, which have been previously correlated with the less likelihood of 
liver fibrosis progression (Puoti et al., 2001).  
Previously treating HCV in co-infection was associated with a poorer response to 
HCV treatment than treatment of HCV mono-infection and faster liver fibrosis 
progression (Rockstroh et al., 2008; Soriano et al., 2007). Regarding the response to 
HCV therapy with IFN- and ribavirin the rates of SVR were 40-50% in genotype 1 
(GT1) and 70-80% in GT2 and 3 in mono-infected groups (Ilyas et al, 2011). As 
mentioned above, co-infected patients presented SVR rates of 17-36% in GT1 and 4 
(Carrat et al., 2004; Chung et al., 2004).   
Since 2011, the emergence of direct acting antivirals (DAAs) has been a landmark 
for the treatment of HCV. DAAs protease inhibitors such as telaprevir, boceprevir or 
faldaprevir in combination with pegylated interferon and ribavirin were the first 
generation of triple therapy that have reported high cure rates of HCV (Zeuzem et al., 
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2011; Bacon et al., 2011). In particular, they presented a high curative rate in patients 
with advanced liver disease and GT1 (Back & Else, 2013; Ryder, 2015). Promising 
results with telaprevir and boceprevir were reported with similar SVR rates in mono-
infected and co-infected patients (Sitole et al., 2013; Jacobson et al., 2011; Higgins et 
al., 2003). Therefore, the co-infected patients appear to be “equivalent” to mono-
infected groups with satisfactory SVR rates.  
Hepatitis C treatment has undergone several changes since the widespread use of 
interferon- mono-therapy. Initially ribavirin was added in 2001 to increase the rate of 
sustained virological response (SVR). SVR was defined as an undetectable HCV viral 
load at 6 months after completion of HCV treatment. Ribavirin is a synthetic nucleoside 
antiviral agent that acts via polymerase inhibition and is shown to be effective against 
HCV replication (Davis et al., 1989). Ribavirin can cause reduction in T cell numbers 
that in combination with interferon- exacerbates immune function impairment and has 
been hypothesised as a mechanism to induce depression of mood (Miller & Raison, 
2016). The mechanism of action of interferon-induced depression includes direct effect 
of interferon- and ribavirin in the immune system via tryptophan metabolism (Lotrich, 
2015; Huckans et al., 2015) that accelerates spontaneous apoptosis in CD4+ T-cells 
(Fallarino et al., 2002; Ivanova et al, 2007). The peripheral administration of HCV 
therapy disturbs the tryptophan (trp) mechanism by activating indoleamine 2,3 
dioxygenase (IDO) which is an enzyme expressed in different cell types, such as 
microglia, astrocytes, macrophages, that when up-regulated cause trp depletion.  
Tryptophan depletion has been significantly associated with depression related 
symptoms (Schaefer et al., 2005; Christmas et al., 2011; Oxenkrug et al., 2014; Comai 
et al., 201., Zignego et al., 2007).  A different potential pathway of interferon- induced 
IDO activity was suggested involving serotonin (5-HT) metabolism (Loftis et al., 2013). 
In patients with HCV interferon based treatment a significant association was found 
between lower plasma concentrations of 5-HT and increased symptoms of depression 
(Raison et al., 2009). It has been suggested that IDO converts trp into kynurenine and as 
a consequence of this reduction in the trp availability, there is decreased serotonin (5-
HT) in the brain. In the context of serotonin depletion researchers have reported a 
significant association with interferon-induced depression (Zhu et al., 2006).  
Changes in basal ganglia due to interferon- exposure have also been suggested as a 
possible mechanism for interferon-induced depression (Capuron et al., 2004). Several 
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studies have speculated that interferon- via dopamine neurotransmission might induce 
depression like behaviour (Capuron et al., 2002a; Capuron et al., 2004); however this 
hypothesis requires further testing to develop a clear model of the pathways involved.  
Another mechanism proposed to underlie interferon- induced depression includes 
activation of the hypothalamic-pituitary-adrenal (HPA) axis (Eccles et al., 2012). It has 
been suggested that interferon-  induces hyperactivity of HPA axis by releasing high 
levels of corticotropin-releasing hormone that have been associated with depressive like 
behaviour (Udina et al., 2014). In addition interferon- induces the production of pro-
inflammatory cytokine IL-6 that has been shown to induce HPA activity leading to 
emergence of depressive symptoms (Capuron et al., 2004). Despite the complexity and 
diversity of these proposed HCV treatment mechanisms that trigger immune and 
inflammatory reactions, the common result is depressive associated behaviour (Felger & 
Lotrich, 2013; Bufalino et al., 2013).  
This combination therapy was poorly tolerated, with associated severe 
neuropsychiatric side effects (Chasser et al., 2017).  When the first generation of 
protease inhibitors (boceprevir and telaprevir)  was introduced in 2013, these were 
combined with interferon  and ribavirin (Ryder, 2015).  These protease inhibitors were 
expected to increase efficacy due to higher antiviral activity. This combination had over 
90% efficacy. Subsequently in 2014 oral direct-acting antiviral regimes were introduced 
(DAA), enabling interferon free -treatment regimes, with initial research indicating 
higher HCV cure rates than previous treatments (Chasser et al., 2017).  These DAA 
interferon-free therapies are shorter in treatment duration but appear to remain 
associated with mild neuropsychiatric effects, in particular fatigue (Zopf et al., 2016).  
The primary outcome with DAA treatment is to achieve undetectable HCV RNA at 
week 12 or 24 after initiation, which implies permanent elimination of HCV infection 
(European Association for the Study of the Liver, 2017). This more effective treatment 
with DAA is more likely to eliminate the risk of liver disease progression (Gelson & 
Alexander., 2017) including regression of fibrosis, reduction in risk of hepatocellular 
carcinoma and 90% reduction in liver related mortality (Bidel et al., 2016). It may also 
reduce the rate of  HCV related extra-hepatic diseases such as stroke (Hsu et al., 2013), 
diabetes (Milner et al., 2014), lymphoma (Kawamura et al., 2007) and cognitive 
function impairment. (Kraus et al., 2013).  
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The development of DAAs was based on targeting structural proteins that take part 
in every stage of the HCV life cycle (Li, & De Clercq, 2017). For example, NS3/4A 
inhibitors (boceprevir; telaprevir); NS5A inhibitors (velptasvir); nucleotide inhibitors 
(sofosbuvir) and non-nucleotide inhibitors (dasabuvir). In comparison, interferon- 
controls viral infection by activating a number of cellular genes and these genes inhibit 
viral infection (Chung et al., 2008), This mechanism is  less effective that the direct 
effect of DAAs on the HCV life cycle .   
According to the National Institute for Health and Care Excellence (NICE) 
guidelines these newer DAA preparations have 90% cure rate (Gelson & Alexander., 
2017). The treatment options include simeprevir, sofosbuvir, declatasvir, a combination 
of ledipasvir and sofosbuvir, a combination of ombitasvir, paritaprevir and ritonavir, 
taken with or without dasabuvir and a combination of sofosbuvir and velpatasvir. 
However, new agents of treatment are under development and several clinical trials are 
on-going to attempt to increase cure rates with shorter treatment durations and lesser 
neuropsychiatric side effects.  
As we move into an era of DAA use, there are several factors that may have an 
impact on who receives this treatment. DAAs are highly cost effective but virological 
response may be impaired by interactions with other HIV drugs and resistance 
associated with HCV variants (Back & Else, 2013; Paolucci et al., 2015) in particular  
GT 3 (Ryder, 2015).  
Among co-infected patients, a high rate of HCV reinfection has been observed 
(Hullegie et al., 2015). The incidence of reinfection in co-infected MSM per 100 
patient’s years of follow-up, increased from 7.8 to 15.2 (Lambers et al., 2011; Martin et 
al., 2013).  Several studies have identified risk behaviours as cause of reinfections 
(Ingiliz et al., 2014; Martin et al., 2013; Micallef et al., 2007; van de Laar et al., 2009). 
It seems that reinfection is a behavioural-based issue with severe consequences. The 
risk of reinfection and DAA use is potential emergence of DAA-resistance, impairing 
the efficacy of the new treatments (Franco et al., 2014), however this has not yet 
emerged. These barriers continue to make interferon-α a valid option for treatment. 
Nevertheless it is remarkable that interferon free therapies present cure rates in excess 
of 90%, are safe and need shorter treatment duration (12 weeks) (Ryder, 2015).  
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1.4. Outcomes of Meta-Analysis on behavioural changes in HIV HCV co-infection 
Neuropsychiatric aspects in HIV mono infection (Ford et al, 2015) and HCV mono-
infection are well known (Schaefer et al, 2012). Conversely, the co-infected group has 
been understudied, probably because of the high level of clinical and psychosocial 
complexity and small samples (Operskalski & Kovacs, 2011). However, recently it has 
become an important clinical group to look at due to the increasing rates of (re) 
infection, particularly among MSM populations.  
In order to clarify the nature of neuropsychiatric manifestations associated with co-
infection and to explore knowledge gaps in the literature, it was important to search the 
symptom profiles of co-infected samples. We aimed to synthesize results of studies on 
depression and cognitive aspects in co-infection; for that purpose systematic reviews 
and meta-analysis were performed.  
 
1.4.1. Cognitive Impairment in HIV HCV Co-infected Patients: A Systematic 
Review and Meta-analysis 
Cognitive impairment has been well described in HIV and HCV mono-infection, 
however in the context of co-infection, research is more limited. The aim of this 
systematic review was to describe the characteristics of cognitive impairment in 
HIV/HCV co-infection and to determine whether, in the current literature, there is 
evidence for differences on cognitive performance between co-infected HIV/HCV, and 
HIV and HCV mono-infected groups.  
From the narrative analysis, some studies highlighted that HIV/HCV co-infected 
patients had a higher degree of cognitive impairment than HIV mono-infected patients. 
However, no significant difference on cognitive impairment between groups was also 
reported. The meta-analysis indicated a significantly higher global deficit score in co-
infected patients than in HIV mono-infected patients. Information processing speed was 
also significantly different, suggesting that the co-infected patients are more likely to be 
impaired than HIV mono-infected patients. No significant differences between co-
infected group and HCV group were reported.  
As expected the presence of two viruses insulting the CNS will probably explain the 
greater cognitive performance impairment. These findings can be challenged by bias 
factors such as a small number of studies, heterogeneity of the studied population, and 
the large variety of methodological procedures. Future research with more consistent 
measures between studies is needed in order to clarify whether being co-infected with 
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HIV/HCV is associated with an increased risk of cognitive impairment. Such 
knowledge will drive clinical service development to address the needs of this specific 
group of patients. 
 
1.4.2. Depressive disorder in HIV HCV Co-infected Patients: A Systematic Review 
and Meta-analysis.  
Depression has been the most commonly reported neuropsychiatric disorder in HIV 
and HCV (Nanni, Caruso, Mitchell, Meggiolaro, & Grassi, 2015; Schaefer et al., 2012). 
However, data in the co-infected population is not clear. The key aim of our systematic 
review and meta-analysis was to describe and explore differences in depression rates 
between HIV/HCV co-infected, and HIV and HCV mono-infected samples. From the 
narrative analysis, studies with retrospective design reported a high prevalence of 
depression among co-infected patients. From prospective studies, mixed findings were 
reported. Some studies suggested that co-infected groups reported higher depression 
levels than mono-infected groups (Baillargeon et al., 2008; Braitstein et al., 2005; Butt 
et al., 2009; Clifford et al., 2005; Sun et al., 2013; Yoon et al., 2011). In contrast, it was 
also reported that diagnosis of depression was significantly less common in co-infection 
patients than HCV mono-infection patients (Tavakkoli et al., 2013). In studies including 
HCV treatment, depression was commonly reported (Alavi et al., 2012; Fumaz et al., 
2007) and considered to be a risk factor for discontinuation of HCV treatment within 
co-infected patients (Laguno et al., 2004; Landau et al., 2001; Myers et al., 2004; 
Moreno et al., 2004; Rockstroh et al., 2002).   
Our meta-analytic results showed that, as measured by depression scales, the co-
infected group was more depressed than either the HIV or the HCV mono-infected 
groups. The variations among the results of the reviewed studies suggest that a clear 
interpretation of how depression outcomes are affected by HIV/HCV co-infection is still 
needed. Clinically, this finding is particularly relevant in that it offers an opportunity for 
targeted screening for depression in populations most at risk. This also allows for the 
potential to diagnose depression early and treat in a timely way before symptoms are 
exacerbated. This is particularly important given that depression is associated with 
stressful life, self-reported poor health, unhappiness with current life, non-adherence to 
treatment, financial problems, psychiatric history and lack of satisfaction with sexual 
life (Slot et al.,  2015). 
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In summary, these qualitative and quantitative narratives have given us a better 
understanding of the neuropsychiatric aspects associated with HIV/HCV co-infection.  
In particular, there is clearly a lack of studies on the neuropsychiatric manifestations 
during hepatitis C treatment within this group. Interestingly, our data are starting to 
shape a profile of the co-infection clinical group. The meta-analytic data indicated that 
the co-infected group is more vulnerable - on depression and cognitive performance - as 
previously predicted. In view of these results, we could start to (re) think potential 
factors that could impact the emergence of neuropsychiatric manifestations, which have 
not been explored within co-infection, such as aetiology of depression factors and 
cognitive vulnerabilities: (1) Is it idiopathic depression different from interferon-
induced depression? If so, does the co-infection cohort are more vulnerable to develop 
depression? (2) Is T cell activation a protective mechanism involved in emergence of 
depression? (3) Does gender plays a role in MDD emergence? (4) Is co-infection 
associated with a poorer cognitive performance, in particular on executive function 
level?  
 
1.5. Neuropsychiatric Side Effects in HCV Treatment: Interferon Induced 
Depression  
Unfortunately, there are a significant number of individuals who are not offered 
treatment because they are unaware of their positive HCV status (Ryder, 2015), poorly 
engage with health services (Grebely et al, 2008), or have psychiatric co-morbidities 
(Nunes et al, 2006). Interferon- is routinely administered to treat HCV infection as 
well as other inflammatory viral infections or cancer (Fritz-French & Tyor, 2012). 
There is a solid body of evidence that interferon- induces neuropsychiatric side effects 
associated with high levels of inflammation (Capuron et al., 2012; Hoyo-Becerra et al., 
2014, Maes, 2011; Miller, 2009; Raison & Miller, 2013). These neuropsychiatric 
manifestations occurring during conventional hepatitis C treatment have been well 
studied, particularly major depressive disorder (MDD) and cognitive impairment 
(Capuron & Miller, 2004; Fialho et al., 2017; Whale et al., 2015; Udina et al., 2012) 
which have been associated with treatment interruption and negative treatment response 
(Landau et al., 2001; Laguno et al., 2004; Meyers et al., 200; Moreno et al., 2004; 
Rockstroh et al., 2002).  
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Studies on neuropsychiatric side effects on triple therapy are scarce, although it has 
been reported that there was no significant difference in risk of developing MDD 
between pegylated interferon and ribavirin, and triple therapy (Fialho et al., 2014). 
Regarding the interferon free regimens, we can’t discard the possibility of emergence of 
neuropsychiatric side effects due to the influence of risk factors, such as previous 
history of depression and or mental illness (Basseri et al., 2010, Schaefer et al., 2012), 
HCV itself (Carta et al., 2012), drug use and alcohol use and adverse social 
circumstances (Hilsabeck, Castellon & Hinkin, 2005). Data on the effect of interferon 
free regimes and psychiatric side effects is scarce.  
In summary, we expect that in the presence of inteferon-, the side effects may be 
exacerbated due to a state of an overstimulation of pro-inflammatory cytokines. 
Furthermore, the potential causes for emergence of neuropsychiatric side effects during 
hepatitis C treatment do not rely exclusively on the inflammatory hypothesis. The 
multifactorial aspects of treatment and co factors (host, viral and environment) also 
contribute to an aggravated negative emotional response.   
 
1.5.1. Co-infection with HIV Associated With Reduced Vulnerability to Depressive 
Symptoms in Hepatitis C Patients 
As mentioned above, the co-infected patients were more likely to experience 
worse neuropsychiatric side effects during interferon-based therapies. The factors 
underlying this increased vulnerability are currently unclear. The natural research 
question that emerged was exploring potential differences between HCV and co-
infected patients undergoing HCV treatment, expecting higher rates of MDD and 
depression symptoms severity in the co-infected group than the HCV mono-infected 
group.  
Interferon- treatment may be responsible for the emergence of two distinct 
behavioural syndromes; the neurovegetative and mood-cognitive syndrome (Capuron et 
al., 2002a, Capuron & Miller, 2004). The neurovegetative syndrome tends to appear 
rapidly, associated with symptoms such as anorexia; fatigue and psychomotor slowing.  
The development of this syndrome has been associated with changes in the basal 
ganglia functions (Capuron et al., 2007; Dowell et al., 2015 Kamata et al., 2000). 
Neuroimaging studies strongly suggested that interferon- rapidly induces changes in 
striatal structure causing fatigue (Dowell et al., 2015).  In contrast, the mood- cognition 
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syndrome implicates symptoms of anxiety, depressive mood and cognitive dysfunction. 
These symptoms are common at a later stage of the treatment.  The pathophysiological 
mechanisms may involve alterations in the serotonin metabolism that is related with 
tryptophan metabolism (Capuron et al., 2003a, Raison et al., 2010b).  
In HCV chronic patients treated with INF, it was found that kynurenine (kyn) 
levels and kyn/tryptothan (trp) ratio were high in the presence of depressive symptoms 
(Comai et al, 2011). These data suggest that INF- boosts indoleamine-2,3-dioxygenase 
(IDO) activity, enhancing trp metabolism  into kyn overstimulation and serotonin 
depletion (Capuron et al., 2004; Wichers et al., 2005). Another potential pathway is the 
hypothalamic-pituitary-adrenal (HPA) mechanism. INF induces pro-inflammatory 
cytokines that trigger HPA axis via overproduction of corticotropin-releasing factor 
(CRF) that has been associated with mood and cognitive symptoms (Capuron & Miller, 
2004; Eccles et al., 2012).  
Despite the mechanisms underlying interferon therapy, it seems that interferon-
induced depressive disorder is a specific sub-type of mood disorders that are exclusively 
associated with higher expression of the neurovegetative syndrome. Most of the 
evidence comes from the HCV mono-infected population leaving a research gap within 
the HIV HCV co-infected group.  The key aim of our study was determine if there were 
differences in the expression of depressive symptoms during INF treatment between 
HCV mono-infected and HIV/HCV co-infected patients. In particular, we investigated 
the depressive symptoms subtypes associated with the emergence of depression during 
HCV treatment, and investigated whether this association was different across the two 
study groups.  
A prospective study design was conducted at the outpatients HCV clinic at the 
Royal Sussex County Hospital, Brighton, UK. All patients eligible to start hepatitis C 
treatment with pegylated INF and ribavirin, or DAA triple therapy (composed of 
pegylated INF, ribavirin and telaprevir) were included. Both treatments involved 24 
weeks of pegylated INF. Ethical approval was obtained and all participants gave 
written consent. Behavioural and clinical data were gathered at baseline, before starting 
treatment, during and after finishing treatment, with a 6 months period of follow-up 
(SVR endpoint). Depression assessments were conducted through a semi-structured 
clinical interview (SCID-I) and with the Hamilton Depression Rating Scale (HAMD).  
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Our results confirmed the depressogenic nature of INF with the greatest increase in 
neurovegetative symptoms. Surprisingly, the HIV-HCV co-infected group appeared less 
vulnerable to develop depression when compared with the HCV mono-infected group.  
There are several explanations for our findings, such as the nature of our cohort, 
potential influence of behavioural and genetic moderators, HCV chronicity and 
psychosocial variables. The clinical relevance of our findings are associated with 
developing better strategies to help patients going through treatment, taking into 
account the specific neurovegetative symptoms. If not screened and treated, depression 
can become recurrent and resistant to treatment. Additionally, what stood out was the 
resilience to develop severe depression symptoms in the HIV-HCV co-infected group. It 
seems that being co-infected is a protective factor to developing depression, under an 
inflammatory acute condition, such as HCV interferon based treatment.  
These findings started to draw a specific co-infection signature. The need to 
understand what factors could interfere with the resilience to develop depression within 
co-infection was emerging. Regardless, it is noteworthy to point out that the emergence 
of neuropsychiatric aspects remains, even without INF- treatment. In chronic 
infection, several factors have been associated with high rates of MDD, such as personal 
and familiar previous history of mental illness (Carta et al., 2012), alcohol and drug 
abuse (Boscarino et al., 2015) and immune mechanisms (Lotrich, 2015). It seemed that, 
we were not looking at a vulnerable group; instead our data were suggesting a resilient 
clinical cohort less likely to be depressed and with similar rates of SVR when compared 
with the HCV mono-infected group. Taking our data into account and the hypothesis 
that alteration in T cell activation is one protective mechanism involved in emergence of 
depression, a sub study was developed to explore the potential association between 
depression and immune markers in a co-infected MSM sample.  
 
1.5.2. Major depressive disorder and immune response in HIV HCV co-infection 
men during hepatitis C treatment. 
In chronic somatic diseases, MDD is 1.5 to 2 times higher than when compared with 
the general population (Harter et al., 2007). MDD is characterized by somatic 
symptoms, cognitive impairment, low mood and anxiety mapping a heterogeneous 
disease profile. According with meta-analysis, the co-infected group were more likely to 
present depressive symptoms that the HIV and HCV mono-infected groups (Fialho et 
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al., 2017). Several risk factors were identified as predictors of greater depression 
symptoms in co-infection, such as high rates of intravenous drug abuse (Clifford et al., 
2005, Backus et al., 2005), alcohol abuse (Pantalone et al., 2012), psychiatric 
comorbidities (Backus et al., 2005) and risky sexual behaviour (Martin et al., 2013).  
In the context of inflammation, as seen in HIV and HCV infection, depression 
symptoms may be a response to the infection itself, or side effects to treatment, or an 
adjustment disorder to receiving a diagnosis of HIV and or HCV, or the combination of 
these factors. Nevertheless, it seems that inflammation remains the common 
denominator for the development of depression in chronic somatic diseases (Haroon et 
al., 2012). Furthermore, patients who are under a chronic low-grade of inflammation are 
at a higher risk of developing depression (Danzter et al., 2008). Considering the 
interactions between MDD and immune dysregulation, the emergence of depression 
symptoms may depend on the onset, duration and intensity of the immune markers 
(Capuron et al., 2011; Sperner-Unterweger et al., 2014).  
In patients with HIV, depression has been associated with a decreased CD4 T cell 
count and increased rate of progression to AIDS related death (Lesernam, 2008; 
Ickovics et al., 2001; Stommel et al., 2002).  Interestingly, it seems that depression and 
T cell dysfunction share the same pathways, highlighting the role of T cells in the 
emergence of depression via immune-inflammatory processes (Miller, 2010).  
T cells are part of the immune system and it has been reported an association 
between low T cells count and depression (Zorilla et al., 2001), with evidence of T cell 
alterations in patients with MDD (Irwin & Miller, 2007; Zorilla et al., 2001). The 
mechanisms involved in T cell alterations are not clear, however it has been reported 
that in depressed patients CD4 T cells exhibited accelerated spontaneous apoptosis 
(Szuster-Ciesielska et al., 2008). Another hypothesis that has been proposed to explain 
the relationship between MDD and reduced T cells is glucocorticoid function (Bauer et 
al., 2002, Pariante & Miller, 2001) and inflammatory cytokines (Miller et al., 2009).  
The role of T cells in emergence of depression is not clear. It is well known that 
decreases in T cell response are associated with depression (Irwin & Miller, 2007; 
Zorilla et al., 2001). There is however, emerging data suggesting that T cells might be a 
protective factor against depression (Brackman et al., 2015; Lewitus et al., 2008) 
through their neuroprotective and anti-inflammatory effects (Miller, 2010). In animal 
models it was observed that enhanced trafficking of T-cells to the brain was associated 
with an increased ability to adjust to stress (Lewitus et al., 2008). The T cells seem to 
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have a “protective auto-immunity” response that could represent a mechanism to control 
negative emotional states (Brackman et al., 2015; Lewitus et al., 2008; Schwartz, 2001; 
Raison & Miller, 2016).  
MDD is the most common side effect of interferon-based therapies in patients with 
hepatitis C (Whale et al., 2015; Fialho et al., 2014; Lotrich et al., 2009) and with co-
infection (Alavi et al., 2012; Fumaz et al., 2007). Particularly, in the co-infected group, 
depression has been reported as the major cause of treatment discontinuation (Laguno et 
al., 2004; Landau et al., 2001; Myers et al., 2004; Moreno et al., 2004; Rockstroh et al., 
2002). 
MDD as behaviour response is caused by inflammation and immune activation 
(Wirleitner et al, 2003; Neurauter et al, 2008a, Danzter et al, 2008). As stated previously 
the potential mechanisms that immune activation and interferon treatment share are the 
serotonergic system and IDO pathway (Myint et al., 2012). IDO activity integrates 
endogenous regulator mechanisms of T cells proliferation (Mellor et al., 1999). On the 
other hand, interferon- induces increased IDO expression causing up-regulation of 
trp/kynurenine metabolism (Capuron et al., 2009, Wishers et al., 2005). As a 
consequence, serotonin synthesis is reduced leading to depression (Nemeroff & Owens, 
2009). Several studies in chronic hepatitis C infection found that elevated 
concentrations of trp levels were associated with the deficiency of serotonin expression 
(Raison et al, 2009) and with depression (Oxenkrug et al., 2014). In contrast, there is 
evidence that failed to find differences in KTR (trp/kynurenine ratio concentrations), 
defined as a marker of IDO activity, and between HCV patients with and without 
interferon induced depression (Oxenkrug et al., 2014). Another study found that 
depression was associated with trp depletion without an enhanced kynurenine pathway 
(Hughes et al., 2012). Cytokine genes may also influence trp breakdown affecting 
depression emergence (Mynt et al., 2013; Oxenburg et al., 2012, 2014). Despite the 
mechanisms involved, the association between immune response and an inflammatory 
cascade on depression, activated by interferon treatment is clear.  
According with the aforementioned paradigm, we aimed to explore if immune 
response, measured by CD4 T cell count, was correlated with depression during HCV 
interferon based therapy in MSM HIV-HCV patients. As expected, there was a 
significant increase in depression symptoms at the beginning of treatment and those 
symptoms remitted at a later stage. There was a significant reduction of CD4 T cells 
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from baseline to week 4, and we did not find a correlation between CD4 T cell count 
and depression and SVR. The depressogenic effect of interferon seems to be transitory, 
and more research is needed in order to clarify the role of T cell on depression 
emergence. 
 
1.5.3. Does Gender Play a Role in new-onset depression during HCV Treatment?  
A research gap in the literature exists about HCV treatment in women. Potential 
reasons for this are the lower rates of treatment prescription due to small cohort 
numbers alongside slow progression of liver disease and they are more likely to 
spontaneous clear the virus when compared with men (Beste, Bondurant, & Ioannou, 
2015). However, risk factors for HCV infection in women have been reported, such as 
substance abuse, HIV infection, smoking and age being over 35 years (Operskalski et 
al., 2008).  
Regarding depression subtyping, increased somatic symptoms were suggested as a 
significant predictor of changes in inflammatory markers, in particular in TNF-alpha in 
females with MDD (Dannehl et al., 2014). In contrast, MDD was not associated with 
inflammatory markers possibly due to an impact of estrogen use (hormonal 
contraceptives) on the inflammatory cascade (Vogelzangs et al., 2012).  In the non-
iatrogenic model of depression it is well established that females are more vulnerable to 
depression (Whale et al., 2015). However, it is not so clear in the inflammatory model 
of depression. Nevertheless, with the vulnerability risk of being a female and adding the 
effects of INF- therapy, a higher rate of depression is expected than men.  
A prospective study design was adopted, including a HCV infection cohort only. Of 
167 participants, 55 were women. The aim of this study was determine if there were 
gender differences in emergence of MDD during treatment, including expression of 
depression symptoms. Participants were assessed for depression before the start of the 
treatment, during and 6 months after treatment ended, defined as SVR.  
During HCV therapy, there was a significant increase in depression from baseline to 
week 4 and a significant decrease from week 24 to SVR. These results are in 
accordance with our previous report, which confirms the depressogenic nature of 
interferon as transient. Regarding the syndrome type, the neurovegetative and mood-
cognitive syndrome were significantly increased at the begining of the treatment and 
markedly dropped at the end. Our data suggested that women were more likely to 
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present MDD at later stage of treatment (week 24). The influence of gender on 
depression emergence at a later stage may be due to the influence of vulnerability 
factors. We found that telaprevir was associated with lower depression rates in women, 
leading us to the possibility notion that the protease inhibitor may play a role in the 
inflammatory model of depression.  
 
1.6. Executive function and Hepatitis C treatment in HIV acute HCV MSM sample  
As previous reported the cytokines induce changes in cognition due their over-
expression (McAfoose & Baune, 2009; Irwin & Miller, 2007; Raison et al., 2006). The 
neuropsychological abnormalities occurring in viral hepatitis, such as HCV, suggest that 
greater disease severity is significantly associated with greater cognitive impairment 
(Cordoba et al., 2003). 
Data on HCV population infers a direct association between HCV infection and 
development of cognitive abnormalities (Monaco et al., 2015; Forton et al., 2008; 
Kenelly, 2013) suggesting that the cognitive impairment is observed even in non-severe 
liver pathology. The profile of cognitive impairment in HCV infected patients (HCV-
associated neurocognitive disorder – HCV-AND) is similar to the HIV associated 
neurocognitive disorders - HAND, composed of executive function, attention, working 
memory, psychomotor speed, verbal learning and verbal recall abnormalities (Monaco 
et al., 2015). 
The hypothesis of a cognitive model of inflammation is based on the neurotoxic 
effect of HCV in the CNS that causes an increased inflammatory response mediated by 
overstimulation of cytokines (Senzolo et al., 2011). On the other hand, in the context of 
interferon-based therapies, it has been reported that there is a functional link between 
IFN- and the brain, which ultimately contribute for cognitive impairment (Lieb et al., 
2006).  
IFN- activation on cognition is not clear in HCV. Some studies have not found 
cognitive impairment (Fontana et al., 2010), whereas other reports observed cognitive 
impairment (Lieb et al., 2006; Pawelczyk et al., 2008). Cognitive impairment associated 
with IFN- has been associated with prefrontal cortex dysfunctions and hippocampus 
(Juengling et al., 2000). It seems that the effect of IFN- on cognition is dose dependent 
and the cognitive features associated are mainly subcortical resulting in executive 
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function, attention, working memory, psychomotor speed, verbal learning and verbal 
recall impairment (Meyers et al., 1991; Fritz-French & Tyor, 2012).  
In HIV patients with identified HIV associated dementia (HAD) was found elevated 
levels of CSF levels of IFN- than in HIV with no HAD (Rho et al., 1995) highlighting 
the potential negative effect of IFN- on neurocognitive status. A subsequent study 
performed on post-mortem brain tissue from HAD individuals showed an up regulation 
of IFN- genes compared with HIV without HAD (Valcour, 2010). Cognitive function 
in co-infected patients appears more impaired than in HIV mono-infecteon as 
highlighted in the post-cART era (Heaton et al., 2011) due to the insult of both virus to 
the CNS and the inflammatory cascade activated by IFN- treatment.  
As previously reported IFN- based therapies induce changes in cognition. One of 
the research avenues that were relevant to explore was the cognitive cluster, in 
particular EF, associated with inflammation in clinical samples, such as HIV and HCV 
infection. Neuroimaging and neuropsychological data revealed a greater impairment in 
EF among HIV HCV co-infected patients when compared with HIV mono-infected 
patients (Winston et al., 2013; Sun et al., 2013; Thiyagarajan et al., 2010). Cerebral 
changes in particular basal ganglia myo-inositol/creatine ratio was strongly associated 
with poor EF performance in acute HIV HCV group (Wintson et al., 2013). 
Additionally the acute HCV stage in HIV patients, lower nadir CD4 T cell count stood 
out as factors associated with EF impairment (Winston et al., 2013). Overall it seems 
that acute HCV stage and cerebral changes are associated with EF dysfunction in HCV 
non-treated co-infected samples.  
Cognitive impairment is reported as part of the neuropsychiatric side effects of IFN-
 (Okanoue et al., 1996; Capuron & Miller, 2004) with evidence of EF impairment 
(Majer et al., 2008, Monchi et al., 2001). However, data on interferon induced cognitive 
impairment - in particular in DAAS - is scarce and the mechanisms underlying the EF 
impairment are multifactorial and understudied.  
Executive function is a complex cognitive domain that facilitates behaviour and 
allows us to approach and adjust to unfamiliar circumstances integrating the ability to 
planning, decision-making and intentionally inhibits a dominant response (Miyaki et al., 
2000; Mendelsohn et al., 2009). These cognitive features are implicated on overall 
functioning (Royall et al., 2002) and map updating, shifting and inhibiting components.  
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The aim of our last study was to explore the EF status in a co-infected and control 
HIV mono-infected group using EF tasks. We expected that the co-infected group 
presented a poor EF performance than the HIV group and during HCV therapy.  
A total of 25 HIV MSM participants enrolled in our study, 12 were HIV 
asymptomatic and 13 were acute HCV HIV assigned for HCV treatment with DAAs. 
Patients were assessed prospectively using a comprehensive EF battery. Our data 
indicated that there was an effect of DAAs on cognition, in particular with the co-
infected group showing a disadvantage on information processing speed, with a 
significant increase on speed of processing performance under prospective memory 
conditions. Clearly more research is needed in order to explore if this cognitive 
impairment is due to the effect of DAAs,  the HIV virus or residual effect of both.  
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2.1. Cognitive impairment in HIV and HCV co-infected patients: A systematic 
review and meta-analysis 
 
Abstract 
 
Cognitive impairment has been well documented in HIV and hepatitis C virus (HCV) 
mono-infections. However, in the context of HIV/HCV co-infection the research is 
more limited. The aim of this systematic review was to describe the characteristics of 
cognitive impairment in HIV/HCV co-infection and to examine the differences in 
cognitive performance between HIV/HCV and HIV and HCV mono-infected patients. 
Of the 437 records initially screened, 24 papers met the inclusion criteria and were 
included in the systematic review. Four studies were included in the meta-analysis. 
Most studies indicated that HIV/HCV co-infected patients had a higher level of 
cognitive impairment than HIV mono-infected patients. Meta-analysis also indicated 
that HIV mono-infected patients had a significantly lower global deficit score than co-
infected patients. The results also indicated that co-infected patients were more likely to 
be impaired in information processing speed than HIV mono-infected patients. These 
findings can be challenged by biasing factors such as the small number of included 
studies, heterogeneity of the samples, and a large diversity of methodological 
procedures. Future research with consistent and comprehensive neuropsychological 
batteries and covering a greater diversity of risk factors is needed, in order to clarify the 
effects of both viruses on cognitive function and the mechanisms that underlie these 
effects. Because cognitive impairments may pose significant challenges to medication 
adherence, quality of life and overall functioning, such knowledge may have important 
implications to the planning and implementation of effective interventions aimed at 
optimising the clinical management of these infections. 
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Introduction 
Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) have been 
individually associated with cognitive impairment. Despite the era of combination 
antiretroviral therapy, the incidence of HIV-associated neurocognitive disorders 
(HAND) in milder and mild forms, defined respectively as asymptomatic 
neurocognitive impairment (ANI) and mild neurocognitive disorder (MND), has 
remained stable but still prevalent (Letendre, 2011; Simioni et al., 2010). There is 
evidence indicating that cognitive impairment occurs in a substantial proportion (15-
50%) of HIV-infected patients (Schouten, Cinque, Gisslen, Reiss, & Portegies, 2011). 
Cognitive impairment has been associated with disease stage (Woods, Moore, Weber, & 
Grant, 2009), poor adherence to treatment, HCV infection and other comorbid 
conditions such as substance use and mental illness (Anand, Springer, Copenhaver, & 
Altice, 2010; Cysique et al., 2009; Martin-Thormeyer & Paul, 2009). Abnormalities in 
the neurocognitive profile of HAND have been shown in executive function, memory, 
information processing speed, attention/working memory, motor skills, language/verbal 
fluency and sensoriperception (Grant, 2008; Woods et al., 2009). The prevalence of 
HIV-associated cognitive impairment is high even in patients with undetectable HIV 
RNA. The cause of this remains unclear, although there is evidence that immune 
activation, neuroinflammation, genetic and behavioural factors may have an important 
role (Hong & Banks, 2015; Simioni et al., 2010). 
In hepatitis C, the rates of cognitive impairment described range from 0% to 
82% (Hilsabeck, Perry, & Hassanein, 2002), and several studies demonstrated evidence 
of cognitive impairment across a variety of domains. Particularly, attention, 
concentration, working memory, executive function and psychomotor speed have been 
shown to be the cognitive domains most likely to be impaired (Perry, Hilsabeck, & 
Hassanein, 2008; Posada et al., 2009). Several risk factors for cognitive impairment in 
HCV have been identified. Among these, history of alcohol and drug misuse (Foster, 
Goldin, & Thomas, 1998), depression (Fontana et al., 2005), severity of liver disease 
(Hilsabeck et al., 2002; Letendre et al., 2005) and high levels of pro-inflammatory 
cytokines (Gershon, Margulies Gorczynski, & Heathcote, 2000) were the most 
consistent. Despite the complexity of mechanisms and associated risk factors, 
investigations of cognition in viral hepatitis have one common finding of greater disease 
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severity being associated with more significant cognitive impairment (Córdoba et al., 
2003). 
Among HIV/HCV co-infected patients, the rates of cognitive impairment are 
less well-defined, although it appears prevalent (Hilsabeck, Castellon, & Hinkin, 2005; 
Hinkin, Castellon, Levine, Barclay, & Singer, 2008; Martin-Thormeyer & Paul, 2009). 
Existing literature suggests that the presence of co-infection with both viruses leads to 
greater cognitive deficit than in mono-infection, though with a different pattern of 
cognitive impairment (Letendre et al., 2005; Martin et al., 2004). The aim of this 
systematic review and meta-analysis was to bring more clarity to this area by analysing 
the differences on cognitive domains between HIV/HCV co-infection and HIV and 
HCV mono-infections, as well as to describe the characteristics of cognitive impairment 
in HIV/HCV co-infected patients. 
 
Methods 
 
Information sources and search strategy 
The Cochrane Central Registered of Control Trials Library, SCOPUS, Medline, 
PsycINFO and ScienceDirect were systematically searched for records from the earliest 
data available online to April 2014. Each database was searched separately using the 
following key terms “cognitive impairment” AND “HIV HCV co-infection”, where 
AND was the Boolean operator. The search was supplemented with information from 
references lists of the eligible articles, conferences abstracts, and contact with the key 
academics in the field of cognitive impairment and HIV/HCV. The selection was 
limited to publications written in English. The study was designed according to the 
PRISMA statement (Moher, Liberati, Tetzlaff, & Altman, 2009). 
 
Eligibility criteria 
Study inclusion criteria were: (1) type of studies: prospective experimental 
studies concerning cognitive aspects in co-infection with HIV and HCV; retrospective 
cohort studies with data collected from previous medical records on cognitive domains; 
(2) Participants: individuals diagnosed with HIV/HCV co-infection and individuals with 
HIV and HCV mono-infection; (3) interventions: no intervention and all interventions, 
including HCV treatment. No description of intervention was necessary, as this review 
did not aim to compare intervention between groups; (4) primary outcome measures: 
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any cognitive outcome measure described in the HIV/HCV co-infected group. 
 
Data extraction 
Two authors (RF and MB) independently reviewed references from electronic 
and non-electronic sources and selected the relevant studies. Data extraction was 
conducted independently (by RF and MB) and reviewed by the lead author. 
Disagreements were resolved by consensus. Information on the following items was 
extracted from each study: year of publication, design, sample size, and population 
characteristics (e.g., gender, age, clinic stage of HIV and HCV, past and/or current 
intravenous drug use (IDU), and domains and measures of cognitive impairment). If the 
full-text article did not provide sufficient data, the authors of the studies were contacted 
for clarification or additional data. Risk of bias assessment was undertaken on each 
selected study. A checklist was created based on a quality assessment instrument, and 
included the following items: aims explicitly stated, selection and representativeness of 
the sample, inclusion/exclusion criteria, measures clearly identified, data adequately 
reported, and discussion addressing cognitive outcomes (Higgins & Green, 2011). 
 
Primary outcomes 
 Data were extracted to address all cognitive domains available. For the meta-
analysis, the global deficit score (GDS) was also extracted, which was defined as a 
unitary global score representing overall neuropsychological tests performances. Each 
individual cognitive test score was converted to T-scores demographically corrected 
(for education, age and gender) (Rempel et al., 2013; Letendre et al., 2005; Sun, 
Abadjian, Rempel, Monto, & Pulliam, 2013). The meta-analyses were performed for: 
(a) the studies that provided a GDS score; and (b) the studies that reported specific 
neurocognitive domains. 
 
Data analysis 
 Meta-analyses quantifying the differences in cognitive impairment between co-
infected and mono-infected groups were performed using the Review Manager software 
(RevMan; version 5.2, The Cochrane Collaboration, 2012). The meta-analysis was 
carried out for continuous variables using inverse variance with standardised mean 
differences (SMD) and 95% confidence intervals (CI). Heterogeneity was assessed 
using 2 and I2 tests, with an I2 more than 50% being regarded as substantial 
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heterogeneity (Higgins & Thompson, 2002; Higgins, Thompson, Deeks, & Altman, 
2003). If significant heterogeneity was identified, a random-effects model was adopted. 
 
Results 
Study selection 
 The study selection process is described in Figure 1. Briefly, the electronic 
search identified 434 records. Three additional records were identified by non-electronic 
methods of searching. After the removal of duplicates and of the initial screening 
(application of the pre-defined inclusion criteria and of PICO parameters), 40 full-text 
articles were assessed for eligibility. After full-text reading, 16 studies were further 
excluded, and 24 studies were included in the systematic review. Four studies (16.7%) 
were included in the meta-analysis process. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow diagram outlining the study selection process 
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A low risk of bias was observed when considering the identification of aims, 
inclusion and exclusion criteria, the procedures associated with how outcomes were 
determined, reporting of relevant results, and discussion addressing cognitive outcomes. 
However, bias was found, most notably in relation to the selection of participants (e.g., 
a systematic difference between the characteristics of groups that were compared was 
identified), which limited their representativeness. 
 
Study characteristics 
 The 24 studies of this systematic review included a total of 5,674 participants 
from 6 countries (one study from Australia, Canada, Italy and Germany, three studies 
from the UK; and 17 studies from the USA). Selected studies were published between 
2004 and 2013. Study designs were largely cross-sectional (n = 14, 58.3%) and cohort 
(n = 8, 33.3%), and included a comparison between co-infected and HIV mono-infected 
groups (n = 14, 54.2%). The majority of studies included both male and female 
participants and two studies included only female participants (Crystal et al., 2012; 
Richardson et al., 2005). The proportion of male participants ranged from 56.2% (von 
Giesen et al., 2004) to 100% (Martin et al., 2004; Rempel et al., 2013; Sun et al., 2013; 
Winston et al., 2010). Regarding the clinical stage, 22 studies included participants in 
HCV chronic stage. In relation to HIV stage, the majority of studies included HIV-
infected participants who were chronic and clinically stable (n = 16). General 
characteristics of included studies are described in Table 1. 
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Table 1. Characteristics of the 24 studies included in the systematic review: study design, sample size, age of participants and clinical stage of HIV and 
HCV infections 
Authors, Year Study design 
Sample size (N) Sample characteristics (Age)a Clinical stage 
HIV/ HCV HCV HIV Controls HIV/HCV HCV HIV Controls HIV HCV 
Aronow et al., 2008 Cross sectional 31  128  NA  42.6 (7.8)  
Late-stage HIV 
infection 
Chronic 
Cherner et al., 2005 Cross sectional  83  347  40.9 (7.3)  36.3 (9.3)  Chronic  Chronic 
Ciccarelli et al., 
2013 
Cross sectional  50 50 50  48 (45-53)b 48 (42-52)b 48 (42-55)b  Clinically stable Chronic 
Clifford et al., 2005 Cross sectional 30  234  40.27 (7.75)  38.05 (8.63)  Clinically stable Chronic 
Clifford et al., 2009 Retrospective  249  310  NA  NA  Clinically stable Chronic 
Cohen et al., 2011 Cohort 9  21 34 NA  NA 46.0 (15.9) Clinically stable Chronic 
Crystal et al., 2012 Cohort 184 42 721 392 47.8 (6.3) 45.9 (8.2) 38.3 (8.8) 36.1 (9.8) All stages Chronic 
Devlin et al., 2012 Cross sectional  42 9 73 63 NA NA 45.4 (9.48) NA Clinically stable Chronic 
Garvey et al., 2012 
Case-control 
study 
24  57  41 (36-44)b  47 (39-56)b  Clinically stable Acute 
Hinkin et al., 2008 Cohort  35  83  44.7 (8.4)  42.5 (8.3)  
HIV in several 
HAND stages 
Chronic 
Letendre et al., 
2005 
Cross sectional  112  414  42  37  Chronic Chronic 
Martin et al., 2004 Cross sectional  28 20 39 69 45.2 (4.2) 44.9 (4.3) 41.6 (5.0) 40 (10.6) Clinically stable Chronic 
Morgello et al., 
2005 
Cohort  67  116  NA  NA  Advanced stage Chronic 
Parsons et al., 2006 Cohort  20  45  42.8 (4.9)  40.0 (6.8)  All stages Chronic 
Perry et al., 2005 Cohort  29 47   43.90 (10.27) 47.28 (7.21)   Clinically stable Chronic 
Rempel et al., 2013 Cross sectional  17 19 36 28 54.5 (5.2) 56.6 (4.5) NA NA Clinically stable Chronic 
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Richardson et al., 
2005 
Cross sectional  70 27 75 48 39.6 (6.5) 37.3 (9.2) 33.8 (7.2) 33 (8.6) Chronic Chronic 
Ryan et al., 2004 Cross sectional  67  49  45.1 (7.2)  41.9 (7.2)  Advanced stage Chronic 
Sun et al., 2013 Cross sectional  17 19 14 28 54.5 (5.2) 56.6 (4.5) 51.6 (7.2) 53.2 (6.0) Clinically stable Chronic 
Thein et al., 2007 Cross sectional  15 19 30 30 35.5 (7.0) 42.2 (6.5) 34.7 (7.4) 34.8 (8.2) Clinically stable Chronic 
Thiyagarajan et al., 
2010 
Cross sectional  27  45  46 (8.0)  48 (11.0)  Clinically stable Chronic 
Vivithanaporn et 
al., 2012  
Cohort  91  365  NA  NA  
HIV in several 
HAND stages 
Chronic 
von Giesen et al., 
2004 
Cross sectional  43 44 43  38 (8.1) 43.2 (13.7) 37.4 (7.8)  
AIDS and non-
AIDS stage 
Chronic 
Winston et al., 
2010 
Cohort  10  10 10 40 (9.2)  39 (5.9) 32 (8.9) Chronic Acute 
Note: SD = Standard deviation; HAND: HIV-Associated Neurocognitive Disorder; NA: Not available 
a Unless indicated, data are presented as mean (SD or range); b Data is presented as Median (Interquartile range) 
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Cognitive impairment 
Qualitative synthesis of findings 
Regarding cognitive impairment, the existing literature has produced 
inconsistent findings. Overall, most studies reported that the HIV/HCV co-infected 
patients were generally more impaired than HIV and HCV mono-infected patients and 
controls (Cherner et al., 2005; Ciccarelli et al., 2013; Clifford, Evans, Yang, & Gulick, 
2005; Devlin et al. 2012; Hinkin et al., 2008; Letendre et al., 2005; Martin et al., 2004; 
Parsons et al., 2006; Rempel et al., 2013; Ryan et al., 2004; Sun et al., 2013; 
Vivinhatanaporn et al., 2012; von Giesen et al., 2004). Other studies found no 
differences on cognitive performance between HIV/HCV and HIV mono-infected 
groups (Aronow, Weston, Pezeshki, & Lazarus, 2008; Thiyagarajan et al., 2010), 
between HIV/HCV and HCV mono-infected groups (Clifford et al., 2009; Perry et al., 
2005), and between HIV/HCV and both HIV and HCV mono-infected groups (Thein et 
al., 2007). A qualitative synthesis of the relevant findings is presented in Table2. 
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Table 2. Synthesis of findings on cognitive impairment of the 24 studies included in the systematic review 
Authors, Year Cognitive domains Cognitive measures Main results  Group more 
cognitively impaired  
Aronow et al., 2008 
 
Verbal fluency, speed of 
information processing, learning, 
memory, executive functions, 
attention and working memory. 
Controlled Oral Word Association Test, Wechsler 
Adult Intelligence Scale (WAIS) III digit symbol 
and symbol search, letter number sequencing sub 
tests, Trail Making Test A/B, Hopkins Verbal 
Learning Test Revised, Brief Visuospatial Memory 
Test Revised, Wisconsin Card Sorting Test, 
Grooved Pegboard Test 
The co-infected group was 
more impaired than the HIV 
mono-infected group.  
 
HIV/HCV  HIV 
Cherner et al., 2005 Learning, recall, 
attention/working memory, speed 
information processing, verbal 
fluency, motor ability, 
abstraction/problem solving 
Wide Range Achievement Test-3, Controlled Word 
Association Test Letters F, A, S; Category Fluency 
Animals, Paced Auditory Serial Addition Task 
(PASAT), WAIS III Letter Number Sequencing, 
Digit Symbol and Symbol Search sub tests, Trail 
Making Test A/B, Stroop task interference, Heaton 
Story Memory Test, Hopkins Verbal Learning Test 
rev, Heaton Figure Memory Test, Brief Visuospatial 
Memory Test rev, Wisconsin Card Sorting Test, 
Halsted Category Test, Grooved Pegboard Test 
HCV infection has an 
independent adverse effect on 
cognitive impairment 
performance. HIV/HCV co-
infection status was a predictor 
of global impairment. 
NA 
Ciccarelli et al., 2013 Memory, attention, executive 
functions, speed of psychomotor 
processing and language 
Rey auditory verbal learning test, Stroop test, Trail 
Making Test A/B, WAIS R digit symbol, Grooved 
Pegboard Test and Letter Fluency 
The HIV/HCV co-infected 
group showed lower 
neuropsychological 
performance (auditory verbal 
learning and letter fluency) than 
the mono-infected groups. 
HIV/HCV  HIV 
HIV/HCV  HCV  
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The prevalence of minor 
cognitive impairment was 
significantly higher in 
HIV/HCV co-infected patients 
(54%) than in mono-infected 
groups. 
Clifford et al., 2005 Motor persistence, attention, 
response speed, visuomotor 
coordination, conceptual 
shifting/tracking 
Trail Making Test A/B, Digit Symbol sub test from 
WAIS III 
The HIV/HCV co-infected 
group performed worse on 
attention and psychomotor 
speed than HIV mono-infected 
group. 
There were no differences in 
the proportion of patients with 
neurological impairment 
(HIV/HCV: 33%; HIV: 25%). 
HIV/HCV  HIV 
Clifford et al., 2009 Attention and motor persistence 
 
Trail Making Test A/B, WAIS R digit symbol test There were no significant 
differences on cognitive 
performance between HIV 
mono-infected and HIV/HCV 
co-infected groups. The 
cognitive impairment was not 
exacerbated by HCV viral load. 
HIV/HCV  HIV 
Cohen et al., 2011 Attention, executive function and 
psychomotor processing speed 
 
Trail Making Test A/B, Stroop Test, Grooved 
Pegboard Test, WAIS-III Digit Symbol Coding, 
Letter Number sequencing and Symbol Search sub 
tests 
The cognitive performance in 
HIV/HCV co-infection was 
associated with high levels of 
specific cytokines (IL-6, IL-16, 
NA 
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MIP-1). 
Crystal et al., 2012 Speed information processing, 
perceptual motor ability and 
cognitive flexibility 
Symbol Digit Modalities Test, Trail Making Test 
A/B, Stroop Test 
HCV infection was not 
associated with cognitive 
status. 
NA 
Devlin et al., 2012 Speed of information processing, 
attention/working memory, 
executive functioning, learning, 
memory, verbal fluency and 
psychomotor speed 
Hopkins Verbal Learning Test – revised, Brief 
visuospatial memory test- revised, Controlled Oral 
Word Association Test, Stroop Color and Word 
Test, Trail Making Test A/B, Digit Symbol Coding, 
Symbol Search, Letter-number sequencing sub tests 
from WAIS III 
No significant differences were 
found in cognitive performance 
between the study groups. 
HIV viral load and HIV/HCV 
co-infection were significant 
predictors of overall cognitive 
performance. HIV/HCV co-
infection was associated with 
reduced processing speed, 
learning and memory. 
HIV/HCV  HIV 
HIV/HCV  HCV 
HIV/HCV  Controls 
Garvey et al., 2012 Psychomotor function, 
identification, learning, working 
memory and executive function 
 
CogState Battery No significant differences were 
observed on overall cognitive 
tests between HIV mono-
infected and HIV/HCV co-
infected groups. 
The acute HIV/HCV co-
infection was independently 
associated with poorer 
executive function scores. 
Disturbance of cerebral 
HIV/HCV  HIV 
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metabolites were poorer in the 
acute HIV/HCV group. 
Hinkin et al., 2008 Attention/working memory, 
speed of information processing, 
learning, memory, verbal fluency, 
abstract executive functioning, 
motor/psychomotor speed 
A comprehensive battery of neuropsychological 
tests 
The HIV/HCV co-infected 
group was significantly more 
likely to be globally cognitively 
impaired than was the HIV 
mono-infected group (63% vs. 
43%). Learning and memory 
domains were the most 
impaired cognitive domains. 
HIV/HCV  HIV 
Letendre et al., 2005 Verbal fluency, attention and 
working memory, speed of 
information processing, learning, 
delayed recall, abstraction, 
problem solving and motor 
ability 
 
Letter fluency, Category fluency, Paced Auditory 
Serial Addition Task and WAIS-III Letter Number 
Sequencing, Digit Symbol, Symbol Search sub tests 
and Trail Making Test A/B, Stroop Test, Heaton 
Story Memory Test and Hopkins Verbal Learning 
Test, Heaton Figure Memory Test, Brief 
Visuospatial Memory Test, Wisconsin Card Sorting 
Test, Halstead Category Test and Grooved 
Pegboard Test 
The HIV/HCV co-infected 
group had worse cognitive 
performance, as measured by 
the GDS, which was 
independent of 
methamphetamine dependence. 
Higher HCV viral load was 
associated with neurocognitive 
impairment. 
HIV/HCV  HIV  
Martin et al., 2004 Executive functions, attention  Stroop Test The HIV mono-infected group 
was impaired on the executive 
component of the Stroop task 
while the HCV mono-infected 
group presented overall slowed 
information processing. 
NR 
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Morgello et al., 2005 Psychomotor speed, attention, 
memory, verbal fluency, 
executive function and premorbid 
cognitive function 
Grooved Pegboard Test, Trail Making Test A/B, 
Digit Symbol, Symbol Search, Letter Number 
Sequencing, Paced Auditory Serial Addition Task, 
Hopkins Verbal Learning Test, Brief Visual 
Memory Test, Wisconsin Card Sorting Test, Wide 
Range Achievement Test-3 
HIV/HCV co-infected patients 
were more likely to have 
previous history of drug 
misuse, greater impairment in 
executive function and meet 
diagnostic criteria for AIDS 
dementia when compared with 
the HIV mono-infected group. 
HIV/HCV  HIV 
Parsons et al., 2006 Attention/concentration, 
psychomotor speed, executive 
functioning, verbal memory, 
visual memory, motor 
functioning 
Paced Auditory Serial Addition Task (PASAT), 
Stroop Test, Digit Symbol, Trail Making Test A/B, 
Auditory Verbal Learning Test, Complex Figure 
Test, Finger Tapping, Timed Gait 
The co-infected group showed 
poorer visual memory and 
motor functioning than the HIV 
mono-infected group prior to 
antiretroviral therapy.  
Before cART, a greater 
percentage of co-infected 
patients performed poorly on 
the neuropsychology summary 
score (HIV/HCV: 50%; HIV: 
20%). After being exposed for 
six months to antiretroviral 
therapy, no differences were 
found between groups. 
HIV/HCV  HIV 
before cART  
 
HIV/HCV  HIV after 
cART 
 
Perry et al., 2005 Attention, concentration, 
psychomotor speed and working 
memory 
 
Trail Making Test A/B, Symbol Digit Modalities 
test, WAIS-III symbol search sub test 
No significant differences were 
found in cognitive performance 
between HIV/HCV co-infected 
and HCV mono-infected 
HIV/HCV  HCV 
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patients.  
Greater fibrosis was associated 
with poorer cognitive status. 
Rempel et al., 2013 Attention, working memory, 
information processing speed, 
executive functions, motor 
ability, verbal fluency, visual and 
verbal learning 
 
A comprehensive battery of neuropsychological 
tests 
The HIV/HCV group was 
significantly more cognitively 
impairment than the HIV and 
HCV mono-infected groups.  
HIV/HCV co-infection was 
associated with a type 1 
interferon monocyte activation 
profile that was correlated with 
cognitive impairment. 
HIV/HCV  HIV 
HIV/HCV  HCV 
HIV/HCV > Controls 
Richardson et al., 2005 Learning, recall, attention, mental 
flexibility and psychomotor speed 
Color trails, WHO/UCLA Auditory Verbal 
Learning Test, Grooved Pegboard, Symbol Digit 
Modalities Test, Visual Reproduction subtest of the 
WAIS, Mental Alternations Test 
HIV/HCV co-infected women 
had increased odds of cognitive 
impairment. 
NR 
Ryan et al., 2004 Psychomotor speed, attention, 
memory, verbal fluency, 
executive function and premorbid 
cognitive functioning 
 
Trail Making Test A/B, Grooved Pegboard Test, 
Hopkins Verbal Learning Test, Brief Visual 
Memory Test Revised, Digit Symbol, Symbol 
search, Letter Number Sequencing, Controlled Oral 
Word Association Test, Wisconsin Card Sorting 
Test, Reading sub test of the Wide Range 
Achievement Test-3 
The prevalence of impaired 
neuropsychological 
performance was equivalent in 
HIV/HCV (55%) and HIV 
mono-infected patients (53%). 
There was a trend however for 
co-infected patients perform 
poorly on neurocognitive tests. 
HIV/HCV co-infected patients 
performed worse on executive 
HIV/HCV  HIV 
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functioning and were more 
likely to present previous 
history of drug abuse than HIV 
and HCV mono-infected 
patients. 
Sun et al., 2013 General intellect, 
attention/working memory, 
information processing speed, 
executive function, fine motor 
skills, verbal fluency, visual 
learning memory, verbal learning 
memory 
 
WAIS-III digit span, Brown Peterson 18,36, 
Symbol digit oral and written, Stroop word and 
color, Wisconsin Card Sorting Test, Grooved 
Pegboard Test, Finger Tapping, Controlled Oral 
Word Association Test, Brief Visuospatial Memory 
Test, California Verbal Learning Test  
The rates of impairment based 
on GDS were higher in 
HIV/HCV co-infection (65%) 
than HCV mono-infection 
(42%), HIV mono-infection 
(29%) and controls (18%). 
HIV/HCV co-infection 
significantly increased the risk 
of cognitive impairment in 
patients with controlled HIV 
viral loads; 
HCV RNA in HCV mono-
infection was correlated with 
worsening general cognitive 
scores but not in HIV/HCV co-
infection. 
HIV/HCV  HIV 
HIV/HCV  HCV 
HIV/HCV > Controls 
Thein et al., 2007 Global cognitive function, 
psychomotor function, visual 
attention, executive function, 
learning and memory 
National Adult Reading Test, Trail Making Test 
A/B, CogState battery 
No significant difference in 
cognitive performance was 
found between study groups. 
The prevalence of impaired 
cognition was of 21% for HCV 
HIV/HCV  HIV 
HIV/HCV  HCV 
HIV/HCV  Controls 
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mono-infected patients and 
6.7% for HIV-HCV co-infected 
patients. 
Thiyagarajan et al., 2010 Psychomotor function, nonverbal 
learning, visual and divided 
attention, visual learning, 
memory, working memory and 
executive functions. Screening 
test for HIV dementia 
CogState, Prospective and Retrospective Memory 
Questionnaire, International HIV Dementia Scale 
(IHDS) 
No significant differences in 
cognitive performance were 
observed between the groups. 
However, the HIV/HCV co-
infected group reported 
significantly poorer IHDS 
scores than the HIV mono-
infected group. 
The prevalence of cognitive 
impairment was of 11% for co-
infected patients and of 22% for 
HIV mono-infected patients. 
HIV/HCV  HIV 
 
Vivithanaporn et al., 2012 Memory, executive functions, 
psychomotor function, attention, 
concentration  
Memorial Sloan Kettering Scale (MSK), Symbol 
Digit Modalities Test, Grooved Pegboard Test, Trail 
Making Test A/B 
The HIV/HCV co-infected 
group showed a higher 
prevalence of multiple 
neurologic disorders compared 
with the HIV mono-infected 
group (60.4% vs. 46.6%).  
Symptomatic HIV associated 
neurocognitive disorders were 
more severe in the co-infected 
group. 
HIV/HCV  HIV 
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von Giesen et al., 2004 Premorbid verbal intelligence, 
attention, working memory and 
screening test for HIV dementia 
MWT-b and HIV Dementia Scale  The HIV/HCV co-infected 
group performed slower in 
reaction time. No significant 
differences were found on 
cognitive status among the 
groups. 
HIV/HCV  HIV 
HIV/HCV  HCV 
 
Winston et al., 2010 Associated learning, detection 
identification, congruent reaction, 
monitoring and one card learning 
CogState battery Abnormalities in cognitive 
functions were observed with 
monitoring domain being 
impaired and significant 
reductions in RBG mI/ Cr ratio 
in acute HIV/HCV co-infected 
group 
HIV/HCV  HIV  
Note: cART; combination antiretroviral therapy; NA: Not applicable; NR: Not reported 
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Meta-analyses 
Among the studies that measured the GDS (Letendre et al., 2005; Rempel et al., 
2013; Sun et al., 2013), the meta-analysis revealed statistically significant differences 
between groups (SMD = 0.56, 95% CI: 0.36, 0.75, p < .00001). Specifically, the results 
indicated that HIV/HCV co-infected groups were more globally impaired than HIV 
mono-infected groups. No significant heterogeneity among studies was detected (Figure 
2). Due to overlapping samples of the two studies that compared HIV/HCV co-infected 
and HCV mono-infected groups, the meta-analysis was not performed. 
 
 
Figure 2. Forest plot of meta-analysis of differences between HIV/HCV co-infected and 
HIV mono-infected patients in GDS. Abbreviations: SD, standard deviation; CI, confidence 
interval 
 
In order to explore the existence of differences between HIV/HCV co-infection 
and HIV and HCV mono-infections on specific cognitive domains, data from each 
specific domain were also combined and SMD differences with 95%CI were performed. 
In the meta-analysis, two studies were included (Devlin et al., 2012; Rempel et al., 
2013). The forest plots of the assessed cognitive domains are presented in Figures 3 and 
4. 
Regarding verbal fluency, significant heterogeneity in the meta-analysis was 
detected (I2 = 61%; p = .11). Consequently, a random effects model meta-analysis was 
adopted. No significant difference between comparison groups was found (SMD = - 
0.08, 95%CI: -0.25, 0.42, p = .63). The meta-analysis of the two studies assessing 
information processing speed indicated that the HIV/HCV group was more likely to 
report impairment in this domain than the HIV mono-infected group (SMD = -0.47, 
95% CI: -0.81, -0.14, p = .006). In relation to working memory and attention, the meta-
analysis revealed no differences between HIV/HCV co-infected and HIV mono-infected 
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groups (SMD = - 0.00, 95% CI: -0.34, 0.33, p = .98). No significant heterogeneity 
among studies was detected in these two domains. 
 
 
 
Figure 3. Forest plots of meta-analyses of differences in (a) verbal fluency, (b) processing 
speed; and (c) working memory and attention between HIV/HCV co-infected and HIV mono-
infected patients. Abbreviations: SD, standard deviation; CI, confidence interval 
 
 Regarding the comparison between HIV/HCV co-infected and HCV mono-
infected patients, no significant differences were found in relation to verbal fluency 
(SMD = - 0.15, 95% CI: -0.64, 0.33, p = .53), information processing speed (SMD = - 
0.09, 95% CI: -0.57, 0.40, p = .72) and working memory and attention (SMD = 0.34, 
95% CI: -0.15, 0.82, p = .17). No significant heterogeneity among studies was detected 
in these three domains. 
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Figure 4. Forest plots of meta-analyses of differences in (a) verbal fluency, (b) processing 
speed; and (c) working memory and attention between HIV/HCV co-infected and HCV mono-
infected patients. Abbreviations: SD, standard deviation; CI, confidence interval 
 
Discussion 
The aim of this systematic review was to explore the differences in cognitive 
impairment in co-infection with HIV and HCV, being to our knowledge the first to do 
so. The main contribution of this meta-analytic review is the ascertainment of the 
magnitude of cognitive impairment among co-infected patients, in comparison with 
HIV and HCV mono-infected patients. This is particularly relevant for co-infected 
patients, as cognitive deficits can translate into significant functional consequences, 
such as patients’ difficulties in carrying out a range of important daily routines, which 
may compromise the adherence to complex treatments for HIV and hepatitis C, 
difficulties in remembering important information regarding the management of their 
disease(s), as well as reduced quality of life. 
The findings of this meta-analysis indicate that HIV/HCV co-infection is more 
reliably associated with GDS impairment than HIV mono-infection, reinforcing the 
conclusions of several individual studies (Ciccareli et al., 2013; Hinkin et al., 2008; 
Letendre et al., 2005; Rempel et al., 2013). The meta-analysis also shows that the co-
infected group has significantly poorer information processing speed than the HIV 
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mono-infected group. No differences were found between HIV/HCV co-infected and 
HCV mono-infected patients in the examined cognitive domains.  
Our meta-analysis demonstrates that HIV/HCV patients were more impaired 
than HIV mono-infected patients on the GDS, which has been suggested to be a useful 
method to summarise results of neuropsychological assessment in HIV clinical practice 
(Carey et al., 2004). This finding may reflect differences in immune biomarkers in HIV 
or HCV mono-infected patients compared to HIV/HCV patients (Kushner et al., 2013; 
Rempel et al., 2013) and suggest that the presence of HCV may have a greater impact in 
cognitive impairment in individuals co-infected with HIV, particularly when compared 
with HIV mono-infected patients. Indeed, some studies reported that HIV/HCV co-
infection was an important predictor of neurocognitive impairment, attributing the 
difference to the adverse effect of HCV on cognition mediated by HCV viral load 
(Letendre et al., 2005; Sun et al., 2013), monocyte activation (Rempel et al., 2013), 
plasma inflammatory cytokine levels (Cohen et al., 2011) or the additive effects of both 
virus on specific brain sites (Hilsabeck et al., 2005). In HIV-infected patients, HCV 
replication in the brain has been demonstrated in the frontal cortex, white matter and 
basal ganglia (Letendre et al., 2007). The acute HCV stage is characterized by an active 
HCV replication in the brain and has been associated with cognitive impairment in 
HIV/HCV (Winston et al., 2010). It has also been shown that HCV core protein 
activates human glia and potentiates HIV-associated neurotoxicity (Vivithanaporn et al., 
2010). Among HIV/HCV patients, in a study examining the white matter integrity, 
Stebbins and colleagues (2007) found a trend toward lower fractional anisotropy (FA) 
and a significant increase in mean diffusivity (MD); lower FA and higher MD values 
typically refer to reduced neuronal integrity (Martin-Thormeyer & Paul, 2009), 
therefore suggesting brain compromise among co-infected patients. However, as noted 
by the authors, a positive history of substance abuse was also common in the sample, 
which may have influenced the results. This seems to be particularly relevant to justify 
the lack of differences between HIV/HCV and HCV mono-infected groups. Indeed, in 
the studies included in the meta-analysis, the participants of both groups had significant 
rates of drug abuse (> 63%) and lifetime substance dependence. Thus, we cannot 
exclude the fact that this higher proportion of participants with history of drug misuse, 
which has been consistently associated with cognitive impairment (Martin-Thormeyer 
& Paul, 2009) may also have influenced our findings.  
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In relation to cognitive impairment in HIV, potential influencing factors may be 
incomplete viral suppression in the central nervous system (CNS) of HIV-infected 
patients, increased age, poor CNS penetration of some antiretroviral drugs, time of 
antiretroviral exposure, presence of drug resistance and psychiatric comorbidities 
(Ciccarelli et al., 2013; Nightingale et al., 2014; Rosca, Rosca, Chirileanu, & Simu, 
2011; Woods et al., 2009). It is also noteworthy that persistent cognitive impairment in 
HIV-infected stable patients is generally attributed to inflammatory influences. An 
association between inflammation, characterised by high levels of plasma cytokines, 
and cognitive impairment has been shown in HIV/HCV (Cohen et al., 2011). Moreover, 
cytokines are involved in neurodevelopmental processes (McAfoose & Baune, 2009). 
Another mechanism involved in cognitive impairment is immunosuppression; 
particularly, nadir CD4+ T-cells have been suggested to be an indicator of cognitive 
decline. For example, ANI has been associated with an increased in risk for earlier 
development of symptomatic HAND (Grant et al., 2014). The authors of this study also 
noted that those patients with ANI had evidence of lower nadir CD4+ T-cells and were 
more likely to develop everyday life problems. 
Overall, the diverse findings abovementioned are noteworthy and represent 
important advances in understanding the mechanisms underlying cognitive deficits in 
HIV and HCV mono-infections. However, as the CNS may be compromised by these 
comorbid medical conditions via additive or synergistic processes, the field of 
HIV/HCV co-infection and the study of joint mechanisms in cognitive impairment 
would still benefit from additional research. 
This review also indicates that the HIV/HCV group reported more impairment in 
information processing speed than the HIV mono-infected group. Information 
processing speed describes the ability to rapidly process serial cognitive operations; 
when impaired, information processing speed interferes negatively with other cognitive 
processes due to the reduction of available information needed and the limited time for 
task execution (Salthouse, 1996). Earlier studies have reported impairment in this 
domain as a cognitive marker of HIV-associated dementia, reflecting its broad impact 
on cognitive flexibility (Becker & Salthouse, 1999). An association between HCV 
chronic infection and impairment in processing speed has been also reported (Cherner et 
al., 2005; Vigil et al., 2008). A possible explanation for greater impairment in the co-
infected patients may be the higher risk of neurotoxicity due to CNS insults by both 
viruses in fronto-striatal areas. Particularly, high levels of HIV have been found in the 
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basal ganglia (notably the substantia nigra) and fronto-cortical areas (Kumar, 
Borodowsky, Fernandez, Gonzalez, & Kumar, 2007), and it has been shown that fronto-
striatal neuronal circuitry mediates processing speed (e.g., Fellows, Byrd, & Morgello, 
2014; Kumar, Ownby, Waldrop-Valverde, Fernandez, & Kumar, 2011; Salthouse, 
1996). Additionally, there is evidence that fronto-striatal circuits are rich in 
dopaminergic activity and it is hypothesised that dopamine depletion exacerbates 
processing speed impairment in HIV (Kumar et al., 2011). 
Some limitations in this review should be acknowledged. First, the literature 
search was restricted to articles written in English. Second, only few studies with 
consistent measurement methods were identified. The lack of the consistency in the 
cognitive domains and measures, as well as the inability to compile a GDS from the 
information supplied, resulted in a rather small number of studies included in the meta-
analysis. Methodological differences between the studies should also be noted, 
including the great heterogeneity of the samples’ characteristics, the relatively small 
sample sizes, the predominance of studies with cross-sectional design and the large 
variability of cognitive measures and domains. Although the inclusion of studies of 
varying quality is common in most meta-analyses, these biasing factors are noteworthy 
and require some caution in the interpretation of the cumulative results. Studies on 
neurocognitive complications of HIV/HCV (as in the general HIV context) are 
essentially based on studies involving men, and women are still under-represented in 
neuropsychological studies. Moreover, it is notable that most studies were conducted in 
the USA (17 out of 24), and very limited research has been conducted in other settings 
where these diseases are more widespread. 
Illicit drug use causes deficits in cognition and in combination with mental 
health disorders and social/behavioural factors may exacerbate cognitive impairment 
(Gill & Kolson, 2014; Martin-Thormeyer & Paul, 2009). The variability of age across 
studies may also affect the classification and rate of patients classified as cognitively 
impaired. It is possible that HIV-related cognitive impairment reported in this study 
may be impacted by either advanced age (Rempel et al., 2013; Sun et al., 2013) or by 
the emergence of cognitive decline due to AIDS indicator conditions (Letendre et al., 
2005). Another relevant factor relates to cognitive reserve (CR), which was been 
demonstrated to modulate cognitive impairment (Stern, 2003), and that has been shown 
to be protective factor of cognitive impairment, both in HIV (Foley et al., 2012; Morgan 
et al., 2012; Vázquez-Justo, Piñón, Vergara-Moragues, Guillén-Gestoso, & Pérez-
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García, 2014) and HCV (Sakamoto et al., 2013). In future research, it will be important 
to include appropriate controls/comparison groups, longitudinal follow-up of cohorts 
with repeated measures, comprehensive neuropsychological batteries, as well as social 
and behavioural factors and levels of cognitive reserve that may increase the prevalence 
of cognitive impairment. This will be a significant opportunity to determine whether 
these effects are independent or additive, to identify similarities and differences in the 
neuropsychological patterns of HIV/HCV co-infected and HIV and HCV mono-infected 
patients, as well as to clarify the discrepancies of the prevalence rates of cognitive 
impairment reported in the literature.  
In conclusion, HIV and HCV infections have detrimental effects on 
neurocognitive function, which in turn may have a significant impact on patients’ 
quality of life and overall functioning, adherence to treatments, and management of risk 
behaviours. Patients with HIV and HCV usually present several cofactors, where 
interactions and cumulative effects may well increase their vulnerability to cognitive 
impairment. Therefore, biological, behavioural and social risk factors that could 
influence cognitive dysfunction need to be defined more accurately and will require 
special clinical attention. Moreover, with greater understanding of cognitive 
dysfunction, new avenues for treatment and prevention can be developed, as this 
knowledge may contribute to improve disease(s) management and optimise medication 
adherence, to facilitate treatment decision-making, to reduce risk behaviours and, 
ultimately, to maximise the patients’ health outcomes. 
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2.2. Depression in HIV and HCV co-infected patients: A systematic review and 
meta-analysis 
 
Abstract 
 
Depression has long been acknowledged as a significant predictor of negative clinical 
outcomes in HIV and hepatitis C infections. Patients with both viruses may be however 
at increased risk. The aim of this study was to carry out a systematic review and meta-
analysis of the differences in the prevalence of depression and presence of depressive 
symptoms between HIV/HCV co-infection, HIV mono-infection, and HCV mono-
infection. A systematic electronic search of bibliographic databases was performed to 
locate articles published from the earliest available online until December 2014. 
Prospective and retrospective studies were included. Outcomes of depression were 
based on clinical interviews and validated self-reported measures of 
depression/depressive symptoms. Of the 188 records initially screened, 29 articles were 
included in the descriptive systematic review and six were included in the meta-
analysis. Consistent with the individual conclusions of the studies included in the 
descriptive review, the meta-analytic results indicated that, as measured by self-reported 
measures of depression, HIV/HCV co-infected patients were significantly more likely to 
report depressive symptoms than either HIV (SMD = 0.24, 95% CI: 0.03-0.46, p = .02) 
or HCV mono-infected (SMD = 0.55, 95% CI: 0.17-0.94, p = .005) patients. The 
variability of the results of the reviewed studies, largely dependent on the samples’ 
characteristics and the methods of assessment of depression, suggests that a clear 
interpretation of how depression outcomes are affected by the presence of HIV/HCV 
co-infection is still needed. Failing to diagnose depression or to early screen depressive 
symptoms may have a significant impact on patients’ overall functioning and 
compromise treatments’ outcomes. 
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Introduction 
Depression is the most common neuropsychiatric manifestation in HIV infection 
(Nanni, Caruso, Mitchell, Meggiolaro, & Grassi, 2015). A meta-analysis examining the 
risk for depression in HIV found that HIV-infected patients were more likely to have 
had an episode of major depressive disorder (MDD) than HIV-negative patients (Ciesla 
& Roberts, 2001). Regarding hepatitis C virus (HCV) infection, there is also evidence 
of an increased prevalence of neuropsychiatric disorders, with depression being one of 
the most significant disorders during hepatitis C treatment as well as in untreated HCV-
infected patients (Schaefer et al., 2012). The high prevalence of psychiatric 
comorbidities in HCV-infected patients has been associated with direct effects of the 
virus on the central nervous system (Raison et al., 2009) or adverse effects of hepatitis 
C treatment (Udina et al., 2012). Because the diagnosis of MDD during interferon 
treatment if often missed (Leutscher et al., 2010) and depression is a well-known risk 
factor for treatment failure (Schaefer et al., 2012), a timely screening and treatment of 
depression is of major relevance. 
This may be more complex in the presence of HIV/HCV co-infection. This is 
particularly important because dual-diagnosed patients may face numerous emotional 
and psychosocial stressors (e.g., adjustment to and management of two chronic medical 
conditions, coping with stigma and discrimination, and coping with changes in 
relationships and social networks), which pose unique challenges for mental health 
providers (Silberbogen, Ulloa, Janke, & Mori, 2009). However, the prevalence of 
depression and depressive symptoms in HIV/HCV has been less studied, and the 
comparison with mono-infected populations yielded heterogeneous findings. 
Summarizing the results of studies comparing the prevalence of depression among co-
infected patients with HIV and HCV mono-infected patients is needed to improve 
current understanding of the consequences of depression/depressive symptoms for dual-
infected patients, particularly because of the evidence suggesting that depressive 
symptoms may compromise antiretroviral treatment compliance (Roux et al., 2013) and 
add complexity to treatment planning (Baillargeon et al., 2008). This knowledge is also 
of major importance, as it may allow for a closer monitoring of co-infected patients, 
who may be at increased risk of poorer mental health and thus may benefit from 
additional psychosocial support or antidepressant treatment. 
Accordingly, the aim of this study was to carry out a systematic review and 
meta-analysis of the differences in the prevalence of depression and of depressive 
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symptoms between HIV/HCV co-infected, HIV mono-infected, and HCV mono-
infected patients.  
 
Methods 
 
Search strategy  
The Cochrane Central Registered of Control Trials Library, SCOPUS, Medline 
and PsycINFO were systematically searched for records from the earliest data available 
online to December 2014. Each database was searched separately. The key terms 
“depress*” AND “HIV - HCV co-infection” were used, combining search strategies 
using Boolean operator (AND) and (*) related terms. The search was supplemented 
with additional information from reference lists and contact with the authors in the field 
of depression and HIV/HCV co-infection. The selection was limited to English 
publications only. The study was designed according to the PRISMA statement (Figure 
1; Moher, Liberati, Tetzlaff, & Altman, 2009). 
 
Eligibility criteria 
Study inclusion criteria were: (1) Type of studies: prospective and retrospective 
studies assessing depression or presence of depressive symptoms in HIV/HCV co-
infection; (2) Participants: individuals diagnosed with HIV/HCV and control subjects 
from these studies with either HIV or HCV mono-infection; (3) Interventions: with and 
without HCV treatment; and (4) Primary outcome: incidence of depression/depressive 
symptoms in co-infected patients, including during HCV treatment, as assessed by 
clinical interview or any validated depression measure. Secondary outcome: any other 
reported assessment measure of depressive symptoms. The following exclusion criteria 
were applied: (1) studies with participants under 18 years; (2) post-mortem studies; (3) 
articles with overlapping samples (samples duplicated in different research reports); and 
(4) articles not written in English. 
 
Data extraction 
Two authors (RF and MP) independently reviewed all references from electronic 
and non-electronic sources, selected the relevant studies for the review and extracted 
relevant data. Disagreements were resolved by discussion. The following information 
was extracted from each study: year of publication, country, design, sample size, 
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population characteristics (e.g., age, gender, past and/or current intravenous drug use 
(IDU) or IDU as risk factor for infection acquisition), measures to assess 
depression/depressive symptoms and prevalence of MDD and/or symptoms of 
depression. To assess the risk of bias, a checklist was developed based on a quality 
assessment instrument, and included the following parameters: objectives explicitly 
stated, selection and representativeness of the study samples, inclusion/exclusion 
criteria, clear identification of measures, data adequately reported, and discussion 
addressing the primary outcome and validity of depression measures (Higgins & Green, 
2011). 
 
Data analysis 
All studies meeting eligibility criteria were included in the systematic review. Of 
these, a sub-set of six studies with available data to perform statistical synthesis and 
appropriate control groups were entered into the meta-analysis. Meta-analysis 
quantifying the differences in depression outcomes between HIV/HCV, HIV and HCV 
mono-infected groups was performed with the Review Manager, version 5.3. Because 
studies whose results were combinable used different measures to assess depressive 
symptoms, the standardised mean difference (SMD) between HIV/HCV and control 
groups and its associated 95% confidence interval (CI) were computed as the summary 
statistic for the estimate of effects. The heterogeneity between-studies was assessed by 
computing the 2 and I2 statistics. An I2 of 0% indicates no heterogeneity and a value 
above 50% is considered as substantial heterogeneity (Higgins, Thompson, Deeks, & 
Altman, 2003). Though moderate to substantial heterogeneity was identified, as 
suggested by Higgins and Green (2011), both fixed and random-effects models were 
used for testing differences in the summary effects. 
 
Results  
 
Study selection and quality of studies 
 The study selection process is described in Figure 1. Briefly, the electronic 
search identified 188 records. After removal of duplicated articles (n=18), 170 were 
subjected to abstract review. One hundred and thirty-one were excluded, leaving 39 
articles for full-text review and further assessment of eligibility. Twenty-nine papers 
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fulfilled the inclusion criteria and were included in the systematic review. Six of those 
studies were included in the quantitative analysis. Selected studies were published 
between 2001 and 2014. 
 
Figure 1. Flow diagram outlining the study selection process 
 
 For all studies included in the review, a low risk of bias was observed when 
considering the identification of the studies’ aims, definition of inclusion and exclusion 
criteria, reporting of results, and discussion of the main outcomes. However, low-
moderate to high bias was found regarding the selection of participants (e.g., a 
systematic difference between the characteristics of groups that were compared was 
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identified), which limited their representativeness, as well as in identification of the 
procedures associated with how outcomes were determined (e.g., in six studies it was 
not clear how depression was assessed). Regarding the six studies included in the meta-
analysis, with the exception of two studies (Richardson et al., 2005; von Giesen et al., 
2004), in which systematic differences between the comparison groups were identified, 
a low risk of bias was observed. 
 
Study characteristics  
This systematic review covers 29 studies from eight countries (one study from Italy and 
Portugal, two studies from Australia, France and Germany, three studies from Canada 
and Spain, and 15 studies from the USA). The number of co-infected participants 
ranged between 15 and 6,782. Study designs were mostly cross-sectional (n = 16, 
55.2%) and included only a HIV/HCV group (n = 10, 34.5%) or a comparison between 
co-infected and HIV mono-infected groups (n = 10, 34.5%). Most studies included both 
male and female participants and one study included only females (Richardson et al., 
2005). The proportion of co-infected males ranged between 65.1% (von Giesen et al., 
2004) and 100% (Pantalone, Hessler, Bankoff, & Shah, 2012; Sun et al., 2013; Thein et 
al., 2007). Among co-infected patients, the proportion of participants reporting IDU 
(past and/or current) ranged between 31.5% (Pantalone et al., 2012) and 94% (Landau 
et al., 2001). In 18 studies, the proportion of IDU was above 60%. General 
characteristics and comparison groups in each study are described in Table 1.  
 
Descriptive analysis 
A summary of the relevant findings of the 29 studies included in the descriptive 
analysis is presented in Table 2 and briefly described above. 
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Table 1. General characteristics of the 29 studies included in the systematic review 
Authors, Year Country  Design  Sample (N) 
Gender (% 
male) 
Agea  IDU 
Alavi et al., 2012 Australia  Prospective cohort Total = 163 71%  34.3 ± 9.9 76% history IDU 
   HIV/HCV = 50    
Backus et al., 2005 USA Retrospective cohort HIV = 11,567 97.4%  47.9 ± 10.3 20.6% hard drug abuse 
   HIV/HCV = 6,782 98.3%  49.8 ± 6.3 62.9% hard drug abuse 
Baillargeon et al., 
2008 
USA Prospective cohort HIV = 3,783 83.2%  NR NR 
   HIV/HCV = 2,275 87%  NR NR 
Baum et al., 2008 USA Cross-sectional HIV = 135 75.6%  41.0 ± 7.3 10.3% history IDU 
   HIV/HCV = 57 71.9%  45.4 ± 6.5 40.3% history IDU 
Braitstein et al., 2005 Canada  Cross-sectional HIV = 379 97%  43 (mean) 5% history IDU 
   HIV/HCV = 105 82%  42 (mean) 79% history IDU 
Butt et al., 2006 USA Retrospective cohort HCV = 114,005 96.9%  50 38.9% 
   HIV/HCV = 6,502 98.2%  48 56.2% 
Butt et al., 2009 USA Prospective cohort HCV = 241 58.5%  49.7 ± 10.9 50.6% recent IDU 
   HIV/HCV = 158 81.6%  48.4 ± 7.4 60.2% recent IDU 
Ciccarelli et al., 2013 Italy  Cross-sectional HIV = 50 64%  48 (45-53)b 4% history IDU 
   HCV = 50 72%  48 (42-52)b 38% history IDU 
   HIV/HCV = 50 78%  48 (42-55)b 78% history IDU 
Clifford et al., 2005 USA Cross-sectional HIV = 234 80%  38.05 ± 8.63 4% history IDU 
   HIV/HCV = 30 77%  40.27 ± 7.75 47% history IDU 
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Fumaz et al., 2007 Spain  Prospective longitudinal Peg-IFN a-2a = 32 71.8%  40.7 ± 4.08 78.1% IDU risk factor 
   Peg-IFN a-2b = 31 67.7%  39.2 ± 5.03 90.3% IDU risk factor 
Goulet et al., 2005 USA Retrospective cohort HIV = 20,627 94%  47.1 (median) 22%c 
   HIV/HCV = 4,489 98%  46.9 (median) 58%c 
Kemmer et al., 2012 USA Prospective longitudinal HIV/HCV = 329 83.3%  48 (median) NR 
Klein et al., 2014 Canada  Randomized, double-blind 
placebo-controlled trial 
Citalopram = 36 72.2%  45.6 (38.7–50.9)b 52.8% IDU risk factor 
   Placebo = 40 100%  46.7 (42.6–52.9)b 47.5% IDU risk factor 
Laguno et al., 2004 Spain  Randomized open-label Peg-IFN a-2b + RBV = 52 63%  40 (mean) 75% IDU risk factor 
   IFN a-2b + RBV = 43 74%  40 (mean) 91% IDU risk factor 
Landau et al., 2001 France  Prospective longitudinal HIV/HCV = 51 76.5%  39 ± 5 (30-59) 94% 
Michel et al., 2010 France  Cross-sectional HIV/HCV = 328 69.8%  42 (40-46)b 63.6% IDU risk factor 
Moreno et al., 2004 Spain  Prospective longitudinal HIV/HCV = 35 69%  38 (35-39)b 83% IDU risk factor 
Myers et al., 2004 Canada  Open-label study HIV/HCV = 32 78%  40 ± 6 (26-55) 78% history IDU 
Pantalone et al., 2012 USA Cross-sectional HIV = 117 100%  43.75 ± 8.80 6.1% IDU risk factor 
   HIV/HCV = 54 100%  44.80 ± 7.66 31.5% IDU risk factor 
Pereira et al., 2014 Portugal  Cross-sectional HIV = 462  41.19 ± 10.01 19.5% IDU risk factor 
   HIV/HCV = 248  38.75 ± 6.54 68.8% IDU risk factor 
Richardson et al., 
2005 
USA Cross-sectional HIV = 75 100% female 33.8 ± 7.2 NR 
   HCV = 27 100% female 37.3 ± 9.2 NR 
   HIV/HCV = 70 100% female 39.6 ± 6.5 NR 
Rockstroh et al., 2002 Germany  Prospective longitudinal HIV/HCV = 23 78.3%  42 (median) NR 
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Ryan et al., 2004 USA Cross-sectional HIV = 49 77.6%  41.9 ± 7.2 NR 
   HIV/HCV = 67 73.1%  45.1 ± 7.2 NR 
Sulkowski et al., 2004 USA Randomized open-label Daily IFN + RBV = 90 77.8%  43.7 ± 5.7 57.8% history IDU 
   TIW IFN + RBV = 90 74.4%  43.7 ± 8.6 65.6% history IDU 
Sun et al., 2013 USA Cross-sectional HIV = 14 100%  51.6 ± 7.2 NR 
   HCV = 19 100%  56.6 ± 4.5 63% history IDU 
   HIV/HCV = 17 100%  54.5 ± 5.2 71% history IDU 
Tavakkoli et al., 2013 USA Cross-sectional HCV = 65 56.9% 47.5 ± 7.1 50.8% 
   HIV/HCV = 102 75.5% 49.7 ± 9.6 54.9% 
Thein et al., 2007 Australia Cross-sectional HIV = 30 100%  34.7 ±7.4 NR 
   HCV = 19 63.2%  42.6 ±6.5 89.5% history IDU 
   HIV/HCV = 15 100% 35.5± 7.0 86.7% history IDU 
von Giesen et al., 
2004 
Germany  Cross-sectional HIV = 43 65.1% 38.0 ± 8.1 62.8% IDU risk factor 
   HCV = 44 35.6% 43.2 ± 13.7 18.2% IDU risk factor 
   HIV/HCV = 43 65.1% 37.4 ± 7.8 62.8% IDU risk factor 
Yoon et al., 2011 USA Cross-sectional HIV = 604 88% 45 (median)  15% IDU risk factor 
   HIV/HCV = 160 83%  63% IDU risk factor 
NR: Not reported; RBV: Ribavirin; Peg-INF: pegylated interferon; INF: interferon; TIW: thrice-weekly. 
a Unless indicated, data are presented as mean ± SD (or range); b Data is presented as Median (Interquartile range); c Comorbid drug disorder 
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Table 2. Synthesis of findings on depression/depressive symptoms of the 29 studies included in the systematic review 
Authors, Year Depression measures Main Findings 
Alavi et al., 2012 Mini International Psychiatric Interview 
(MINI). 
Depression, Anxiety and Stress Scale 
(DASS-21) 
Before HCV treatment, at baseline, the co-infected group was significantly less 
depressed than the HCV mono-infected group. During treatment, the prevalence of 
new-onset depression was higher among the co-infected group when compared with 
the HCV mono-infected group (38% vs. 33%), but the difference was not significant.  
Backus et al., 2005 Clinical notes based on the International 
Classification of Diseases, 9th Revision 
(ICD9) 
Both co-infected and HIV mono-infected patients presented high prevalence of 
mental illness, particularly depression. However, the HIV/HCV co-infected group 
was more likely to present a diagnosis of depression, alcohol abuse and substance 
abuse compared with the HIV mono-infected group.  
Baillargeon et al., 2008 Clinical appointments using the 
International Classification of Diseases 
(ICD-10) 
In comparison to HIV mono-infected inmates, those with HIV/HCV co-infection had 
an elevated prevalence of any psychiatric disorder (20.6% vs. 16.7%). No increased 
odds were observed in relation to Major Depression (8.4% vs. 7%).  
Baum et al., 2008 NR In comparison to HIV mono-infected patients, the HIV/HCV co-infected patients 
reported depression (36.8% vs. 8.1%), fatigue, headache, diarrhoea and apathy as the 
most prevalent physical and mental health symptoms.  
Braitstein et al., 2005 Centre for Epidemiologic Studies 
Depression Scale (CESD) 
The co-infected group showed higher scores on symptoms consistent with 
depression, increased fatigue and poorer quality of life. The impact of HCV on 
quality of life, depression and fatigue was better explained by socio-demographic 
factors related to poverty and IDU than by HCV itself.  
Butt et al., 2006 Clinical notes using the ICD9 codes The HIV/HCV co-infected group were more frequently diagnosed with major 
depression (23% vs. 18.4%) and mild depression (35.4% vs. 32.4%) than the HCV 
mono-infected group. Additionally, depression was associated with a lower 
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likelihood of hepatitis treatment prescription.  
Butt et al., 2009 Structured questionnaires  HIV/HCV co-infected patients were more likely to be depressed (67.4% vs. 39.9%) 
and tended to present higher prevalence of ongoing alcohol abuse than HCV mono-
infected patients.  
Ciccarelli et al., 2013* Zung Depression Scale  No significant differences were found in the depression scores between HIV/HCV 
co-infected groups and the HIV and HCV mono-infected groups.  
Clifford et al., 2005* Centre for Epidemiologic Studies 
Depression Scale (CESD) 
The HIV/HCV co-infected group presented significantly more depressive 
symptomatology than the HIV mono-infected group (57% vs. 32%).  
Fumaz et al., 2007 Beck Depression Inventory (BDI) Among HIV/HCV co-infected patients, there were no significant differences in 
depression scores between types of hepatitis C treatment; however, the rates of 
depressive symptoms were high in both groups during treatment (overall, 58.7% of 
patients presented mild to moderate depressive symptoms).  
Goulet et al., 2005 Clinical notes using the ICD9 codes The HIV/HCV co-infected patients were significantly more likely to have psychiatric 
disorders, including depression (43% vs. 28%), than HIV mono-infected patients. 
Kemmer et al., 2012 Centre for Epidemiologic Studies 
Depression Scale (CESD) 
Depression was significantly associated with a decline in role, social and cognitive 
function in HIV/HCV co-infection.  
Klein et al., 2014 Beck Depression Inventory-II (BDI-II) 
Montgomery–Åsberg Depression Rating 
Scale (MADRS) 
Structure Clinical Interview for DSM-IV 
Axis I Disorders (SCID-I) 
Prophylactic citalopram compared to treatment of emergent depression was not 
associated with a reduction in treatment-limiting depression, nor did significantly 
reduce depressive symptoms among HIV/HCV co-infected patients during hepatitis 
C treatment.  
Laguno et al., 2004 World Health Organization Scale A high incidence of depressive symptoms was reported among HIV/HCV co-infected 
patients (43%); however, most of them were not severe and improved with 
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antidepressant therapy, without reduction or cessation of hepatitis C treatment. 
Landau et al., 2001 NR Depressive symptoms were reported in 8% of HIV/HCV co-infected patients under 
hepatitis C treatment.  
Michel et al., 2010 Centre for Epidemiologic Studies 
Depression Scale (CESD) 
Depressive symptoms and treatment for depressive symptoms was significantly 
associated with the cognitive, social and physical dimensions of fatigue impact.  
Moreno et al., 2004 World Health Organization Scale A prevalence of 9% of depression was reported as an adverse event during hepatitis C 
treatment. 
Myers et al., 2004 NR Psychiatric manifestations were the main reason for discontinuation of hepatitis C 
treatment (19%); depression was the most common reason for discontinuation, 
followed by agitation and delirium and anxiety.  
Pantalone et al., 2012* Centre for Epidemiologic Studies 
Depression Scale (CESD) 
Depression scores were elevated in HIV mono-infected and HIV/HCV co-infected 
groups; HIV/HCV co-infected MSM were significantly more depressed than HIV 
mono-infected MSM.  
Pereira et al., 2014 Brief Symptom Inventory (BSI) HIV/HCV co-infected patients reported significantly higher scores on the subscale 
Depression of the BSI than HIV mono-infected patients. As well, compared to HIV 
mono-infected patients, a greater proportion of HIV/HCV co-infected patients met 
caseness for depression (17.7% vs. 12%). 
Richardson et al., 2005* Centre for Epidemiologic Studies 
Depression Scale (CESD) 
The depression scores were not significantly different between HIV/HCV, HIV and 
HCV mono-infected groups.  
Rockstroh et al., 2002 NR During hepatitis C treatment, 3 out of 9 patients developed depression, which resulted 
in treatment discontinuation.  
Ryan et al., 2004 Psychiatric Research Interview for 
Substance and Mental Disorders (PRISM) 
There were no significant differences on the prevalence of primary mental disorders 
between HIV/HCV co-infected and HIV mono-infected patients. However, past and 
 
 
89 
 
current depression was the most common diagnosis in both groups. 
Sulkowski et al., 2004 NR Depression was observed in patients during hepatitis C treatment among HIV/HCV 
co-infected patients. 
Sun et al., 2013* Beck Depression Inventory (BDI-II) The HIV/HCV co-infected group was found to have significantly more depressive 
symptoms than the HCV mono-infected group and the healthy controls, after 
adjusting for education and general intellect (IQ). 
Tavakkoli et al., 2013 Patient Health Questionnaire -9 (PHQ-9) A diagnosis of major depression was significantly less common among HIV/HCV 
co-infected patients, in comparison to HCV mono-infected patients (24.7% vs. 
41.4%). 
Thein et al., 2007 Depression Anxiety Stress Scales (DAAS) The mean DAAS scores were similar between HIV/HCV co-infected, HIV and HCV 
mono-infected patients and uninfected controls prior to hepatitis C treatment. 
von Giesen et al., 2004* Hamilton Depression Rating Scale 
(HAMD) 
HCV mono-infected patients presented significantly lower scores of depression than 
HIV mono-infected and HIV/HCV co-infected patients.  
Yoon et al., 2011 Patient Health Questionnaire -9 (PHQ-9) A high prevalence and severity of depression was found among HIV/HCV co-
infected patients, even adjusting for differences in substance use. The mean 
depression severity scores for HIV/HCV patients were 3.4 points higher than for HIV 
mono-infected patients; the association between HCV and greater depression severity 
remained significant even adjusting for antidepressant medication and current illicit 
drug use. 
* Studies included in the meta-analyses 
NR: Not reported; MSM: Men who have sex with men 
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Depression in HIV/HCV patients without HCV treatment 
A total of 18 studies assessed depression among co-infected patients outside 
HCV treatment. The three retrospective studies used the International Classification of 
Diseases (ICD-9) codes to assess depression. Of these, two studies reported that co-
infected patients had a higher prevalence of depression than HIV mono-infected patients 
(Backus, Boothroyd, & Deyton, 2005; Goulet, Fultz, Mcginnis, & Justice, 2005) and 
one study found that the co-infected group had a higher prevalence of depression than 
the HCV mono-infected group (Butt, Justice, Skanderson, Good, & Kwoh, 2006). 
Cross-sectional and prospective studies similarly indicated that co-infected 
patients were more likely to report depressive symptoms than HIV mono-infected 
patients (Baillargeon et al., 2008; Baum, Jayaweera, Duan, & Ms, 2008; Braitstein et 
al., 2005; Butt et al., 2009; Clifford, Evans, Yang, & Gulick, 2005; Pantalone et al., 
2012; Pereira, Fialho, & Canavarro, 2014; Sun et al., 2013; Yoon et al., 2011) and HCV 
mono-infected patients (Sun et al., 2013). In three studies no significant differences 
were found between the co-infected group and the HIV and HCV mono-infected groups 
(Ciccarelli et al., 2013; Richardson et al., 2005; Thein et al., 2007), and one study did 
not find differences between co-infected and HIV mono-infected patients (Ryan et al., 
2004). Additionally, one study indicated that depression was associated with HIV 
illness progression in co-infection (Michel et al., 2010). Tavakkoli and colleagues 
(2013) found that a diagnosis of major depression was significantly less common 
among HIV/HCV patients than among HCV mono-infected patients. 
 
Depression in HIV/HCV patients during HCV treatment 
 Ten studies assessed depression during hepatitis C treatment. Alavi and 
colleagues (2012) described similar proportions of new-onset depression during 
treatment between HCV mono-infected (33%) and co-infected patients (38%). Fumaz 
and colleagues (2007) indicated that 59% of co-infected patients as having treatment-
emergent mild or moderate depression. One study showed that depression did not 
influence treatment outcomes (Alavi et al., 2012) and another indicated that increased 
depressive symptoms was significantly associated with reduced role, social and 
cognitive functioning (Kemmer et al., 2012). Six studies reported occurrence of 
depression during HCV treatment (Laguno et al., 2004; Landau et al., 2001; Moreno et 
al., 2004; Myers et al., 2004; Rockstroh et al., 2002; Sulkowski et al., 2004) and five 
indicated depression as cause of treatment discontinuation (Laguno et al., 2004; Landau 
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et al., 2001; Moreno et al., 2004; Myers et al., 2004; Rockstroh et al., 2002). Klein and 
colleagues (2014) found that prophylactic citalopram compared to treatment of 
depression was not associated with reduce depression symptoms among co-infected 
patients. 
 
Meta-analysis: Depression in HIV/HCV vs. HIV and HCV mono-infection 
 Six out of the 29 studies included data enabling meta-analysis. Because in these 
studies, depressive symptoms were assessed with different measures (see Table 2), 
SMD were computed as the summary statistic for the estimate of effects. 
The meta-analysis (random-effects model) comparing HIV/HCV and HIV 
mono-infected patients indicated a significant difference between groups, showing that 
the HIV mono-infected groups were less likely to report symptoms of clinical 
depression than the HIV/HCV co-infected groups (SMD = 0.24, 95%CI: 0.03-0.46, p = 
.02). Similarly, the meta-analysis comparing HIV/HCV and HCV mono-infected groups 
indicated that the latter groups were less likely to exhibit depressive symptoms than the 
co-infected groups (SMD = 0.55, 95%CI: 0.17-0.94, p = .005) (see Figure 2). In both 
comparisons, moderate to substantial heterogeneity was found (I2 range = 39%-62%). 
Data analysis using fixed-effects models yielded similar results in the comparison with 
HIV mono-infected (SMD = 0.24, 95%CI: 0.08-0.40, p = .004) and HCV mono-infected 
groups (SMD = 0.53, 95%CI: 0.30-0.76, p <.00001). 
 
 
Figure 2. Forest plots of meta-analyses of differences in depression outcomes between 
study groups. Abbreviations: SD, standard deviation; CI, confidence interval 
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Discussion 
 In this first systematic review and meta-analysis examining the prevalence of 
depression and depressive symptoms among patients co-infected with HIV and hepatitis 
C, in comparison to HIV and HCV mono-infected patients, the main findings indicate a 
significant difference in depression outcomes between the comparison groups, and 
suggest that patients co-infected with HIV and HCV are more likely to report depressive 
symptoms than those with mono-infections. 
Our results indicate a relevant prevalence of depression/depressive symptoms 
among co-infected patients, and suggest that the stigmatisation and strain of living with 
HIV is likely to be greater when coexisting with other medical conditions. Potential 
explanations for this result may be related to well-known psychosocial factors that are 
common among co-infected patients, such as the higher prevalence of past history of 
IDU, ongoing alcohol and drug abuse (Backus et al., 2005; Clifford et al., 2005) and 
greater psychiatric comorbidity (Backus et al., 2005; Pereira et al., 2014). These factors, 
cumulatively with antiviral treatments and its side-effects are likely to increase the 
vulnerability of developing mental health disorders of co-infected patients, particularly 
in comparison with mono-infected patients. Interestingly, our findings indicated that the 
SMD was greater in the comparison between HIV/HCV and HCV mono-infected 
patients. This may be associated with the findings of one study (von Giesen et al., 
2004), in which the mean score on depression was significantly lower among HCV 
mono-infected patients (2.34 vs. 6.86), probably because of the lower proportion of 
mono-infected patients reporting IDU as risk factor (18.2% vs. 62.8%). 
It is also likely that depression may represent a behavioural side effect of these 
viruses. For instance, research demonstrated that depression associated with HIV is in 
part driven by immune dysregulation, characterized by an increased production of pro 
inflammatory cytokines and proliferation of immune cells (Nasi, Pinti, Mussini, & 
Cossarizza, 2014). Recent evidence also suggested that in a healthy brain, inflammation 
is an acute and controlled process; but when inflammation is chronic, it may contribute 
to the development of depression (Jones & Thomsen, 2013). HCV chronic infection 
also represents a chronic inflamed state that is maladaptive and that has been associated 
witg an elevated choline/creatine ratio in basal ganglia and white matter, depression and 
cognitive dysfunction (Forton et al., 2008; Weissenborn et al., 2004). Since these same 
changes would be anticipated in both HIV and HCV, the fact that co-infected patients 
were more depressed than HIV and HCV mono-infected groups also seems to suggest 
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that these inflammation-related changes may represent a determinant factor of 
depression emergence. 
Retrospective studies consistently shown a significant prevalence of depression 
among co-infected patients, and significantly higher than the comparison groups 
(Backus et al., 2005; Butt et al., 2006; Goulet et al., 2005). The sample sizes of these 
studies were large suggesting the relevance of the findings. However, retrospective 
studies may be vulnerable to information bias that can negatively impact the reported 
outcomes, such as non-standardized observations, use of different measures for 
assessing depression, and multiple information sources from clinical notes. It is notable 
that all retrospective studies included veterans with overlapping mental illness 
comorbidities, which reduces the generalizability of the findings to other populations. 
Regarding the descriptive narrative of prospective studies, mixed findings were 
reported. Some studies found that co-infected groups reported higher depression levels 
(or symptoms of depression) than mono-infected groups (e.g., Baillargeon et al., 2008; 
Pereira et al., 2014; Sun et al., 2013) but others did not find such differences (e.g., 
Ciccarelli et al., 2013; Thein et al., 2007). These differing findings may be related to 
several factors, including studies’ differences in methodological approaches (e.g., study 
design, variations in the diagnostic/screening tools for assessing depression) and 
samples’ characteristics. It is noteworthy that most studies included significant 
proportions of participants reporting IDU as a risk factor. However, there is also 
evidence suggesting changes in the epidemiological patterns of co-infection, 
particularly a higher incidence of HCV among HIV-infected men who have sex with 
men (MSM; Pantalone et al., 2012; van de Laar, Matthews, Prins, & Danta, 2010). 
Thus, future studies considering this emerging sexually transmitted infection are 
warranted, particularly because of recent evidence suggesting an association between 
depressive symptoms and higher engagement in sexual risk-behaviours among HIV-
infected MSM (O’Cleirigh et al., 2013). 
Studies in the context of HCV treatment indicated that depression was common 
(Alavi et al., 2012; Fumaz et al., 2007) and considered depression to be a risk factor for 
discontinuation of HCV treatment among co-infected patients (e.g., Laguno et al., 2004; 
Myers et al., 2004; Rockstroh et al., 2002). However, these results should be carefully 
interpreted, particularly because of how depression was measured in these studies. 
Indeed, different measures have been used to assess depression, and in four studies the 
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measures were not clearly reported, thus leading to likely bias, as well as to under or 
over-representation of depression and its potential impact on treatment. 
Regarding hepatitis C treatment, the interferon-induced depression paradigm has 
been robustly studied, and it has been reported that 1 out of 4 HCV patients receiving 
interferon-alpha and ribavirin therapy may develop MDD (Udina et al., 2012). Despite 
the notable advances of antiviral treatments for hepatitis C, particularly the emergence 
of direct acting-antivirals (DAAs), interferon-based therapy is still actively prescribed in 
a sub-set of patients. This means that the risk of depression may remain. Additionally, 
HCV treatment in co-infection is not as straightforward as in HCV mono-infection due 
to potential drug-drug interactions (Chen & Jain, 2015). Accordingly, a routine 
screening of depression in co-infected patients would still be critical to a prompt 
diagnosis and adequate planning of antidepressant treatment during HCV therapy, 
which has been however considered safe (Martin-Subero, & Diez-Quevedo, 2016).  
 This systematic review is not without limitations. First, the literature search was 
restricted to articles written in English. Second, methodological differences between the 
studies should be considered in the interpretation of the results, including the 
heterogeneity of the participants’ characteristics, the relatively small sample sizes, the 
preponderance of cross-sectional studies and the variability of approaches for assessing 
depression/depressive symptoms (only a limited number of studies performed a clinical 
diagnosis of depression). Third, the studies’ methodological heterogeneity, particularly 
the lack of information regarding depression measures and quantitative outcomes did 
not allow us to perform a meta-analysis on depression during HCV treatment. Also, our 
meta-analysis’ results were pooled from a small sample of studies that used different 
depression measures, which may lead to biased results and explain the substantial 
heterogeneity. Despite this limitation, restrict the selection of studies to those that used 
the same instrument would lead to a significant loss of information. Accordingly, the 
interpretation of these findings should be performed with caution. Finally, because of 
the emerging epidemiological patterns in HIV/HCV, this review is largely dependent of 
studies involving participants with history of IDU. Further studies are warranted, 
particularly those involving MSM as well as women, which are still under-represented 
in the HIV/HCV literature.  
This comparative analysis on the prevalence of depression in HIV, HCV mono-
infected and co-infected samples, indicates that depression appears to be more common 
among co-infected patients. This finding has important clinical implications, as it 
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provides an opportunity for targeted and timely screening of depression in populations 
at higher risk, and before the exacerbation of symptoms. In this context, the use of 
reliable measures of depression is essential. Despite the wide-ranging number of well-
established tools for the assessment of depressive symptoms, their scope and scores are 
often different (Uher et al., 2012) and are not directly comparable (Wahl et al., 2014). A 
standardized metric for the assessment of depression severity, as the proposed by Wahl 
and colleagues (2014) may be valuable. For a more complete and accurate assessment, 
the combination of clinician-rated scales and self-reported measures would also be 
useful, as it provide unique information that may be important to predict treatment 
outcomes (Uher et al., 2012). 
Finally, there is evidence that the prevalence of depression in HIV and HCV 
mono-infection as well as in HIV/HCV co-infection vary. Accordingly, a differential 
diagnosis will be critical, because both host factors (e.g., interferon exposure in HCV 
treatment) and virus factors (e.g., CNS-related infections) responsible for mood 
symptoms can be manageable. Moreover, factors such as lack of social support, stress 
and maladaptive coping strategies are also associated with an increased risk of 
depression (Slot et al., 2015). Because these factors are amenable to change, addressing 
these factors may also reduce depressive symptoms and contribute for improved well-
being of patients. As recommended by Schaefer et al. (2012), increased education of 
both patients and health professionals on mental health issues is central to allow early 
detection of psychological symptoms, particularly those that are likely to contribute to 
treatments’ failure. A close monitoring and comprehensive management of 
psychological symptoms is also highly recommended, as it may contribute to maximize 
the likelihood of successful treatments.  
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3. NEUROPSYCHIATRIC SIDE EFFECTS IN HCV TREATMENT: 
INTERFERON INDUCED DEPRESSION IN HEPATITIS C TREATMENT  
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3.1. Co-infection with HIV associated with reduced vulnerability to symptoms of 
depression during antiviral treatment for hepatitis C  
 
Abstract 
 
In this prospective study, we examined new-onset major depressive disorder (MDD) 
and the differential expression of depressive symptoms in a sample of 132 HCV mono-
infected and 40 HIV/HCV co-infected patients initiating pegylated interferon-based 
treatment, including protease inhibitor therapy. The semi-structured clinical interview 
(SCID-I) was used to assess MDD. Severity of depressive symptoms was assessed 
using the Hamilton Depression Rating Scale. Of the total sample, 60 patients (34.9%) 
developed SCID-I defined MDD during antiviral treatment. The proportion of HCV 
mono- and HIV/HCV patients developing MDD during treatment was not significantly 
different (37.9% vs. 25%; p = 0.185). In both groups, there was a significant increase in 
HAMD total score from baseline to week 4, and a significant decrease between week 24 
and 6 months post-treatment cessation. The greatest increase was observed in the 
symptoms of the neurovegetative syndrome. HCV mono-infected patients reported 
higher scores than co-infected patients, particularly impaired activity and somatic 
symptoms, but the differences were only significant at week 12. The finding that co-
infected patients appear less vulnerable to the development of depressive symptoms 
during HCV treatment than HCV mono-infected patients warrants further exploration, 
including a thorough analysis of the biological and psychosocial factors associated with 
this emergence. 
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1. Introduction 
 Based on current estimates, 170 million people worldwide are chronically 
infected with hepatitis C virus (HCV) (Mohd Hanafiah et al., 2013). HCV infection is 
also prevalent among HIV-infected patients (Chen et al., 2009), especially among 
intravenous drug users (IDU; Baum et al., 2008) and is increasing among men who have 
sex with men (MSM; Martin et al., 2013; Webster et al., 2013). When untreated, HCV 
can cause liver cirrhosis and hepatocellular carcinoma (Westbrook & Dusheiko, 2014). 
Meta-analytic data indicated that HIV/HCV co-infected patients are significantly more 
likely to present with cirrhosis than HCV mono-infected patients (relative risk: 2.1) 
(Thein et al., 2008), further highlighting the importance of addressing HCV treatment 
among the co-infected population.  
 Conventionally, chronic HCV infection has been treated using a combination of 
interferon-alpha (IFN-) and ribavirin. The addition of a protease inhibitor (triple 
therapy) has been associated with significantly higher rates of viral clearance in both 
HCV mono- and HIV/HCV co-infected patients (Rockstroh and Bhagani, 2013; 
Sulkowski et al., 2013). However, IFN-α is also associated with neuropsychiatric 
effects, which may diminish treatment compliance and constitute risk factors for 
treatment failure (Martin-Subero and Diez-Quevedo, 2016). The most common effects 
associated with conventional IFN-α treatment in HCV mono-infected patients are major 
depressive disorder (MDD), cognitive impairment, sleep disorders, anxiety and fatigue 
(Schaefer et al., 2002). Among co-infected patients, depression, irritability, sleep 
disorders and weight loss were reported as the most common neuropsychiatric adverse 
events during IFN-α treatment (Sulkowski, 2008). Data on neuropsychiatric effects of 
triple therapy are currently limited, but the prevalence of interferon-induced depression 
remains a significant issue (Alavi et al., 2012; Fialho et al., 2014; Whale et al., 2015). 
The prevalence of new-onset depression during HCV treatment among 
HIV/HCV co-infected patients is high (Fumaz et al., 2007), and has been related to 
treatment disruption (Laguno et al., 2004; Landau et al., 2001; Moreno et al., 2004; 
Myers et al., 2004; Rockstroh et al., 2002). In the population without HCV treatment, 
one study found that co-infected patients had higher prevalence of depression than 
mono-infected patients (Butt et al., 2006) and another study reported that co-infected 
patients were more likely to report depressive symptoms than HCV mono-infected 
patients (Sun et al., 2013). In contrast, it was found that a diagnosis of MDD was 
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significantly less common among co-infected patients than among mono-infected 
patients (Tavakkoli et al., 2013). During HCV treatment, Alavi and colleagues (2012) 
found recently similar rates of new-onset depression during HCV treatment between 
HCV mono-infected (33%) and co-infected patients (38%), although depression at 
baseline was more common among HCV mono-infected patients. However, though 
numerous studies assessed depression during treatment, those examining the emergence 
of depression during antiviral treatment for hepatitis C, and particularly the differences 
in the emergence of depression between HCV mono-infected and co-infected patients, 
are still rather limited. 
Although the exact neurobiological basis of interferon-induced depression is not 
known, there is evidence that HCV can replicate in extra-hepatic sites and has been 
shown to replicate in microglia, macrophages and astrocytes, triggering the release of 
pro-inflammatory cytokines, which are associated with the emergence of depression 
(Loftis et al., 2008). Cytokines, such as IFN- may directly enter the brain (Banks, 
2005; Banks and Erickson, 2010) via parenchyma cells causing an activation of IFN- 
gene expression (Wang et al., 2008), and by leaky regions in brain blood barrier (BBB) 
at circumventricular organs (Pan and Kastin, 2003), or non-directly through effects on 
the central nervous system (CNS) by induction of cytokines and growth factors that are 
able to cross the BBB (Reyes-Vázquez et al., 2012; Schaeffer et al., 2002). During HCV 
treatment, depressive disorders may therefore emerge due to IFN- acting on the CNS 
causing a neuro-inflammatory response (Capuron and Miller, 2004; Dantzer et al., 
2008; Raison et al., 2005). The hypothesis that inflammatory cytokines are involved in 
the pathogeneses of depression has been well supported (Hoyo-Becerra et al., 2014). 
Across multiple studies and medical conditions, there is evidence that the administration 
of cytokines to humans induces depressive symptoms in healthy subjects (Harrison et 
al., 2009), in HCV treatment (Udina et al., 2013), as well as in cancer (Archer et al., 
2012), kidney disease (Taraz et al., 2012) and HIV (Poudel-Tandukar et al., 2014). 
 During HCV therapy, higher levels of depression have been reported (Udina et 
al., 2012), particularly at earlier stages of treatment. It has also been suggested that 
patients with IFN-induced depression show significantly more symptoms of the 
neurovegetative syndrome and less cognitive-affective symptoms (e.g., guilt) (Capuron 
et al., 2009). In this context, and considering this biphasic model of depression, it was 
found that neurovegetative symptoms tend to develop early and depressive-cognitive 
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symptoms tend to occur later (Capuron et al., 2002a). Regarding the specific symptoms 
of the neurovegetative syndrome, psychomotor slowing was shown to be a consistent 
predictor of later emergence of depression (Capuron et al., 2001; Raison et al., 2005; 
Whale et al., 2015). Recently, in a sample of HCV mono-infected patients, Loftis et al. 
(2013) found that neurovegetative symptoms increased at an early stage of interferon 
treatment (week 2), though no significant changes in the cognitive-affective factor were 
observed. Though more limited, there is also evidence in co-infected populations 
indicating that depressive symptoms emerge in the first months after IFN-α treatment 
initiation (Fumaz et al., 2007; Laguno et al., 2004). 
 These findings seem to suggest that continuing interferon tends to induce a 
specific sub-type of mood disorder, characterised by a high expression of 
neurovegetative symptoms. However, most of the existing evidence in support of this 
comes from HCV mono-infection studies, leaving a significant research gap in the 
context of HIV/HCV co-infection. Thus, the objective of this study was to compare the 
new-onset IFN--induced MDD (defined as the development of depression during 
treatment among participants who were not depressed prior to the initiation of 
treatment) and the expression of depressive symptoms in HCV mono- and HIV/HCV 
patients. Specifically, we analysed the clusters of depressive symptoms associated with 
the new-onset depression during HCV treatment, and investigated whether this 
association was different across the two study groups. Based on the existing literature, 
although mostly outside the context of HCV treatment, we hypothesized that the co-
infected group would be more likely to present higher prevalence of depression than the 
HCV group. We also hypothesized that the expression of the neurovegetative syndrome 
would be more prominent than that of the mood-cognitive syndrome in both groups. 
 
2. Methods 
 
2.1. Participants and procedure 
 This prospective study was conducted at the outpatient HCV clinic at the Royal 
Sussex County Hospital, Brighton UK. All participants gave informed written consent 
for participation. Ethical approval was obtained through the National Research Ethics 
Service (NRES) Committee South East Coast. 
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 A cohort of 176 patients initiating hepatitis C treatment with a combination of 
pegylated interferon-α and ribavirin, or pegylated interferon-α, ribavirin and teleprevir 
were consecutively recruited between June 2014 and October 2015. The following 
exclusion criteria were applied: female, autoimmune disorder or any cause of liver 
disease other than HCV, history of neurological disease, acute psychiatric illness, 
current diagnosis of MDD, being on methadone, and intravenous drug or alcohol abuse 
within the month prior to the beginning of hepatitis C treatment. All HIV-infected 
patients had HIV infection confirmed by a positive ELISA positive and Western-blot 
analysis. Positive HCV RNA confirmed HCV infection by polymerase chain reaction 
(PCR) assay. Four participants were excluded from the analyses because of current IDU 
and to missing information in the main outcome at week 24 and at SVR. Therefore, the 
final sample consisted of 172 participants. 
 All participants were eligible to start hepatitis C treatment with the standard 
combination of PEG-IFN 2α 180 μg weekly sub-cutaneously and oral ribavirin 800-
1200mg daily (depending on weight and HCV genotype) or PEG-IFN 2α 180 μg 
weekly sub-cutaneously and oral ribavirin 800-1200mg daily and protease inhibitor 
telaprevir orally (750 mg) every 8 hours. Both treatments involved 24 weeks of 
interferon exposure. 
Participants were assessed at five time points: baseline, week 4, week 12, week 
24, and six months after treatment completion (sustained virological response [SVR] 
endpoint). 
 
2.2. Measures 
At baseline, socio-demographic information (e.g., age, gender), HCV-related 
variables (e.g., mode of HCV acquisition, HCV stage, genotype), and information such 
as past psychiatric history, past drug use and HCV re-infection (defined as having 
detectable HCV RNA following a positive treatment outcome or spontaneous self-
clearance) were collected. Positive response to treatment was measured by the SVR, 
defined as negative HCV viral load measured by polymerase chain reaction assay (PCR, 
HCV RNA  1.9 log IU/mL) six months after treatment completion. 
 The diagnosis of MDD was determined through a semi-structured clinical 
interview (SCID-I) (First et al., 1996) for the major DSM-IV Axis I diagnosis. For the 
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purpose of defining depression threshold, criterion A12D of the SCID-I (excluding 
other organic aetiologies) was discarded. 
Severity of depression and sub-syndrome features were assessed with the 
Hamilton Depression Rating Scale (HAMD; Hamilton, 1960), which consists of 21 
items. The total score ranges between 0 and 66, and higher scores correspond to higher 
severity of depressive symptoms. This scale provided detailed rating of both somatic 
and non-somatic components of depression. In this study, the dimensional structure 
suggested by Capuron et al. (2009) was used: (1) depressive symptoms composed of 
depressed mood, feelings of guilt and suicide items; (2) anxiety symptoms composed of 
anxiety psychological, hypochondriasis, agitation and anxiety somatic items; (3) 
impaired activity/decreased tone composed of work/activities and retardation; (4) sleep 
alterations composed of early, middle and late insomnia items; and (5) somatic 
symptoms composed of somatic symptoms gastrointestinal, somatic symptoms general, 
genital symptoms and loss of weight. The neurovegetative syndrome aggregates 
impaired activity, sleep alterations and somatic symptoms. The mood-cognitive 
syndrome combines depressive and anxiety symptoms. Alpha reliability in this sample 
ranged from .84 (Week 4) to .94 (SVR). 
 
2.3. Data analysis  
Data were analysed using the Statistical Package for Social Sciences (IBM SPSS 
20.0). A Chi-square (χ2) analysis was conducted to assess whether both groups had 
statistically different proportions in categorical variables, and Student’s t tests were 
used for comparisons in continuous variables. Repeated-measures multivariate analysis 
of covariance (MANCOVA) was used to assess changes in depressive symptoms across 
groups (between-subjects) and over time (within-subjects). Bonferroni adjustments were 
applied to correct for multiple comparisons (p < 0.01). Logistic regressions were 
performed to examine the association between the study variables and the development 
of MDD during treatment. Participants were coded for either transition to MDD or no 
transition to MDD at any time point during the study period. Effect sizes were 
calculated for all analyses. For Chi-square: small: Cramer’s V ≥ 0.10; medium: 
Cramer’s V ≥ 0.30; large: Cramer’s V ≥ 0.50. For t-test: small: Cohen’s d ≥ 0.20, 
medium: Cohen’s d ≥ 0.50; large: Cohen’s d ≥ 0.80) (Cohen, 1992). 
 
3. Results 
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3.1. Participants’ characteristics 
 The sample comprised 172 participants, with a mean age at treatment initiation 
of 46.58 years (SD = 10.44). Forty patients were co-infected with HIV and 132 patients 
were HCV mono-infected. Most participants were infected with genotype 2 virus (n = 
77; 44.8%), followed by genotype 1 (n = 58; 33.7%). Regarding antiviral treatment, 
most patients received pegylated INFα and ribavirin dual therapy (n = 113; 65.7%). 
Seventy-seven patients (44.8%) reported past psychiatric history, out of which 65 
(84.4%) specified previous history of depression. A SVR response was achieved in 150 
patients (87.2%). HIV/HCV co-infected patients were less likely than HCV mono-
infected patients to report a past psychiatric history and HCV infection through IDU. As 
summarised in Table 1, no significant differences were found between HCV and 
HIV/HCV patients in the remaining baseline study variables. 
 
Table 1. Demographic and clinical characteristics of participants receiving HCV 
treatment (N = 172) 
 HCV 
(n = 132) 
HIV/HCV 
(n = 40) χ2 Cramer’s V 
n (%) n (%) 
Marital status   2.93 0.13 
Single 67 (50.8) 21 (52.5)   
Married/Cohabiting  56 (42.4) 19 (47.5)   
Separated/Divorced 9 (6.8) -   
HCV stage    1.25 0.09 
Chronic 115 (87.1) 32 (80.0)   
Route of HCV infection   30.06*** 0.42 
IDU 85 (64.4) 6 (15.0)   
Genotype   1.33 0.09 
1 45 (34.1) 13 (32.5)   
2 60 (45.5) 17 (42.5)   
3 18 (13.6) 5 (12.5)   
4 9 (6.8) 5 (12.5)   
HCV treatment    0.24 0.04 
PEG-IFN 2α +Ribavirin + 
Teleprevir 
44 (33.3) 15 (37.5)   
PEG-IFN 2α + Ribavirin  88 (66.7) 25 (62.5)   
Past psychiatric history    0.11 0.03 
No  72 (54.5) 23 (57.5)   
Past drug use    23.52*** 0.37 
Yes  90 (68.2) 10 (25.0)   
Treatment status   0.11 0.03 
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Naïve  124 (93.9) 37 (92.5)   
Antidepressant treatment during 
interferon therapy 
  1.45 0.09 
No 82 (62.1) 29 (72.5)   
SVR    0.004 0.01 
Yes 115 (87.1) 35 (87.5)   
 M (SD) M (SD) t Cohen’s d 
Age  47.06 (10.37) 45.00 (10.63) 1.10 0.20 
*** p < 0.001 
 
3.2. Depressive symptoms at baseline and development of MDD during treatment 
At baseline, the mean HAMD total score across groups was 4.10 (SD = 5.51; 
range: 0-23). Four patients had a HAMD total score at baseline > 20, suggesting 
moderate depressive symptoms, despite not having a SCID defined MDD. No 
significant differences were found between HCV (M = 4.13, SD = 5.31) and HIV/HCV 
co-infected patients (M = 4.03, SD = 6.19) regarding baseline HAMD score, F(1, 170) = 
0.10, p = 0.917.  
A total of 60 patients (34.9%) developed SCID defined MDD during HCV 
treatment of the whole sample. Twenty-eight patients developed MDD by week 4 and 
40 patients by week 12 representing a cumulative percentage of 66.7% of patients with 
new-onset depression within the first 12 weeks of treatment. Regarding differences 
between groups in each time point, the results indicated that HCV mono-infected 
patients were more likely than co-infected patients to have a MDD diagnosis at week 4 
(26.5% vs. 10%; 2(1) = 4.78, p = 0.029, Cramer’s V = 0.17), week 12 (31.1% vs. 15%; 
2(1) = 3.99, p = 0.046, Cramer’s V = 0.15) and week 24 (24.6% vs. 7.9%; 2(1) = 4.99, 
p = 0.026, Cramer’s V = 0.17). 
 
3.3. Depressive symptoms during HCV treatment 
In order to control for potential confounders associated with the severity of 
depressive symptoms during treatment, preliminary univariate logistic regressions were 
conducted to examine the associations between baseline factors (age, marital status, 
HCV stage, past drug use, genotype, type of treatment and prior treatment status) and 
the emergence of MDD, in the total sample, as well as in each group separately. No 
baseline variables were significantly associated with increased odds of developing 
MDD during treatment. Nevertheless, analyses of the changes of symptoms of 
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depression during treatment were adjusted for anti-depressant treatment, as this was 
defined a priori as a potential confounder. 
Regarding HAMD total score, the multivariate analysis, adjusted for 
antidepressant treatment, indicated a significant effect of time, Wilks’ λ = 0.45, F(4, 
166) = 51.47, p < 0.001, ηp2 = 0.55, group, F(1, 169) = 9.34, p = 0.003, ηp2 = 0.05, and 
time x group interaction, Wilks’ λ = 0.93, F(4, 166) = 3.05, p = 0.018, ηp2 = 0.07. 
Regarding time, subsequent univariate analyses (Bonferroni corrected) indicated a 
significant increase in HAMD total score from baseline to week 4 (Mean difference = 
7.20, p < 0.001), and a significant decrease between week 24 and SVR endpoint (Mean 
difference = 9.74, p < 0.001). No significant differences were found between week 4 
and week 12, or between week 12 and week 24. 
In relation to group comparisons, HCV mono-infected patients reported higher 
scores than HIV/HCV co-infected patients. The group x time interaction, after 
Bonferroni’s correction, indicated that the between-group differences in HAMD total 
score were only significant at week 12, F(1, 169) = 13.82, p < 0.001. Longitudinal 
changes in depressive symptoms during and following treatment are shown in Figure 1. 
 
 
Figure 1. Time course of HAMD mean scores and standard errors (SE) in HCV mono-
infected and HIV/HCV co-infected patients during HCV treatment 
 
3.4. Changes in depressive symptoms subtypes during HCV treatment  
Regarding the five HAMD factors, the descriptive results are summarised in 
Table 2. Repeated measures MANCOVA indicated a significant main effect of time, 
Wilks’ λ = 0.25, F(20, 150) = 22.43, p < 0.001, ηp2 = 0.75. The main effect of group 
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was not significant, Wilks’ λ = 0.95, F(5, 165) = 1.84, p = 0.109, ηp2 = 0.05. The time 
by group interaction was significant, Wilks’ λ = 0.81, F(20, 150) = 1.77, p = 0.029, ηp2 
= 0.19, suggesting that the groups present with significant behavioural differences.  
Subsequent tests indicated that, with the exception of the factor ‘depressive 
symptoms’ (p = 0.035), there was a significant increase in all other factors during 
treatment (anxiety symptoms, impaired activity symptoms, sleep alterations and somatic 
symptoms), most notably between baseline and week 4 (all p < 0.001). Overall, the 
depressive symptoms subtypes with the greatest increase from baseline to week 4 were 
impaired activity (Mean difference = 0.78, p < 0.001), somatic symptoms (Mean 
difference = 0.56, p < 0.001) and sleep alterations (Mean difference = 0.50, p < 0.001). 
In addition, a significant decrease in all factors was observed between week 24 and the 
SVR endpoint (all p < 0.001) – see Supplementary Figure. 
Group comparisons, after Bonferroni correction, indicated that HCV mono-
infected patients reported significantly higher scores than HIV/HCV patients only in 
impaired activity. The interaction between group and time indicated that differences 
between co-infected and mono-infected patients were only significant at week 12 in 
respect to sleep alterations (Mean difference = 0.37, p = 0.004) and somatic symptoms 
(Mean difference = 0.37, p < 0.001). 
To further examine the longitudinal changes in the two clusters of depressive 
symptoms, a repeated measures MANCOVA was conducted. The results indicated a 
significant main effect of time, Wilks’ λ = 0.29, F(8, 162) = 50.07, p < 0.001, ηp2 = 
0.71, group, Wilks’ λ = 0.95, F(2, 168) = 3.91, p = 0.022, ηp2 = 0.05, and time x group 
interaction, Wilks’ λ = 0.87, F(8, 162) = 2.95, p = 0.004, ηp2 = 0.13. Follow-up 
ANCOVAs indicated a significant increase in both mood-cognitive and neurovegetative 
syndromes during treatment, particularly between baseline and week 4 (p < 0.001). 
Consistent with prior findings, a significant decrease in both syndromes between week 
24 and SVR endpoint was found (all p < 0.001) – see Figure 2. 
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Table 2. Descriptive statistics in HAMD factors during interferon-based therapy for HCV 
 Baseline Week 4 Week 12 Week 24 SVR 
Time (F) Group (F) 
Time X 
Group (F)  M (SE) M (SE) M (SE) M (SE) M (SE) 
Depressive symptoms      10.72*** 3.86 1.85 
HCV 0.19 (0.03) 0.43 (0.04) 0.47 (0.04) 0.38 (0.04) 0.04 (0.02)    
HIV/HCV 0.22 (0.06) 0.24 (0.07) 0.32 (0.08) 0.32 (0.07) 0.02 (0.04)    
Anxiety symptoms      15.69*** 6.09* 1.68 
HCV 0.22 (0.03) 0.55 (0.05) 0.63 (0.05) 0.53 (0.05) 0.04 (0.01)    
HIV/HCV 0.21 (0.06) 0.36 (0.09) 0.41 (0.09) 0.35 (0.09) 0.003 (0.03)    
Impaired activity      57.20*** 7.30** 1.62 
HCV 0.24 (0.04) 1.10 (0.06) 1.18 (0.06) 1.01 (0.07) 0.07 (0.03)    
HIV/HCV 0.23 (0.08) 0.92 (0.11) 0.93 (0.11) 0.70 (0.12) 0.02 (0.05)    
Sleep alterations       35.63*** 2.50 2.75* 
HCV 0.38 (0.05) 0.87 (0.06) 0.92 (0.06) 0.84 (0.06) 0.05 (0.02)    
HIV/HCV 0.39 (0.09) 0.89 (0.11) 0.55 (0.11) 0.69 (0.11) 0.03 (0.04)    
Somatic symptoms      53.28*** 4.77* 5.09** 
HCV 0.16 (0.03) 0.81 (0.05) 0.91 (0.04) 0.76 (0.05) 0.05 (0.02)    
HIV/HCV 0.26 (0.05) 0.72 (0.08) 0.55 (0.08) 0.67 (0.09) 0.01 (0.04)    
* p < 0.05; ** p < 0.01; *** p < 0.001 
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Group comparisons indicated that HCV mono-infected patients reported 
significantly higher symptoms scores than HIV/HCV patients in both the mood-
cognitive, F(1, 169) = 5.79, p = 0.017, ηp2 = 0.03, and neurovegetative syndrome, F(1, 
169) = 6.55, p = 0.011, ηp2 = 0.04. The group x time was only significant for the 
neurovegetative syndrome, F(8, 162) = 5.10, p = 0.001, ηp2 = 0.03. Subsequent 
ANCOVAs indicated that the differences were only significant at week 12 (Mean 
difference = 0.35, p < 0.001), with the HCV group showing higher scores at this time 
point. 
 
Figure 2. Time course of HAMD syndromes mean scores and standard errors (SE) in 
HCV mono-infected and HIV/HCV co-infected patients during HCV treatment. 
Neurovegetative syndrome (A) was defined by HAMD criteria by impaired activity; 
sleep alterations and somatic symptoms. Mood-cognitive syndrome (B) defined by 
HAMD criteria by depressive and anxiety symptoms.  
 
 4. Discussion 
In this study, we found a high prevalence of new-onset MDD during interferon-
based treatment in both groups. However, our findings also indicated that the HCV 
mono-infected patients were more likely to develop MDD earlier in treatment (week 4). 
This early emergence of symptoms has been previously reported and should be 
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considered, as it may be a significant factor in treatment compliance and drop outs. For 
both study groups, the severity of depressive symptoms increased significantly during 
treatment and showed a significant decrease after treatment ended. The cluster of 
depressive symptoms showing the greatest increase during treatment includes the 
neurovegetative syndrome (impaired activity, somatic symptoms and sleep alterations), 
with the HCV mono-infected group reporting significantly higher scores than the co-
infected group, particularly at week 12. 
In contrast to our hypothesis, HCV mono-infected patients reported significantly 
more depressive symptoms, although not achieving MDD threshold, than co-infected 
patients during treatment., a pattern also reported by Tavakkoli et al. (2013). These 
results suggest that depression in HCV mono-infected patients may be under diagnosed, 
therefore increasing the risk of treatment discontinuation and depression severity. It has 
been indicated that having HCV is itself a risk factor for depression (Carta et al., 2012; 
Smith et al., 2011), and various studies found high rates of depression and fatigue in 
chronic untreated HCV-infected patients compared to the general population (Basseri et 
al., 2010; Poynard et al., 2002). In our study, though current drug use or use of 
methadone replacement treatment were exclusion criteria at enrolment, these results 
may potentially be explained by specific characteristics of patients of this HCV cohort, 
who are more likely to present with a past history of IDU and past psychiatric history. 
These factors have been identified as underlying a significant risk for developing MDD 
during HCV treatment (Hilsabeck et al., 2005, Udina et al., 2016). An alternate 
explanation may be the chronic inflammatory status identified in 85.5% of our 
participants, which has been also related to depression (Berk et al., 2013), and an 
association that has been found to be independent of IFN- treatment, substance and 
alcohol misuse (Boscarino et al., 2015; Carta et al., 2012). HCV chronicity, 
characterized by a persistent long term HCV replication, implies a low grade of 
inflammatory activation that triggers a high level of immune reaction followed by 
depressive like behaviour (Carta et al., 2012; Maes et al., 2012). The state of chronic 
inflammation/chronicity when exposed to interferon treatment may increase risk for 
developing depression, as previously noted (Capuron et al., 2012; Fritz-French and 
Tyor, 2012; Miller et al., 2009; Raison et al., 2010). 
The evidence suggests that neuropsychiatric side effects of IFN- therapy occur 
during the time course of treatment, with a tendency to emerge at the beginning of 
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treatment, between week 4 and week 12 (Cunha et al., 2015; Leutscher et al., 2010; 
Martín-Santos et al., 2007). The HCV mono-infected group reported significantly 
higher scores on depression than the co-infected group only at week 12, which is 
consistent with prior findings (Capuron et al., 2003). This may relate to the time frame 
for specific interferon pathways. Indeed, depression was found to occur in patients who 
showed a reduction in serum tryptophan concentrations at week 12 of treatment 
(Capuron et al., 2003), suggesting that tryptophan degradation may be a mechanism in 
the pathophysiology of interferon-induced depression (Capuron et al., 2003; Réus et al., 
2015). Overall, the fact that in both groups the new cases were observed early in 
treatment are particularly relevant as they suggest that the beginning of treatment is a 
crucial period, requiring a comprehensive monitoring by clinicians.  
Our main findings are consistent with previous reports that have identified a 
significant prevalence of MDD during HCV treatment (Udina et al., 2012, 2016; Whale 
et al., 2015). The percentage found in this study is similar to the overall rate of new-
onset depression (35%) reported by Alavi et al. (2012). Additionally, a significant 
decrease significant decrease in depressive symptoms from week 24 to SVR was 
observed, in line with evidence suggesting that the prevalence of depression 
significantly decreases after cessation of INF-  exposure (Huckans et al., 2014). 
Accordingly, our results are compatible with the inflammatory model of depression, 
showing a pattern of change consistent with the suggestion that inflammation, induced 
by exogenous administration of IFN-, triggers an increased risk of depression like 
behaviour, which may be due to neurotoxic effects in the brain, and despite the presence 
of potential vulnerability factors, the depressive symptoms remit following INF- 
cessation (Lotrich, 2015). 
 Capuron and colleagues proposed that IFN- treatment is associated with the 
emergence of two distinct behavioural syndromes: the mood-cognitive and the 
neurovegetative, which occur separately by IFN- effects on the activation of different 
pathophysiological mechanisms. In this study, all participants showed a significant 
increase in anxiety symptoms, impaired activity, somatic symptoms and sleep 
alterations between baseline and week 4. Most of these symptoms are part of the 
neurovegetative syndrome, which tends to appear rapidly in treatment, as earlier 
reported (e.g., Loftis et al., 2013). Capuron et al. (2007), in a study with patients with 
malignant melanoma, found that four weeks of IFN- therapy was associated with 
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marked increased in glucose metabolism in basal ganglia, and a significant increase in 
fatigue, lassitude and “inability to feel”. The same study suggested that changes in basal 
ganglia activity may play a role in interferon-induced fatigue related syndromes. A 
recent study using microstructural MR imaging technique confirmed the involvement of 
basal ganglia structures in development of fatigue at early stage of INF- exposure, 
however, an association between changes in the striatum and depressive symptoms at a 
later stage was not found (Dowell et al., 2016).  
 The mood-cognitive syndrome, encompassing symptoms of depression and 
anxiety, as well as cognitive dysfunction, appears later during IFN- therapy, between 
week 12 and week 24, and is more likely to respond to anti-depressant treatment than 
neurovegetative symptoms (Capuron et al., 2004). This may imply mechanisms 
involving monoamine transmission dysfunction for this cluster of symptoms. For 
example, there is evidence that changes in tryptophan metabolism triggers 
overstimulation of the enzyme indoleamine-d-oxygenase boosting kynurenine toxicity 
and serotonin depletion, which represents a risk for the emergence of mood and 
cognitive symptoms (Capuron et al., 2004; Eccles et al., 2012; Oxenkrug et al., 2014). 
In our study, the mood-cognitive syndrome was significantly more likely to occur 
between baseline and week 4. We failed however to find elevated scores in this 
syndrome at a later stage of treatment, as previously suggested (Dowell et al., 2016; 
Loftis et al., 2013). A possible explanation may be that the emergence of this syndrome 
early in treatment may reflect an emotional adjustment response to the treatment, which 
often combines anxiety and depression symptoms. However, it should also be noted that 
in healthy volunteers, experimentally-induced inflammation reduce mood within hours 
(Harrison et al., 2009). The impact of inflammation on behaviour has been related not 
only to depression but with other neuropsychiatric disorders, such as anxiety and 
schizophrenia (Fernandes et al., 2015; Miller et al., 2013). Recently, it has been 
suggested that inflammatory-induced symptoms include positive and negative valence 
system activity associated with motivation and motor activity changes (anhedonia, 
fatigue, and psychomotor retardation) and increased threat activity (anxiety, arousal and 
alarm) (Miller and Raison, 2016). 
Several limitations need to be noted. Firstly, the convenience sampling and the 
relatively small sample size of the co-infected group, which imply that generalisation of 
our findings should be undertaken with caution. Secondly, our results and conclusions 
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are also limited by the inclusion of only male participants, mostly due to clinical 
availability, leaving an important research gap in assessing female patients and potential 
sex-based differences in study outcomes. Thirdly, this study relied mostly on the use of 
behavioural data, without taking into account other biological markers (which have 
been proposed to be relevant risk factors for interferon-induced depression; for a review 
see Udina et al., 2012) and a more detailed psychiatric background (e.g., personal 
history of psychiatric disorders, prior resistance to anti-depressant treatment), which 
may have a potential effect on depression outcomes. It is also likely that other variables 
that were not assessed (e.g., inflammatory markers, such as IL-6, IL-1, CRP; 
psychosocial factors) may have been able to enhance our interpretations of differences 
between the HCV and HIV/HCV groups. To overcome these limitations, further studies 
examining a more complete set of factors associated with interferon-induced depression 
in mono-infected and co-infected patients would be valuable. Lastly, the introduction of 
direct-acting antiviral therapy for the treatment of HCV has noticeably transformed the 
treatment of hepatitis C. We assert however that our findings provide an important 
description of interferon-induced depression in HCV mono-infected and HIV/HCV co-
infected patients during HCV treatment, and are relevant to the current inflammatory 
paradigm of depression. 
Despite these limitations, this study has also important strengths. The study 
design was prospective and longitudinal and all patients were followed in a single centre. 
In contrast to many studies that relied only in self-reported symptoms scales to assess 
depression, this study used both a validated measure for assessing the severity of 
depressive symptoms (which is useful for examining individual symptoms and changes 
over time) and a clinical interview based on DSM criteria. Our data suggest that 
interferon-induced depression presents primary a neurovegetative symptoms profile, 
highlighting the need to find more specifically effective anti-depressant treatment, 
particularly because this syndrome appears to be less responsive to anti-depressant 
treatment (Capuron and Miller, 2004). Despite the advent of IFN-free regimens, INF 
remains a valid treatment option for several diseases, such as multiple sclerosis 
(Calabresi et al., 2014) and leukemia (Bohn et al., 2016). Therefore, these findings may 
also have important practical implications in such clinical contexts.  
In sum, our findings indicate that for both HCV mono- and HIV/HCV co-
infected patients receiving treatment for hepatitis C, the emergence of depressive 
symptoms of the neurovegetative syndrome is notable at early stage of IFN- treatment, 
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and that this cluster of symptoms is significantly more prominent among HCV mono-
infected patients than among co-infected patients, particularly at week 12. Additional 
research is needed however to better understand whether the symptoms of depression 
clearly reflect the effects of inflammation, what type of anti-depressant treatment may 
be more effective for neurovegetative symptoms, and which strategies should be 
adopted to prevent future depression episodes and to improve the quality of life of 
patients undergoing HCV therapy, even in interferon-free regimens.  
Despite the significant advances in HCV therapy with the introduction of IFN-α-
free treatment regimens, including in HIV/HCV co-infection (Menard et al., 2016), co-
infected patients will continue to be a population with unique characteristics that 
warrant special attention (Hesamizadeh et al., 2016; Majumdar et al., 2016; Sulkowski, 
2016). Factors such as HCV re-infection following successful treatment, drug-drug 
interactions, and efficacy of HCV shorter treatments should be carefully considered 
(Sulkowski, 2016). The high cost of the new regimens may also be economically 
difficult to justify (Chayama et al., 2015). For these reasons, IFN-α may still have a 
role within co-infection,. Nevertheless, important actions on mental health should not be 
disregarded in the post-interferon era. For example, a recent study found that ongoing 
substance use weakened the short- and long-term benefits associated with curing HCV 
(Yeung et al., 2015), suggesting that mental health professionals should continue to take 
an active role in HCV treatment (Chasser et al., 2017). In our study, a significant 
proportion of patients reported past drug use and psychiatric history. Because HCV and 
HIV are prevalent diseases that continue to disproportionately affect these vulnerable 
populations, reduction of the burden of mental illness and substance misuse before (and 
during) treatment, identification of barriers to adherence, as well as greater awareness of 
the drug-drug interactions that accompany these new treatments (including with 
psychotropic medication), would be of paramount importance to optimize treatment’s 
outcomes.  
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3.2. Major depressive disorder and immune response in HIV/HCV co-infected men 
during Hepatitis C treatment 
 
Abstract 
Objectives: The aims of this study were to examine the rate of development of major 
depressive disorder (MDD) during hepatitis C treatment, the incidence of depressive 
symptoms throughout treatment and the association between the immune response (as 
assessed by CD4+ T-cell count) and the onset of depression and sustained virological 
response (SVR) in a sample of HIV men co-infected with HCV.  
Methods: The sample consisted of 38 MSM HIV/HCV co-infected attending Brighton 
& Sussex University Hospitals NHS Trust, Brighton (UK). Participants were assessed 
using the structured clinical assessment for DSM-IV (SCID) and the Hamilton 
Depression Scale (HAMD) at baseline, during HCV treatment and at SVR endpoint. All 
participants were treated with interferon-based therapies for 12 weeks. HCV treatment 
included pegylated interferon, plus ribavirin and the same combination including 
telaprevir.  
Results: Ten patients (26.3%) developed MDD during treatment. There was a 
significant increase in the HAMD total score from baseline to week 4, and a significant 
decrease between week 24 and SVR endpoint. There was a significant reduction of 
CD4+ T-cell count between baseline and week 4. No significant correlations were 
found between immune response (nadir and baseline CD4+ T-cell count) and 
depression and SVR.  
Conclusions: The advent of new HCV treatment regimens represents an important 
opportunity for reducing treatment-associated adverse events in such co-infected 
patients. However, interferon based therapies remain the only funded treatment for 
patients with HCV acute infection and emergence of depression is still remain a risk for 
treatment discontinuation and or HCV (re)infection.  
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Introduction 
Recent estimates indicate that about 4 to 5 million patients with human 
immunodeficiency virus (HIV) worldwide are also co-infected with hepatitis C virus  
(Berenguer et al, 2012; van de Laar, Matthews, Prins, & Danta, 2010; Wandeler et al, 
2012). There is evidence that these rates are higher among intravenous drug users 
(IDU), though an emerging sexual transmission of HCV has been reported, particularly 
among men who have sex with men, MSM (Urbanus et al., 2009; van de Laar, 
Matthews, Prins, & Danta, 2010, Winston et al., 2013).  
 Interferon- is therapeutically administered to treat hepatitis C infection, 
however, among HIV/HCV co-infected patients, the neuropsychiatric side-effects, in 
particular major depressive disorder (MDD), have been reported as an important cause 
of treatment discontinuation (Butt, Justice, Skanderson, Good, & Kwoh, 2006; 
Dieperink et al., 2000), impairment in quality of life (Thein et al., 2007) and reduced 
likelihood of sustained virological response (SVR) (Leutscher et al., 2010). Recently, 
the advent of direct antiviral agents (DAAs) have changed the direction of the hepatitis 
C treatment (Feld, 2014), but due to their expense the DAAS may not become available 
for all patients and interferon- still represents an important treatment option remaining 
the only funded treatment for patients with acute HCV (Hoyo-Becerra, Schlaak, & 
Hermann, 2014).   
Exposure of peripheral administration pro-inflammatory cytokines, such as 
interferon- increases inflammation response and is a risk factor for developing 
depression-like behaviour (Capuron & Miller, 2004; Forton et al., 2008). Immune 
pathways are involved in this inflammatory condition; in particular T cell responses 
seem to represent a mechanism that affects emergence of depression (Miller & Raison, 
2016).  
 HIV causes an increased production of pro-inflammatory cytokines, such as 
endogenous interferons (IFNs), at the early stage of infection, and throughout treatment 
(Nasi, Pinti, Mussini, & Cossarizza, 2014). It has been suggested therefore that HIV is 
an inflammatory disease (Borges et al., 2015; Nasi et al., 2014). In the acute HIV stage, 
part of the immune response is activated by IFNs’ stimulation, which inhibits HIV 
replication. In the later stage, the systematic HIV replication leads to an overstimulation 
of pro-inflammatory cytokines, which has been associated with high levels of HIV RNA 
(McMichael et al., 2010). As a consequence to high HIV RNA, CD4+ T-cells are 
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gradually lost leading to immune dysfunction (Khaitan & Unutmaz, 2011; Picker, 2006) 
that has been related with symptoms of depression.  
 A significant association has been found between CD4+ T-cell count, depression 
and accelerated spontaneous apoptosis in CD4+ T-cells (Fallarino et al., 2002; Ivanova 
et al, 2007) due to an overstimulation of pro-inflammatory cytokines (Miller et al., 
2009, 2010; Raison et al., 2006). T-cell apoptosis in depression has been associated 
with tryptophan depletion (Mellor et al., 2003). Tryptophan (trp) is essential for 
function of effector T-cells. Therefore, in a tryptophan deprived environment T-cell 
suppression may occur (Mellor et al., 2003, 2005). Interestingly, in the context of HCV 
treatment, interferon therapy may also cause tryptophan depletion, boosting an 
inflammatory response inducing T-cell and indoleamine 2,3-dioxygenase (IDO) enzyme 
activation (Capuron et al., 2001; Maes et al., 2001a), resulting in accumulation of toxic 
metabolites (kynurenine). Tryptophan depletion and kynurenine accumulation have 
been reported as being significantly associated with increased severity of depressive 
symptoms such as appetite changes, pessimistic thoughts, suicidal ideation and loss of 
concentration (Bonaccorso et al., 2002; Capuron et al., 2002). It seems that interferon-, 
trp metabolism and CD4+ T cells are part of a complex immune-inflammatory network 
that contributes to emergence of depression.  
 CD4+ cells may potentially affect the outcome of HCV treatment. The impact of 
baseline CD4+ count on hepatitis C virological response is not clear however. Previous 
data showed that the higher CD4 + cell count was significantly associated with SVR 
(Mausset et al, 1998; Aviden et al, 2009). In contrast, other reports failed to find this 
association in co-infected samples (Dazley et al, 2015; Potter et al, 2010). A study by 
Valerio and colleagues (2008) found that treatment interruption was frequent in 
HIV/HCV co-infected patients with genotype non-1 and baseline CD4+T-cells < 350 
cells/mm3, and no significant association was found between baseline CD4+ T cells 
count and SVR. Another report found no significant differences on SVR in patients with 
baseline CD4+ T-cells ≤ 250 cells/mm3 and with CD4+ T-cells  250 cells/mm3 (Mira 
et al., 2009). CD4+ T cell count had very little change over course of treatment and 
were not associated with SVR (Carrat et al, 2004; Mira et al, 2012; Torriani et al, 2014), 
suggesting that CD4 + cell is independently associated with SVR. 
Despite this, according with the British HIV Association (BHIVA) guidelines 
for management of HCV in adults infected with HIV, beginning HIV therapy for HIV 
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control and CD4+ T-cell count optimisation is recommended, ideally with CD4+ T-cells 
 350 cells/mm3, whether or not HCV therapy is required (Wilkins et al., 2013, 
BHIVA).  
According to the inflammatory paradigm, increased inflammation, induced by 
interferon- therapy, activates immune response that can potentially influence the 
emergence of MDD. Therefore, the aims of this prospective study were to analyse if 
immune response, as measured by CD4+ T-cell count at baseline and nadir CD4+ T-cell 
count, was associated with the development of depression and ultimately SVR among 
patients co-infected with HIV and HCV.  
 
Methods 
 
Participants and procedure 
A total of 38 HIV/HCV co-infected patients were consecutively recruited prior 
to initiating HCV treatment at the outpatient hepatology clinic at Brighton & Sussex 
University Hospitals NHS Trust, UK. All participants had a diagnosis of HIV infection 
with acute or chronic hepatitis C infection. Patients receiving IFN and ribavirin 
treatment with or without telaprevir were included. All HCV genotypes were eligible to 
participate. Exclusion criteria were the following: auto-immune disorder or any other 
cause of liver disease other than HCV, history of neurological disease, being on 
efavirenz, presence of acute psychiatric illness, MDD at baseline, being on methadone, 
and active intravenous drug use or alcohol abuse. Ethical approval was obtained through 
the National Research Ethics Service (NRES) Committee South East Coast 
[Reference14/LO/0688]. All participants provided written informed consent.  
Participants were assessed for depression, using the measures described below, 
at different time points within the study as follows: baseline, week 4, week 12, week 24, 
and 6 months after treatment completion (SVR).  
 
 Hepatitis C treatment 
HCV treatment was defined as the standard combination of PEG-IFN 2α 180 
μg weekly subcutaneously and oral ribavirin 800-1200mg daily (weight based) for 24 
weeks if HCV RNA remained undetectable by this point. When HCV RNA was 
detectable at week 24, the length of treatment was extended to 48 weeks. However, for 
 135 
 
the purposes of our study we considered the patients that required only 24 weeks of 
treatment. Triple therapy was defined as PEG-IFN 2α 180 μg weekly sub-cutaneously 
and oral ribavirin 800-1200mg daily and protease inhibitor telaprevir orally (750 mg) 
every 8 hours. The combination of PEG-IFN, ribavirin and telaprevir was administered 
for 12 weeks. Among patients with undetectable HCV RNA at week 4 and 12, 
telaprevir was discontinued and PEG-IFN associated with ribavirin was continued until 
week 24. All patients started PEG-IFN, ribavirin and telaprevir. At week 12 if HCV 
RNA was undetectable telaprevir was discontinued. All patients continued treatment to 
week 24.  Overall, both treatments had 24 weeks of interferon exposure. 
 
Measures 
Baseline data were gathered during a face-to-face interview, and included 
collection of sociodemographic, HIV and HCV-related characteristics. Assessment of 
MDD diagnosis was undertaken with the semi-structured clinical interview for DSM-IV 
Axis I diagnosis (SCID-I) (First, Spitzer, Gibbon, & Williams, 1996). For the purpose 
of defining depression threshold, criterion A12D of the SCID-I (excluding other organic 
aetiologies) was discarded. The severity of depression and sub-syndrome features were 
assessed with the 21-item Hamilton Depression Rating Scale (HAMD) (Hamilton, 
1960). This scale is of particular use in this context due to its detailed rating of both 
somatic and non-somatic components of depression.  
Positive response to treatment was measured by sustained virological response 
(SVR), defined as negative HCV viral load measured by polymerase chain reaction 
assay (PCR, HCV RNA  1.9 log IU/mL) 6 months after the end of treatment.  
 
Data analysis  
Data were analysed using the Statistical Package for Social Sciences (IBM 
SPSS, version 20.0). Descriptive statistics with means and standard deviations (SD) 
were reported for continuous variables, and frequencies were reported for categorical 
variables. Changes in depressive symptoms during hepatitis C treatment were analysed 
using repeated measures multivariate analysis of variance (MANOVA). A Pearson’s 
correlation coefficient was performed to measure the relationship between immune 
response and depression, and immune response and clearance. The level of significance 
was two-tailed and set at 0.05. 
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Results 
 
Participants’ characteristics  
 The sample consisted of 38 HIV/HCV co-infected men, with a mean age of 45.66 
years (SD = 10.78). The majority of participants had college education (60.5%) and 
were with no regular partner (57.9%). Most participants had HCV genotype 1 (47.4%), 
followed by genotype 2 (31.6%), and genotype 3/4 (both 10.5%). Mean nadir CD4+ T-
cell count was 239.61 cells/mm3 (SD = 101.53; range: 37-494). At baseline, mean CD4+ 
T-cell count was 639.32 cells/mm3 (SD = 183.16; range: 210-1064). All patients had 
undetectable HIV RNA viral load (< 50 copies/mL). Most patients (63.2%) were HIV 
asymptomatic and 30 patients (78.9%) had chronic HCV infection. Regarding HCV and 
HIV treatments, 22 patients received PEG-IFN 2α and ribavirin treatment (57.9%) and 
all patients were on HIV combination anti-retroviral therapy (cART).  Sixteen patients 
(42.1%) indicated a past history of depression and 2 (5.3%) were re-infected, thought to 
be with HCV.  
 
Depression measured by SCID 
A total of 10 patients (26.3%) developed SCID defined MDD during HCV 
treatment. Patients who developed depression did so mostly by week 12 (n = 6; 60%). 
 
Depression symptoms total score  
At baseline, the mean HAMD score was 3.68 (SD = 5.74; range: 0-20). The expression 
of changes of depressive symptoms indicated that there was a significant increase in 
HAMD total score from baseline to week 4, and a significant decrease between week 24 
and SVR endpoint, Wilks’ λ = .26, F(4, 34) = 23.91, p < 0.001 (Figure 1). 
 
Figure 1 - Time course of HAMD total scores during HCV treatment 
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During HCV treatment, and adjusting for cART, there was significant effect of 
time CD4+ T-cell count, Wilks’ λ = .59, F(4, 25) = 4.31, p = 0.009 (Figure 2). Follow-
up analyses indicated a significant reduction between baseline and week 4 (p = 0.006) 
and a slight increase (non-significant) from week 4 to SVR endpoint. 
 
Figure 2 – CD4+ T Cell count during HCV treatment 
 
CD4+ T-cell count and development of MDD during HCV treatment 
 CD4+ T-cell count at baseline was not significantly correlated with the 
development of MDD during HCV treatment (r = .04, p = .795). Similarly, the 
correlation between nadir CD4+ T-cell count and the development of MDD during 
HCV treatment was not significant (r = -.06, p = .747). In addition, no significant 
associations were found with depressive symptoms throughout treatment (all p > .142). 
 
CD4+ T-cell count and sustained virological response 
SVR was achieved in 33 patients (86.8%). No significant correlations were 
found between nadir and baseline CD4+ T-cell count and SVR (r = -.02, p = .893; r = 
.24, p = .179, respectively). 
 
Discussion 
 The main results of this prospective study corroborate prior evidence (Alavi et 
al., 2012; Udina et al., 2015; Whale et al., 2015) showing a significant increase in 
depressive symptoms during HCV treatment, in particular at an early stage. No 
significant association between immune response, measured by CD4+T cell count, and 
major depressive disorder, measured by SCID-I and SVR was observed. However, a 
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significant decrease of CD4+ T-cells count between baseline and week 4 (p = 0.048) 
was observed and a slight increase from week 4 to SVR endpoint as reported previously 
(Arends et al., 2010, Gilleece et al, 2003).  
Consistent with prior findings in chronic HCV mono-infection (Udina et al, 
2014, 2015; Whale et al., 2015) a significant increase in depressive symptoms was 
observed early in treatment (Capuron et al., 2002a; Capuron & Miller, 2004). Our 
results also importantly indicate that depression decreases or remits after the end of 
treatment, consistent with recent reports (Huckans et al, 2015) supporting a clear role of 
cytokines and activation of immune factors in the pathophysiology of some depression 
disorders (Lotrich, 2015; Huckans et al, 2015) with no long-term effect.  
Depression has previously been associated with a greater decline in CD4+ T-cell 
count (Burack et al., 1993; Ickovics et al., 2001; Leserman, 2008). One explanation for 
T cell alterations in depression is tryptophan depletion. Taking into account the 
combination of depression, CD4+ T-cell decline and tryptothan as potential 
mechanisms for the onset of depressive disorders, it was expected that an 
overstimulation of the inflammatory response via trp mechanisms, as occurs in 
interferon- therapy (Capuron et al., 2003; Wichers & Maes, 2004; Zignego et al., 
2007), would potentially result in high rates of depression (Capuron et al., 2003, Comai 
et al., 2011). Interestingly we did not find an association with CD4+ T-cell and MDD 
during interferon therapy, probably due to the mean of the CD4+ T-cell count being 
above 500 cells/mm3 even during HCV treatment. Also, all of our participants had an 
undetectable HIV viral load and were on anti-retroviral therapy (ARTs).  
As mentioned above increased inflammation is a risk factor for developing 
depression, (Au et al., 2015; Mynt et al., 2013; Duivis et al., 2011;Udina et al., 2015; 
Harrison et al., 2009). On the other hand, it has been suggested that T cells may be a 
resilience factor to depression (Brackman et al, 2015; Lewitus et al, 2008). T cells have 
a role in production of IL-4 within meningeal space and in reducing inflammation, 
influencing resilience to depression and supporting neural integrity (Loveau et al., 2015; 
Kim et al., 2012). The mechanisms involved are not clear and the clinical relevance of T 
cells on depression emergence requires further research. Therefore, it is not surprising 
that there was a lower rate of depression in a sample that we tend to define as 
immunologically and inflammatory controlled. It may be that our group of patients with 
a high mean of CD4+ count and on effective cART suggests that when immune 
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response, CD4+ T-cells and HIV viral load, are controlled there is a low risk for 
depression emergence, even under interferon-based therapy.  
Additionally, we could consider other potential factors that may explain why 
HIV/HCV co-infected patients were less vulnerable to developing depression, such as, 
adherence to treatment and good rate of HCV treatment response.  
 A significant decrease of CD4+ T cell counts between baseline and week 4 was 
observed. However, the CD4+ were not equivalent of immunosuppression, they were 
above 500 cells/ mm3. We did not find a correlation between nadir or baseline CD4+ 
T-cells and SVR. It has been suggested that HCV clearance, measured by SVR, is 
dependent on the patient’s immune status, with a higher CD4+ T-cell count at baseline 
being associated with a better response to treatment (Caetano et al., 2008; Landau et al., 
2001; Mauss et al., 1998; Rosen et al., 2007; Soriano et al., 1996). In contrast, a recent 
retrospective study with HIV/HCV co-infected patients who were treated for HCV 
between 2000 and 2008 reported that the baseline CD4+T cell count was not associated 
with SVR (Aldámiz-Echevarría et al., 2015). Nevertheless, in this large observational 
study, the median baseline CD4+ T cell count was 500 cells/mm3. It seems that having 
a CD4+ T-cell count 500 cells/ mm3 is an indicator of SVR, as per our data. Is clear 
that additional research is needed in order to explore the potential immune and 
inflammatory mechanisms in HCV infection among HIV/HCV co-infected population.  
 HCV infection can be transmitted sexually via high-risk behaviour in HIV MSM 
population (Urbanus et al., 2009; van de Laar et al., 2010, Winston et al., 2013).  There 
is evidence of a significant association between moderate depression and a higher risk 
of engagement in sexual behaviour in HIV-infected MSM (O’Cleirigh et al., 2013). 
Additionally, a high rate of HCV re-infection transmitted by sexual risk behaviour in 
MSM has been reported (van de Laar et al., 2010). Our findings, along with this 
evidence, highlight the complex association with depression, and subsequently the need 
for an early screening of depression in order to prevent further HCV infections. 
Although we did not assess the potential association between depression and risk 
behaviour, it is possible that changes in depression and well-being over time within this 
population could explain the difficulty in the diagnosis and treatment of depression 
(Perdue et al., 2003; Wilson et al., 2014). Overall, in spite of the complex interfaces of 
depression, our data may facilitate the provision of depression screening and prevent 
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further HCV infections making it clinically relevant taking into account inflammatory 
markers.  
This study is not without limitations. First, the study was limited by a relatively 
small sample size, which reduces the power to detect small but potentially important 
differences. Regarding the paradigm of immune-inflammatory response and depression 
the use of other HIV markers, such as CD4/CD8 ratio, trp levels and inflammatory 
markers such as, CRP were not included. A direct link between depression and these 
parameters was not possible to investigate. It has been suggested that patients with 
depression may present a poorer anti-inflammatory T cell response. In future studies, it 
would be relevant to explore the role of T cell as a resilience mechanism to depression 
in particular within HIV MSM and HCV (re) infection.  
This study has however several strengths, including the prospective longitudinal 
naturalistic design with assessments before, during and after HCV treatment. 
Additionally, we used well-established depression measures, with well-established 
psychometric properties and with acknowledged clinical relevance. Therefore, although 
these findings are novel and potentially important, more research is needed to replicate 
and extend the results reported herein.   
In conclusion, immune response, as measured by nadir and baseline CD4+ T-
cells, was not significantly associated with SVR, in HIV/HCV patients. This is an 
interesting finding and may be associated with the sample size or the high rate of SVR 
verified in this sample (88%). Additionally, depression was not significantly associated 
with immune response and SVR, possibly due to the role of T cells as a resilience 
mechanism. Therefore, given the sample size as well as the substantial gap in the 
literature, these results must be viewed as preliminary and in need of further replication 
and extension. 
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3.3. A longitudinal study assessing depression in adults with hepatitis C: Does 
gender play a role in new-onset depression during interferon-alpha treatment? 
 
Abstract 
 
The aim of this prospective study was to examine the differences in new-onset of major 
depressive disorder (MDD) during interferon-alpha based therapy between men and 
women infected with hepatitis C virus (HCV). The sample comprised 155 HCV-
infected patients (47 women), elegible to receive hepatitis C therapy, including direct 
acting-antivirals (triple therapy). The semi-structured clinical interview (SCID-I) was 
used to assess MDD. Severity of depressive symptoms was assessed using the Hamilton 
Depression Rating Scale. Participants were assessed at baseline, during treatment and 
six months after treatment completion. In the total sample, the results indicated a 
significant increase in depressive symptoms from baseline to week 4 and a significant 
decrease from week 24 to sustained virological response (SVR) endpoint. Women were 
more likely to present a diagnosis of MDD at end of treatment (week 24). In both men 
and women, there was a significant increase in neurovegetative and mood-cognitive 
syndromes at the early stage of treatment, which remitted at the end of the course of 
HCV therapy. SVR was similar among female and males (91.5% vs. 87%). Under an 
inflammatory condition, boosted by interferon-based treatments, these results suggest 
that female gender is not associated with increased vulnerability for development of 
depression.  
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Introduction 
There is a high prevalence of hepatitis C virus (HCV) worldwide and HCV 
infection remains the leading cause of liver disease (Mohd Hanafiah et al. 2013). The 
transmission of HCV has been consistently associated with intravenous drug use (IDU) 
and high-risk sexual practices, particularly together with recreational drug use (Ryder 
2015). Most studies in this field have been however based on predominantly male 
samples, leaving HCV-infected women inadequately represented in research. This limits 
the understanding of potentially important gender differences in response to HCV 
treatment, and particularly the neuropsychiatric effects associated with interferon-based 
treatments. 
A recent prospective study suggested that women were more likely than men to 
become infected with HCV, and to report a high risk of injecting behaviours when in a 
sexual relationship with an IDU partner (Tracy et al. 2014). Among women, substance 
abuse, HIV infection, and age over 35 years have been identified as risk factors for 
HCV (Operskalski et al. 2008). These findings highlight the relevance of gender in the 
context of hepatitis C, which is particularly reinforced by recent meta analytic data 
indicating that among HCV-infected women the risk of perinatal infection to children 
was 5.8% [95% confidence interval (CI), 4.2%-15.2%], and that the risk of vertical 
transmission of HCV is increased among women, with 1 in every 20 children of a 
mother with chronic HCV infection being infected (Benova et al. 2014; Buchanan and 
Nash 2015). 
Direct-acting antivirals (DAAs) with pegylated-interferon and ribavirin, and 
interferon-free regimens have emerged as the new treatment options for HCV. Despite 
the emergence of interferon-free regimens, the pegylated-interferon and ribavirin based 
treatment is still a valid option, with high cure response rates in acute and chronic HCV 
infection (Feld 2012). In relation to sex differences, although the research is rather 
limited, existent evidence about the effectiveness of interferon-based treatment is 
mixed, with reports of lack of differences between males and females in the response to 
HCV treatment (Hayashi et al. 1998; McHutchison et al. 2009), but also of lower 
(Akuta et al. 2007; Villa et al. 2011) and higher (Conjeevaram et al. 2006; Grebely et al. 
2014) rates of sustained virological response (SVR) among women. Recent data on 
DAAs indicated absence of significant differences between men and women in response 
to treatment with telaprevir and bocepravir (Jacobson et al. 2011; Poordad et al. 2011). 
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Another study found that women presented a poorer response to treatment (Simoes et al. 
2015). 
The combination of interferon-alpha (IFN-) and ribavirin has been often 
associated with psychiatric side effects, which have a significant negative impact on 
patients’ quality of life and treatment compliance, and are risk factors for treatment 
failure. In this context, major depressive disorder (MDD) has been reported as one of 
the most common psychiatric side effects in the context of interferon-based therapy for 
HCV (Schaefer et al. 2012). During HCV treatment, increased levels of depressive 
symptoms have been reported (Udina et al. 2012), particularly at earlier stages of 
treatment. Moreover, it has been suggested that patients with IFN-induced depression 
show significantly more symptoms of the neurovegetative syndrome than mood-
cognitive symptoms (Capuron et al. 2009). However, if this is true for both men and 
women with hepatitis C remains to be explored. 
It is well-documented that in the the non-iatrogenic model of depression, women 
present higher rates of depression than men (Kessler et al. 1993; Romans et al. 2007), 
particularly in bipolar depression (Parker et al. 2014; Piccinelli and Wilkinson 2000). In 
the general population, there is also evidence that women develop depression at an 
earlier age and experience more depressive episodes than men (Azorin et al. 2014), 
which has been related to a multifactorial model, composed of several vulnerability 
factors, such as childhood sexual abuse, parental loss or disturbed family dynamics, 
neuroticism traits, early onset of anxiety disorders, substance abuse, low social support 
and negative life events (Kendler et al. 2002; van Loo et al. 2015). Interestigly, 
concerning the inflammatory model of depression, such gender vulnerability has not 
been confirmed. In a recent meta-analysis with 845 patients, although female gender 
was found to be a weak risk factor for the emergence of IFN-induced depression (Udina 
et al. 2012), this was not confirmed in a recent study by Whale et al. (2015), which 
found that gender was not a significant risk factor to the emergence of MDD in a cohort 
of patients with HCV infection during IFN-α treatment. However, these studies did not 
focus on the clusters of depressive symptoms (neurovegetative and mood-cognitive), 
across HCV treatment as described by previous reports (Capuron et al. 2009). 
As mentioned, HCV-infected women are an underepresented population in HCV 
studies and specific data during hepatitis C treatment are limited. In addition, although a 
number of studies assessed new-onset depression during treatment, there is still limited 
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understading of depression during HCV treatment among women. Understanding the 
psychiatric side effects during treatment in this population is clinically relevant for 
carefully planning treatment options and implementing tailored interventions to patients 
with hepatitis C. Gender sensitive services also need to be considered to address 
prevention of new HCV infections, mental health comorbidities, as well as unique 
features of the female population, such as vertical transmission of HCV and menopausal 
issues. Therefore, the aim of this prospective study was to explore gender differences in 
the new-onset MDD (defined as the development of depression during treatment among 
participants who were not depressed prior to the initiation of treatment) during hepatitis 
C treatment and, additionally, to longitudinally examine the existence of gender 
differences in the expression of subtypes of depressive symptoms. 
 
Methods 
 
Participants and procedure  
A cohort of 231 patients eligible for HCV treatment were prospectively recruited 
between October 2013 and June 2015 at the outpatient HCV clinic at the Royal Sussex 
County Hospital, Brighton UK. The following exclusion criteria were considered: being 
re-infected with HCV, co-infection with HIV, autoimmune disorder or any cause of 
liver disease other than HCV, history of neurological disease, acute psychiatric illness, 
current diagnosis of MDD, being on methadone, and intravenous drug or alcohol abuse 
within the month prior to the beginning of hepatitis C treatment. Of the 231 participants 
enrolled in the study, 15 were excluded from the study analyses because of HCV re-
infection episodes, 37 because of HIV co-infection, five due to current drug use and 19 
due to baseline MDD. The final sample consisted of 155 participants. 
Participants were eligible to start hepatitis C treatment with interferon-based 
therapies: a combination of PEG-IFN 2α 180 μg weekly sub-cutaneously and oral 
ribavirin 800-1200mg daily (depending on weight and HCV genotype) or PEG-IFN 2α 
180 μg weekly sub-cutaneously and oral ribavirin 800-1200mg daily and protease 
inhibitor telaprevir orally (750 mg) every 8 hours. Only those exposed to 24 weeks of 
treatment were included. All participants were at multiple time points within the study: 
baseline, week 4, week 12, week 24, and six months after treatment completion (SVR 
endpoint). 
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All participants were informed about the aims of the study and gave informed 
written consent for participation. Ethical approval was obtained through the National 
Research Ethics Service (NRES) Committee South East Coast. 
 
Measures 
 At baseline assessment, sociodemographic data (e.g., age, gender, marital 
status), HCV-related variables (e.g., route of HCV infection, HCV stage, genotype, 
HCV therapy), and information related to past psychiatric history, and past drug use was 
collected. Positive response to treatment (viral clearance) was measured by SVR, 
defined as negative HCV viral load measured by polymerase chain reaction assay (PCR, 
HCV RNA  1.9 log IU/mL) six months after treatment completion. 
 The diagnosis of MDD was determined through a semi-structured clinical 
interview (SCID-I) (First et al. 1996) for the major DSM-IV Axis I diagnosis. For the 
purpose of defining depression threshold, criterion A12D of the SCID-I (excluding 
other organic aetiologies) was discarded. Severity of depression and sub-syndrome 
features were assessed with the 21-item Hamilton Depression Rating Scale (HAMD) 
(Hamilton 1960), which consists of 21 items. The total score ranges between 0 and 66, 
and higher scores denote higher severity of depressive symptoms. This study adopted 
the factor structure suggested by Capuron et al. (2009): (1) depressive symptoms 
(depressed mood, feelings of guilt and suicide items); (2) anxiety symptoms (anxiety 
psychological, hypochondriasis, agitation and anxiety somatic items); (3) impaired 
activity (work/activities and retardation); (4) sleep alterations (early, middle and late 
insomnia items); and (5) somatic symptoms (somatic symptoms gastrointestinal, 
somatic symptoms general, genital symptoms and loss of weight). For the present study, 
these factors were combined into a biphasic model of depression: the neurovegetative 
syndrome, which was composed by impaired activity, sleep alterations and somatic 
symptoms; and the mood-cognitive syndrome, which combined depressive and anxiety 
symptoms. Alpha reliability in this sample ranged between .82 (Baseline, for men) 
to .95 (SVR, for men). 
 
 
 
Data analysis  
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Participants were individually coded for either transition to MDD (new-onset 
depression, defined as development of MDD during treatment among participants who 
were not depressed prior to the initiation of treatment) or no transition to MDD at any 
time point during this period. Descriptive statistics with means and standard deviations 
(SD) were reported for continuous variables, and frequencies for categorical variables. 
Characteristicss were compared with Student’s t tests for continuous variables, and χ2 
test and Fisher’s exact test as appropriate, for testing differences in categorical 
variables. Repeated-measures multivariate analysis of covariance (MANCOVA) was 
used to assess changes in depressive symptoms subtypes across groups (between-
subjects; female vs. male) and over time (within-subjects). Subsequent univariate 
analyses of covariance (ANCOVA) were performed to identify the source of the 
multivariate effects. Bonferroni adjustments were applied to correct for multiple 
comparisons (p < .01). Logistic regression analyses were used to identify factors 
associated with development of MDD during treatment. Effect sizes were calculated for 
all analyses (small effects: Cohen’s d ≥ 0.20, Cramer’s V ≥ .10; medium effects: 
Cohen’s d ≥ 0.50, Cramer’s V ≥ .30; large effects: Cohen’s d ≥ 0.80, Cramer’s V ≥ .50) 
(Cohen 1992). Data were analysed using the Statistical Package for Social Sciences 
(IBM SPSS, version 20.0). 
 
Results 
 
Participants’ characteristics 
 The final sample consisted of 155 participants (30.3% female; n = 47), with a 
mean age of 46.93 years (SD = 10.38; range: 25-71). The majority of participants had 
HCV chronic infection (84.5%), and were infected with genotype 2 virus (49%). 
Regarding treatment, most participants received pegylated INF-α and ribavirin (n = 107; 
69%). Sixty-nine (44.5%) patients reported past psychiatric history, out of which 59 
(85.5%) specified prior history of depression. A SVR response was achieved in 88.4% 
of the sample. No differences were found between male and female patients in the 
baseline study variables. Table 1 summarizes the sociodemographic and clinical 
characteristics for the total samples and for the two study groups. 
 
Table 1. Demographic and clinical characteristics of participants receiving HCV 
treatment (N = 155) 
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 Total 
(n = 155) 
Female 
(n = 47) 
Male 
(n = 108) χ2 
Cramer’s 
V 
n (%) n (%) n (%) 
Marital status    1.29 .09 
Single 70 (45.2) 18 (38.3) 52 (48.1)   
Married/Cohabiting  73 (47.1) 25 (53.2) 48 (44.4)   
Separated/Divorced 12 (7.7) 4 (8.5) 8 (7.4)   
HCV stage     1.73 .11 
Acute  24 (15.5) 10 (21.3) 14 (13.0)   
Chronic 131 (84.5) 37 (78.7) 94 (87.0)   
Route of HCV infection    0.00 .001 
IDU 99 (63.9) 30 (63.8) 69 (63.9)   
Non-IDU 56 (36.1) 17 (36.2) 39 (36.1)   
Genotype    2.32 ..12 
1 52 (33.5) 15 (31.9) 37 (34.3)   
2 76 (49.0) 24 (51.1) 52 (48.1)   
3 16 (10.3) 3 (6.4) 13 (12.0)   
4 11 (7.1) 5 (10.6) 6 (5.6)   
HCV treatment     0.35 .05 
PEG-IFN 2α +Ribavirin 
+ Teleprevir  
48 (31.0) 13 (27.7) 35 (32.4)   
PEG-IFN 2α + Ribavirin  107 (69.0) 34 (72.3) 73 (67.6)   
Past psychiatric history     2.06 .12 
No  86 (55.5) 22 (46.8) 64 (59.3)   
Yes  69 (44.5) 25 (53.2) 44 (40.7)   
Past drug use     0.04 .01 
No  50 (32.3) 15 (31.9) 35 (32.4)   
Yes  105 (67.7) 32 (68.1) 73 (67.6)   
Antidepressant treatment 
during therapy 
 
  0.14 .03 
No 99 (63.9) 29 (61.7) 70 (64.8)   
SVR     0.63 .06 
Yes 137 (88.4) 43 (91.5) 94 (87.0)   
 M (SD) M (SD) M (SD) t Cohen’s d 
Age  46.93 (10.38) 47.66 (9.79) 46.61 (10.66) -0.58 0.10 
*** p < .001 
 
Depressive symptoms at baseline  
In the total sample, the mean HAMD total score at baseline was 3.17 (SD = 4.53; 
range: 0-22). No significant differences were found between females (M = 3.13, SD = 
4.66) and males (M = 3.19, SD = 4.50) regarding baseline HAMD total score, F(1, 154) 
= 0.01, p = .933. 
Development of MDD during treatment 
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A total of 73 participants (47.1%) developed SCID-I defined MDD during HCV 
treatment. Of the MDD sample, 35 patients developed MDD by week 4 and by week 
12, 55 patients were diagnosed with MDD. These findings represent a cumulative 
percentage of 75.3% of patients developing MDD within the first 12 weeks of 
treatment. A higher proportion of women developed MDD during treatment (53.2% vs. 
44.4%), although the difference was not statistically significant, 2(1) = 1.01, p = .316, 
Cramer’s V = .08.  
When examining the gender differences in the diagnosis of MDD in each time 
point, the results indicated that females were not more likely than men to be diagnosed 
at week 4 (23.4% vs. 22.2%; 2(1) = 0.03, p = .871, Cramer’s V = .01) or at week 12 
(44.7% vs. 31.5%; 2(1) = 2.49, p = .114, Cramer’s V = .13). However, being female was 
significantly associated with higher odds of having a MDD diagnosis at week 24 
(42.6% vs. 23.6%; 2(1) = 5.64, p = .018, Cramer’s V = .19). 
 
Factors associated with development of MDD: Preliminary analyses 
A range of preliminary analyses (univariate logistic regressions) examining the 
association between baseline factors and new-onset depression during HCV treatment 
was conducted in the total sample and separately by gender. For the total sample, the 
results indicated that having past psychiatric history (Odds ratio [OR] 2.47, 95% 
confidence interval [CI] 1.29-4.73, p = .006) was significantly associated with increased 
odds of developing MDD during treatment. The results also indicated that past drug use 
was associated with the development of MDD only for women (OR 5.25, 95% CI 1.35-
20.40, p = .017). Regarding the type of treatment, there was a significant association 
between being on telaprevir and increased odds of developing MDD only among men 
(OR 0.37, 95% CI 0.16-0.88, p = .024). Thus, in the analyses of the changes in the 
severity of symptoms of depression during treatment, the results were adjusted for these 
potential covariates along with anti-depressant treatment, which was defined a priori as 
a potential confounder. 
 
Changes in depressive symptoms during HCV treatment  
Regarding the HAMD total score, the results of the repeated measures 
MANCOVA indicated a significant effect of time [Wilk’s λ = .74, F(4, 146) = 13.60, p 
< .001, ηp2 = .26]. Neither the effect of group [F(1, 149) = 0.18, p = .666, ηp2 = .001] 
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nor the interaction time x group [Wilk’s λ = .99, F(4, 146) = 0.01, p = .876, ηp2 = .01] 
were significant. Regarding the effect of time, subsequent analysis indicated that there 
was a significant increase in HAMD total score from baseline to week 4 (Mean 
difference = 9.49, p < .001), and a significant decrease between week 24 and SVR 
endpoint (Mean difference = 12.10, p < .001). The increase in depressive symptoms 
from week 4 to week 12, and from week 12 to week 24 was not significant (see Figure 
1). No significant differences were found between men and women in the changes of 
the HAMD total score during treatment. 
 
Figure 1. Time course of HAMD total depression score in HCV mono-infected male 
and female patients during HCV treatment 
 
Regarding the two syndromes of depressive symptoms, the results indicated a 
significant effect of time [Wilk’s λ = .18, F(8, 142) = 79.05, p < .001, ηp2 = .82]. The 
effect of group [Wilk’s λ = .98, F(2, 148) = 1.88, p = .157, ηp2 = .03], and the 
interaction between time and group were not significant [Wilk’s λ = .97, F(8, 142) = 
1.54, p = .766, ηp2 = .03]. The descriptive results are summarised in Table 2. Follow-up 
tests showed a significant increase in both mood-cognitive and neurovegetative 
syndromes during treatment, most notably between baseline assessment and week 4 (p 
< .001). Additionally, a significant decrease in both syndromes between week 24 and 
SVR endpoint was found (all p < .001) – see Figure 2. 
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Figure 2. Time course of HAMD clusters of depressive symptoms in HCV-infected men 
and women during HCV treatment 
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Table 2. Descriptive statistics in HAMD factors during interferon-based therapy for HCV 
 Baseline Week 4 Week 12 Week 24 SVR 
Time (F) Group (F) 
Time X 
Group (F)  M (SE) M (SE) M (SE) M (SE) M (SE) 
Mood-Cognitive syndrome      4.42** 1.41 0.98 
Female  0.17 (0.04) 0.52 (0.07) 0.67 (0.07) 0.60 (0.08) 0.02 (0.02)    
Male 0.17 (0.02) 0.48 (0.05) 0.57 (0.05) 0.47 (0.05) 0.03 (0.02)    
Neurovegetative syndrome      19.64*** 0.26 0.12 
Female  0.19 (0.04) 0.85 (0.07) 0.96 (0.07) 0.86 (0.08) 0.03 (0.03)    
Male 0.20 (0.03) 0.91 (0.05) 0.98 (0.04) 0.85 (0.05) 0.05 (0.02)    
** p < .01; *** p < .001 
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Discussion 
In this prospective study, we found a significant increase in depressive 
symptoms from baseline to week 4 and a significant decrease from week 24 to SVR 
endpoint, a pattern that was similar for both men and women. When examining the 
association between gender and new-onset MDD in each time point of the study, we 
found that women were more likely than men to have a diagnosis of MDD at the end of 
treatment (week 24). During interferon-based therapy, dimensional analyses of 
depressive symptoms developing during treatment also indicated a similar time course 
for men and women, that is, a significant increase in neurovegetative and mood-
cognitive syndromes at the beginning of the therapy, notably at week 4, and a remission 
after the end of treatment. The rate of treatment response (SVR) was high in the overall 
sample (88%), with no differences between men and women.  
For both men and women, the severity of depressive symptoms was high at the 
beginning of treatment and remitted after exposure to treatment, as reported in prior 
studies (Huckans et al., 2015; Loftis and Hauser, 2004) confirming the transient 
depressogenic nature of IFN-α. Our findings also indicate that women were more likely 
to present MDD at week 24 when compared to men (no differences were found in the 
remaining time points however). Although a recent meta-analysis of ten studies 
suggested that female gender was a (weak) predictor of new-onset depression during 
HCV treatment (Udina et al., 2012), all studies included in that meta-analysis did not 
find evidence of differences between men and women (although there was a trend for 
women reporting higher odds of occurrence of interferon-alpha-induced depression). To 
some extent, our findings are consistent with the studies reported in this meta-analysis 
indicating a lack of differences between men and women in new-onset depression. 
There is evidence that residual symptoms, early adverse life events and previous 
episodes of depression are risk factors to recurrence of MDD (Hardeveld et al., 2013; 
Nanni et al., 2012; van Loo et al., 2015). The presence of MDD at a later stage of HCV 
treatment in the female sample may relate to the level of residual symptoms that have 
increased the likelihood of subsequent MDD symptoms, particularly given that more 
than 50% of women of this sample reported past psychiatric history. Moreover, the 
kindling hypothesis suggests that the risk of subsequent MDD may depend on the level 
of stress exposed to (Kendler et al., 2000). Experiencing interferon-based therapy may 
induce high levels of stress, thus enhancing MDD. 
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Regarding the dimensional analyses of depressive symptoms developing during 
treatment, we found that mood-cognitive and neurovegetative syndromes significantly 
increased at the beginning of treatment, a pattern that was similar for males and 
females. The neurovegetative syndrome typically occurs within the first month of 
treatment (Loftis et al., 2013), being less responsive to antidepressant treatment 
(Capuron and Miller 2004). These symptoms are exhibited preferentially with IFN- 
therapy, suggesting that IFN- causes a dysregulation of the cytokine network that may 
involve basal ganglia changes and dopamine depletion (Capuron et al., 2007, 2009, 
2012; Hayley et al., 2013; Wichers et al., 2007). The emergence of the mood-cognitive 
syndrome at the early stage of treatment is not consistent with previous findings 
showing that this syndrome occurs later in treatment (Capuron et al., 2002). There is 
evidence that IFN-induced mood-cognitive syndrome involves abnormalities in 
tryptophan/serotonin metabolism (Capuron et al., 2002; Raison et al., 2010). This 
suggests that IFN- activates different pathophysiological mechanisms causing two 
different behavioural syndromes. What is unclear is why the mood-cognitive syndrome 
develops only in a smaller proportion of patients (Capuron et al., 2007; Musselman et 
al., 2001). Another explanation might be associated with the overlap effects of 
emotional adjustment to HCV treatment that often combines symptoms of anxiety and 
depression, as assessed by the HAMD. The early emergence of these symptoms in 
treatment suggests that the beginning of treatment is crucial for a comprehensive 
monitoring and clinical supervision. 
This study is not without limitations. The convenience sampling and the 
relatively small sample size of the female group imply that the generalisation of our 
results should be undertaken with caution. Despite the inclusion of several 
sociodemographic and HCV-related variables, we could usefully added other variables 
(e.g., inflammatory markers, such as IL-6 and CRP) that have been associated with 
depression (Krogh et al., 2014) and could provide us a better understanding of the 
nature of IFN-induced depression. Despite these limitations, this study has also 
important strengths. To our knowledge, this is the first study reporting a detailed 
assessment of neuropsychiatric side effects in a female sample during HCV treatment. 
The study design was prospective and longitudinal and all patients were followed in a 
single centre. In addition, this study used both a validated measure for assessing the 
severity of depressive symptoms (which is useful for examining individual symptoms 
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and changes over time) and a clinical interview based on DSM criteria conducted by a 
trained clinical psychologist. 
In summary, in this study, a high rate of MDD was observed during HCV 
treatment. Women were more likely to present MDD at a later stage of treatment, which 
may be related to vulnerability factors, such as past psychiatry history and past drug 
abuse. Neurovegetative and mood-cognitive syndromes stood out as significantly higher 
at the beginning of the treatment and both remitted at the end of treatment, indicating 
that these symptoms have a temporary effect caused by the interferon exposure. The 
persistence of depressive symptoms in the female sample (still present at week 24) may 
have been attributable to a more severe past history of risk factors. With interferon-free 
regimens, gender differences are unlikely to be seen, however, because the onset of a 
MDD episode and recurrence depends on multifactorial model characterized by a 
complex interplay between biological, psychological and environmental factors 
(Kendler and Gardner 2014), before starting treatment, it would be valuable to conduct 
a full assessment of well-established risk factors for new-onset depression. This 
screening is crucial to decrease the risk of depression and improve treatment 
compliance and the well-being of this population.  
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4.1. Executive function and interferon based therapy with direct acting antivirals 
in HIV acute HCV co-infection 
 
Abstract 
Background and aims: Executive function (EF) impairment has been significantly 
associated with chronic viral conditions such as HIV and hepatitis C (HCV), with 
implications for overall functioning. As a consequence of interferon-based therapies, 
changes in cognition have been reported, in particular on EF. The aim of the present 
study was to analyse the EF performance in an acute HCV/HIV co-infected sample 
undergoing HCV treatment with direct acting antiviral (DAAs).  
Methods: Twenty-five HIV infected men who have sex with men (MSM) participants 
were recruited of which 13 were HCV acute infected and 12 were HIV mono-infected. 
The groups were matched for age, education and HIV clinical status at baseline, and 
were assessed prospectively before, during and at the end of treatment using EF 
measures. 
Results: The co-infected group showed a significant increase on speed of processing 
under prospective memory conditions from baseline to week 4. Significant results in 
speed components on updating, measured by RNG task, and speed of processing 
measured by TMT part A task, were also observed, which indicated processing speed 
changes between baseline and week 4. The processing speed impairment was confirmed 
on between groups analysis, measured by TMT part A, with the co-infected group being 
more impaired then the HIV group between baseline and week 12.   
Discussion: In acute HCV co-infection there was an effect of  DAAs with IFN- 
treatment on EF performance, in particular with the co-infected group presenting a 
disadvantage on information processing speed. The poor performance on a prospective 
memory (PM) task also adds another layer to the EF model. However, it is not clear 
what pathway mediates this cognitive outcome, if it is the inflammatory condition, or 
HIV itself, or residual effects of both. Clearly more research is needed in a co-infection 
sample to confer external validity.  
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Introduction 
Executive functions (EF) are high-level cognitive processes that includes several 
cognitive operations that are thought to guide our behaviour, allowing individuals to 
behave independently with the ability to make decisions, plan for the future, assess 
risks, and cope with new situations (Lezak, 2004). The EF performance implies 
recruiting automatic responses, switching between tasks, planning, ability to inhibit 
responses in order to control interference to achieve the goal, aspects of verbal fluency 
and of working memory (Friedman & Miyake, 2016).  
It has been proposed that performance of EF is fractionated into sub-processes 
indicating distinct functions. The three-component model of EF proposes updating, 
shifting and inhibiting factors (Miyake et al., 2000; Miyake & Friedman, 2012). 
According to Miyake, updating involves monitoring and coding incoming information, 
replacing the no longer relevant information with the newer. Shifting is defined as the 
ability to switch between tasks sets or responses. Finally, inhibition implies suppressing 
an automatic response in order to make it relevant for the task response (Miyake et al., 
2000).  
The executive functions (EF) framework has been widely studied, examining 
concepts of unity and diversity highlighting that EF performance not only presents 
something common (unity) but also involves specific cognitive features (diversity) 
(Friedman & Miyake, 2016; Miyake et al., 2000). Classic literature proposed that the 
correlation between levels of EF argues in favour of the unity paradigm (Friedman et 
al., 2011; Teuber, 1972; Wiebe, Espy, & Charak, 2008) but at the same time other 
reports using multivariate statistical analysis confirmed the EF diversity (Miyaki et al., 
2000). There is a rich literature on the parcellation of EF, although the findings differ 
across studies. According to the bifactor model based on correlated factors analysis, 
unity was considered as a common EF inhibition level and diversity embedded by 
updating and shifting components (Friedman et al., 2008). However, evidence failed to 
extract an independent inhibition component questioning the concept on common factor 
(Banich & Depue, 2015; Friedman et al., 2008; Miyake et al., 2000). Possibly this was  
due to the nature of the tasks. The association between the EF components is still 
debatable. The EF component that seems to play a key role in EF performance is 
inhibition (Hall & Fong, 2015), in particular when task performance requires goal 
relevant information (Friedman & Miyake, 2016). Some reports suggest that inhibition 
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and updating are significantly correlated (Klauer, Schmitz, Teige-Mocigemba, & Voss, 
2010); others failed to replicate this findings (Hull et al, 2008). Inhibition and shifting 
were predictors of PM performance, highlighting the correlation between EF 
components and the influence of other cognitive constructs such as prospective memory 
(PM) and decision-making (Schnitzspahn et al, 2013). What seems to be consensual is 
that shifting is separable from inhibition and updating (Brydges et al., 2014). 
EF impairment has been strongly associated with HIV neurocognitive disorders- 
HAND (Reger et al., 2007), which has been linked with sub-cortical pathology 
(Gongvatana et al., 2007; Thames et al., 2012). In HIV asymptomatic patients on 
combination antiretroviral therapy (cART) EF impairment is frequent (Heaton et al., 
2011) with reports of a significant association between poor performance on executive 
tasks (Trail Making Test, Grooved Pegboard and Digit symbol) and decrease levels of 
glutamate and glutamine in frontal white matter (Mohamed et al., 2010). HIV literature 
describes a significant association between EF impairment and decision-making 
impairment (Hardy et al., 2006; Iudicello et al., 2013; Martin et al., 2013). EF and 
decision-making constructs tend to be traditionally assessed due to recruitment of 
executive functions to select the most advantageous response from a variety of options 
(Bechara, 2004; Bechara & Damasio, 2005). Also decision-making impairment presents 
similar symptoms in conditions of frontal lobe lesions (Bechara et al., 1994) and 
substance use disorders (Duarte et al., 2012; Ludicello et al., 2012; Verdejo-Garcia et 
al., 2006). The HCV associated neurocognitive disorder (HCV-AND) profile also 
involves EF impairment, which has been linked with significant brain metabolic 
changes due to influence on glial cells (Monaco et al., 2015). In HIV/HCV co-infection 
it is reasonable to hypothesize that EF may be worse than in HIV mono-infection 
because the presence of both viruses leads to greater cognitive functioning deficits 
(Letendre et al., 2005; Martin et al., 2004; Webster et al., 2013) due to the viruses’ 
replication in the brain and cerebrospinal fluid (Aronow et al., 2008; Hinkin et al., 
2008). 
 The impact of inflammation on cognitive functions has been widely 
investigated, most notably the role of cytokines in cognitive processes such as learning 
and memory (McAfoose et al., 2009) and in particular executive functions (Cohen et al., 
2011). Cytokines, such as interferon- (IFN-) are peripheral inflammatory mediators 
that influence cognition by entry into the central nervous system (CNS) (Rothwell, 
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1999; Wilson et al., 2002). A strong association has been observed between cytokine 
concentrations and cognitive performance, with reduced performance on executive EF, 
measured by the Trial Making Test part A, associated with elevated IL-16 and IP-10 
concentrations and reduced levels of IL-10. The Trail Making Test part B was also 
associated with elevated IL-6 and reduced IL-10 concentrations (Cohen et al., 2011).  
The significance of impairment on executive functions via inflammatory 
mechanisms is not clear; however some empirical evidence for the inflammatory 
paradigm comes from hepatitis C interferon based treatment. In this context, a 
significant association with subjective complaints of memory loss, depression, impaired 
motor activity and executive functioning deficits have been reported (Hilsabeck et al., 
2005; Lieb et al., 2006; Wilson, Finch, & Cohen, 2002). In a chronic HCV sample with 
IFN- treatment a significant impairment in working memory and executive functions 
has been observed (Pawelczyk et al., 2008). Another study found that the cognitive 
decline, including EF performance, during therapy was clinically significant and 
persistent after treatment ended (Cattie et al., 2014). Similar results revealed reduced 
verbal learning after 3 months of IFN- therapy (Juengling et al., 2000).  
The literature has not always been consistent. There is evidence that the effects 
of IFN- on cognitive performance in HCV patients seem to improve after treatment, 
associated with a reduction in glia cell inflammation in patients who had a positive 
treatment outcome (Byrnes et al., 2012). Kraus et al. (2013) investigated neurocognitive 
performance in 70 chronic HCV patients exposed to IFN-. Cognitive computer based 
tasks were performed at pre-treatment, during and at the end of treatment. Cognitive 
changes on an attentional performance battery during treatment were observed, but 
significant improvement in executive function and working memory was reported after 
treatment in patients who achieved a sustained virological response (SVR) over those 
who failed the treatment. Interferon-based therapy was associated with normal scores in 
attention and executive function tasks performance, and a significant increase in motor 
slowing (Majer et al., 2008). A possible explanation for these results is that IFN- 
potentially affects motor areas, such as the putamen, substantia nigra and thalamus. 
These brain areas have some separation from the neuronal network that is related to 
executive functions performance, which involves the basal ganglia and prefrontal cortex 
(Majer et al., 2008; Monchi et al., 2001). These findings suggest that EF alterations 
following IFN- treatment were related to inflammatory processes itself and are 
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reversible when associated with eradication of HCV (Byrnes et al., 2012; Forton et al., 
2002; Kraus et al., 2013).  
A recent study reported that co-infection is a significant risk factor for 
neurocognitive decline, in particular in memory and global functioning, during HCV 
treatment with interferon and ribavirin therapy (Miller et al., 2016). Cognitive deficits, 
and particularly executive functions, are frequently reported as a neuropsychiatric 
response to interferon-based therapy. Few studies however have examined executive 
function changes in acute HCV infection in HIV patients undertaking direct acting 
antivirals (DAAs) IFN- based therapy. Furthermore, to the best of our knowledge, this 
is the first study to analyse whether diverse EF latent variables are involved in EF 
performance under an induced inflammatory condition. Despite the debate about unity 
and diversity of EF, for the purposes of our study we considered the tripartite model 
(Miyake, 2000) of EF, measuring inhibition, updating and shifting, to provide more 
detailed information about the potential cognitive aspects involved in EF performance 
in co-infected patients. Therefore, the aim of this study was to prospectively explore 
specifically the effect of DAAs with IFN- treatment on EF status in a sample of HCV 
acute infection in HIV patients. We hypothesized that the HIV/HCV co-infected 
patients would present deterioration in EF performance throughout treatment when 
exposed to DAAs IFN- based therapy. We expected treatment related decrements on 
cognition and to obtain a better understanding of the impact of HCV treatment on EF 
status. We expected that the co-infected group would present differences on EF 
performance when compared with HIV control group.  
 
Methods 
 
Participants  
 A total of 25 HIV men who have sex with men (MSM) were recruited between 
March 2014 and December 2015, from the outpatient HCV clinic at the Royal Sussex 
County Hospital. Brighton UK. Of the total sample, 13 were HIV and acute HCV co-
infected patients, who were about to initiate HCV treatment with a combination of 
pegylated INF-, ribavirin and telaprevir (INF-+) and 12 were HIV mono-infected 
patients on cHART (INF- -).  
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The inclusion criteria for the co-infected group were as follows: aged 20-60 
years old, HIV infection confirmed by an ELISA positive and a Western-blot analysis 
and HCV infection confirmed by positive HCV RNA based on polymerase chain 
reaction (PCR) assay, on cART, fulfilled NICE guidelines criteria for initiation of HCV 
treatment and fluent in English. It is noteworthy that this study includes the hepatitis C 
new treatments (DAAs) only. Exclusion criteria were: active HIV-related opportunistic 
infections, concurrent hepatitis B virus (HBV) infection, hepatocellular carcinoma, 
current treatment for alcohol or drug abuse, major depression disorder (MDD) at 
baseline and during treatment, history of learning disabilities or neurological illness, and 
being on Efavirenz (due to clear effect on sleep patterns).  
In relation to the HIV mono-infected group, the inclusion criteria were: 
diagnosis of HIV infection confirmed by an ELISA positive and a Western-blot 
analysis, patients aged 20-60 years old, and CDC classification system A1 (500 
cells/L), A2 (200-499 cells/L), and symptomatic stage B1 ( 500 cells/L), with and 
without HIV therapy. The exclusion criteria were as follows: active HIV-related 
opportunistic infections, HBV, current treatment for alcohol and drug abuse, current 
diagnosis of MDD, history of learning disabilities and neurological illness.  
 
Procedure 
 All participants gave informed written consent for participation. Ethical 
approval was obtained through the National Research Ethics Service (NRES) 
Committee East of England.  
 Clinical interviews were conducted to collect relevant demographic (e.g., age, 
marital status, years of education) and clinical data (e.g., route of HIV and HCV 
infection, HCV genotype, HCV and HIV therapy, HIV and HCV viral load, HIV and 
HCV clinical stage, prior history of psychiatric illness). A battery of executive function 
tasks was also administered. The HIV/HCV co-infected group was followed 
longitudinally before starting HCV treatment (baseline), at the early stage of the 
treatment approximately at week 4 and at a later stage of the treatment, approximately at 
week 12 (see Table 1). The HIV group was followed up at equivalent times to the co-
infected group before initiation of treatment (baseline) and at week 12 (see Table 1). To 
control potential influence of major depressive disorder, semi-clinical interview for 
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DSM-IV (SCID-I; First et al., 1996) was administered in all sessions for all the 
participants.  
 
Table 1. Time line of EF assessments sessions during HCV treatment  
 Baseline Week 4 Week 12 
Assessment Sessions  
HIV  HIV 
HIV HCV HIV HCV HIV HCV 
 
Measures 
 As previously described the present study considered the three factor model of 
EF paradigm (Miyaki et al., 2000). For that purpose the EF measures were selected 
taking into account the specific EF components of inhibition, updating and shifting. 
Inhibition has been proposed as the common EF factor suggesting being the core EF 
component with significant associations with updating (Friedman & Miyake, 2016; Hull 
et al., 2008). The associated EF components are related with significant correlations 
between diminished control over behaviour (inhibition) and evaluation of positive and 
negative consequences on decision making (Golub et al., 2012; Martin et al., 2013).  
 
 
Fig. 1. Executive Function Paradigm based on Miyake model (Miyake et al., 2000) 
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Random Number Generation (RNG) 
The Random Number Generation (RNG) task requires the suppression of 
stereotyped sequences (inhibition) and tracking and updating responses (updating) 
(Peters et al., 2007). Participants were told to say out loud a random sequence of digits 
(1-10), more specifically it was explained that a random sequence is one that does not 
contain repetition of the same numbers and does not contain sequences or adjacent 
numbers (Towse & Neil, 1998). Following procedure described in Towse & Neil (1998) 
participants were asked to generate 30 numbers; their responses and time of 
performance were annotated on a sheet of paper. To quantify indices of randomisation 
performance the RNG index was calculated using a computer program (RgCalc) 
(Evans, 1978; Towse & Neil, 1998).  
  
Trail Making Test  
The Trail Making Test requires mental flexibility and motor ability (O’Downell 
et al., 1994). Particularly, the Part B performance is indicative of ability to flexibly shift 
between two elements of the course of an ongoing task (shifting) (Kortte et al., 2002). It 
is a pen and pencil task consisting of two parts, A and B. In part A, the participants have 
to connect the numbers 1 to 25 in ascending order; this provides a baseline measure of 
speed of processing. In part B, the participants must connect two sequences in an 
ascending order, alternating between numbers (1-25) and letters (A-O) (i.e., 1-A-2B) 
(Bowie & Harvey, 2006; Corrigan, 1987). A derived score measure was calculated (B-
A) based on the difference score of TMT B – TMT A to remove the individual motor 
speed element from the task. (Corrigan & Hinkeldey, 1987; Lamberty et al., 1994; 
Lezak, 1995; Misdraju & Gass, 2010).  
 
GoStop Impulsivity Paradigm  
The GoStop Impulsivity Paradigm was used to measure response inhibition 
(Dougherty, 2003). In this task, the participant has to respond to a series of visual 
stimuli (a 5 digit number) when a target ‘go’ signal appears and inhibit the response 
when a ‘stop’ signal occurs. Participants were instructed to click the mouse when 
presented with the ‘go’ (black) stimulus but withhold clicking the mouse if the target 
changes from black to red, the target ‘stop’ stimulus (Dougherty & Mathias, 2003). For 
each trial, a novel stimulus, unseen set of 5 digits, is presented followed by a target 
stimulus, a set of 5 digits identical to the previous number presented in black. A 
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proportion of the ‘go’ signals were unpredictably accompanied by a ‘stop’ signal, when 
the target stimuli changed from black (go) to red (stop), to which the participant must 
withhold their response. The task used fixed stop signal intervals, which remain fixed 
throughout the session with the changing signals from, go (black) to stop (red) at 
latency intervals of 50 msec, 150 msec, 250 msec and 350 msec. A lower percentage of 
inhibited responses reflects the proportion of correctly inhibited responses to the 
number of stop signals presented out of total responses found in the latency intervals 
(50 msec, 150 msec, 250 msec and 350 msec). Thus, an increased percentage in failing 
the inhibition response in this measure reflected greater impulsivity (Marsh et al., 2002).  
 
Card Sort Prospective Memory Task  
The Card Sort Prospective Memory Task (Rusted & Trawley, 2006) is a 
computerised task that measures both decision-making and prospective memory (PM) 
ability. For the on-going component of the task participants were presented with 52 card 
stimuli displayed successively on the screen. Each card image remained on the 
computer screen for 750 ms. In each trial, participants were asked to press the heart key 
for hearts and spades key for spades; and to inhibit response if presented diamonds or 
clubs. Participants were allowed 1,750 ms from stimulus onset to respond and received 
the instruction to respond as quickly and accurately as possible (Marchant et al., 2010; 
Rusted et al., 2009). Next, the Prospective Memory (PM) instruction was given. 
Participants were asked to press “space” when any card with the number 7 was 
presented on the computer screen. Two further decks of the on-going task were 
presented following the PM rule assignment. Sort accuracy and reaction times were 
recorded. A PM cost measure was calculated by comparing the performance between 
these two conditions (sort RT with PM instruction – sort RT with no PM intention) to 
provide us information regarding the cost of carrying a PM intention on ongoing 
decision making task (sort task). 
 
Stroop Task  
The Stroop task (Hutchison et al., 2010) was used to measure inhibition. In this 
study, a computerised version was used. Participants were given verbal instructions in 
which they were cued prior to each trial whether they should name the colour of the 
word presented on the computer screen or if they should name the word itself (Rogers & 
Monsell, 1995). Stimuli consisted of four colour words (blue, red, yellow and green) 
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and four neutral words (poor, legal, bad, deep). Forty trials were congruent when a 
neutral word appeared in any of the four colours and 48 trials were classified as 
incongruent when a colour word appeared in a non-matching colour font. Participants 
completed 24 practice trials and 88 experimental trials. Participants responded verbally, 
using a microphone, with latency of response being recorded by a serial response box. 
Accuracy of response was coded for each trial as correct, error or self-corrected error. 
Taking into account that cognitive slowing is a main feature of HIV associated 
neurocognitive disorders (Martin et al., 2004) we performed analysis of the Stroop 
interference effects described when one mental operation degrades the performance of 
another (Brown 2011) which could give us an indicator of executive inhibition control 
type and shifting; (Brown 2011). Stroop interference was calculated for correct trials 
only, by calculating reaction time difference for RT incongruent – RT neutral control 
(MacLeod, 1991; Monsel, 2003). 
 
Data analysis  
Statistical analyses were performed using the Statistical Package of Social 
Sciences (IBM SPSS version 22.0). For sociodemographic and clinical data, descriptive 
analysis was performed and reported as means, standard deviations (SD) and 
frequencies. A two-way contingency analysis (χ2) was conducted to assess whether both 
groups had statistically different proportions in categorical variables, and Student’s t 
tests were performed to compare groups in continuous variables. Across experimental 
tasks, mixed model repeated-measures analysis of variance (ANOVA) was used to 
assess changes on EF performance between study groups and over time (within- and 
between-groups analysis). For assessing changes in EF performance during treatment at 
baseline, week 4 and week 12, in the co-infected group, repeated-measures analysis of 
variance (ANOVA) (within group analysis) were performed. All statistical tests were 
two-tailed with p values < .05 as criterion of statistical significance. 
 
Results 
 
Participant’s characteristics 
 The total sample consisted of 25 HIV MSM, with a mean age of 45.60 years (SD 
= 4.28; range: 38-52). The 12 HIV mono-infected interferon free (IFN-) group had a 
mean age of 45 years (SD = 4.20; 38-51) and 13 HIV/HCV co-infected group with 
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interferon exposure (IFN+) had a mean age of 46.15 years (SD = 4.45; 38-52). The 
majority of participants were single (72%), had college education (76%) and reported 
no history of intravenous drug use. Nine patients (36.0%) reported other type of drug 
use, most frequently cocaine. No significant differences were found between the study 
groups in the baseline characteristics (see Table 2). At baseline all participants were on 
HIV therapy with HIV negative viral load. Regarding HCV treatment measures, all co-
infected patients were seronegative for HCV at week 12.  
 
Table 2. Baseline characteristics for participants 
  
Total sample 
HIV/HCV 
(n = 13) 
HIV 
(n = 12) 
n (%) n (%) n (%) 
Age  45.60 (4.28) 46.15 (4.45) 45 (4.20) 
Single  18 (72.0) 9 (69.2) 9 (75.0) 
College education 19 (76.0) 10 (76.9) 9 (75.0) 
Recreational drug use 9 (36.0) 5 (38.5) 4 (33.3) 
Past history of clinical depression 19 (76.0) 11 (64.6) 8 (66.7) 
Family psychiatry history 10 (40.0) 5 (38.5) 5 (41.7) 
HCV re-infected 9 (36.0) 9 (69.2) - 
 
 
Within group analysis for HCV treatment over time 
 
GoStop Paradigm Task 
The means scores (SD) of inhibition errors response at each experimental 
condition (50 msc, 150 msc, 250 msc, 350 msc) and at each time point (baseline, week 
4 and week 12) are shown in Table 3. Repeated measures ANOVA did not indicate any 
significant change in inhibition response across time, F(2, 11) = 2.34, p = .143, but a 
significant effect of latency intervals was observed, F(3, 10) = 30.05, p < .001.  The 
results indicated a significant decrease of inhibition errors response at increased latency 
intervals. The interaction between time and interval was not significant, F(6, 7) = 2.30, 
p = .150.  
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Table 3. GoStop Paradigm task performance during treatment. 
 HIV/HCV 
 Baseline Week 4 Week 12 
 Mean (SD) Mean (SD) Mean (SD) 
Inhibition errors response (%)    
50 msc 78.46 (24.09) 92.30 (8.80) 84.61 (28.90) 
150 msc  63.07 (31.72) 71.92 (21.84) 64.23 (32.45) 
250 msc 43.46 (30.37) 60.76 (20.49) 50.76 (27.52) 
350 msc 36.15 (24.76) 45.38 (24.27) 33.07  (22.03) 
 
 
Card sort Prospective Memory task  
The analysis performed on this task were focused on the decision making 
component based on several performance measures: reaction time (RT) and accuracy to 
the on-going task of decision making control; RT decision-making card sort task under 
PM condition and RT cost of the PM intention (the difference in RT to the ongoing 
decision-making task when there was a concurrent PM requirement). See Table 4 for a 
summary of performance on this task. 
 Decision-making control deck RT and accuracy: Between baseline and end of 
treatment, repeated measures ANOVA showed no significant effect of time on reaction 
time, F (2, 11) = 2.99, p = .092. Similarly, no significant effect of time was found 
regarding the levels of accuracy, F (1, 12) = 0.06, p = .819.  
 Decision-making card sort under PM condition: The results indicated a 
significant decrease on RT between baseline and end of treatment, F (2, 11) = 60.72, p 
< .001. The decrease was however only significant between baseline and week 4 (Mean 
difference = -21.61, p < .001).  
Cost of carrying a PM intention: Regarding PM cost, there was a significant 
effect of time, F(2, 11) = 46.71, p < .001, indicating a significant increase from baseline 
to week 4 only (Mean difference = -35.82, p < .001). There was a decrease on PM cost 
from week 4 to week 12, which was not statistically significant (Mean difference = -
11.22, p = .464).  
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Table 4. Performance on the card sort task during treatment  
  HIV/HCV 
  Baseline Week 4 Week 12 
  Mean (SD) Mean (SD) Mean (SD) 
Decision making control 
deck 
Reaction Time 497.92 (8.59) 512.20 (8.48) 493.44 (8.92) 
 Accuracy 25.23 (0.75) 25.21 (0.69) 25.23 (0.72) 
Decision making card 
sort under PM condition 
Reaction Time 748.54 (7.15) 726.93 (9.81) 721.46 (5.14) 
PM cost   252.61 (8.90) 269.79 (2.30) 258.01 (10.95) 
 
Stroop Task 
For summary of Stroop Task performance see Table 5. Repeated measures 
ANOVA were performed on the Stroop incongruent trials and no effect of time was 
found within HIV/HCV co-infected group throughout treatment, F (2,10) = .14, p = 
.865. No significant effects were observed on Stroop neutral trials, F (2, 10) = .48, p = 
.762, and on Stroop interference, F (2, 10) = .28, p = .913.,  during treatment.  
Regarding errors, no significant differences were found across time, F (6, 40) = 1.19, p 
= .334. F (6, 40) = .09, p = .913. 
 
Table 5. Stroop task performance during treatment. 
 HIV/HCV 
 Baseline Week 4 Week 12 
Condition Mean (SD) Mean (SD) Mean (SD) 
Incongruence   890.052(203.50) 895.87 (201.78) 864.04 (106.83) 
Neutral  872.73 (210.28) 857.07 (206.17) 815.60 (155.95) 
Stroop interference 17.29 (85.81) 41.86.(90.86) 49,07 (85.58) 
 
RNG task 
Table 6 shows the means scores (and SD) on the RNG task during treatment. 
The effect of time on the RNG index was not significant during treatment, F(2, 11) = 
0.50, p = .622. Overall, there was an increase in the time needed to execute the task 
(reaction time) among the co-infected group, F(2, 11) = 26.12, p < .001. The results 
indicated a significant increase from baseline to week 4 (Mean difference = 12.39, p < 
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.001). The decrease from week 4 to week 12 was not significant (Mean difference = 
1.46, p = 1.000).  
 
Table 6. RNG task performance during treatment. 
  HIV/HCV 
  Baseline Week 4 Week 12 
  Mean (SD) Mean (SD) Mean (SD) 
RNG task  Reaction Time 42.0 (5.0) 54.38 (4.7) 52.92 (3.81) 
 RNG index 0.14 (0.06) 0.14 (0.07) 0.16 (0.07) 
 
TMT task 
For the summary of TMT task performance see Table 7. Regarding the 
composite TMT B-A, a measure of shifting capacity, the effect of time was not 
significant, F(2, 11) = 1.53, p = .259. Further analyses on speed processing of the task 
were performed. During HCV treatment there was a significant effect of time, as 
measured by TMT part A, F(2, 11) = 5.20, p = .026. Particularly, there was a significant 
increase from baseline to week 4 on TMT part A (mean difference = 15.15, p = .044) 
and a significant decrease from week 4 to week 12 (Mean difference = 10.69, p = .044).  
 
Table 7. TMT task performance during treatment 
  HIV/HCV 
  Baseline Week 4 Week 12 
  Mean (SD) Mean (SD) Mean (SD) 
TMT task  TMT A 53.77 (15.95) 68.92 (21.30) 58.23 (17.83) 
 TMT B-A 84.69 (79.51) 121.53 (86.00) 94.69 (66.99) 
 TMT B 138.46 (89.49) 190.46 (87.93) 149.84 (82.59) 
 
Differences between groups over time 
 
GoStop Paradigm task 
Table 8 shows the mean scores (SD) of GoStop Paradigm task of both groups at 
baseline and week 12. Repeated measures ANOVA indicated no significant differences 
on inhibition performance between study groups, F(1, 23) = 1.66, p = .210, as well as 
 183 
 
no significant effect of time between baseline and week 12, F(1, 23) = 0.43, p = .519. 
The interaction time x group was not significant, F(1, 23) = 0.07, p = .800. The effect of 
latency interval was significant, F(3, 21) = 46.24, p < .001. No significant effects were 
found on the interaction latency interval x group, F(3, 21) = 0.65, p = .594, latency 
interval x time, F(3, 21) = 2.72, p = .070, as well as in the interaction time x latency 
interval x group, F(3, 21) = 1.37, p = .279. 
 
Table 8. GoStop Paradigm task performance at baseline and week 12  
  Baseline Week 12 
  HIV HIV/HCV HIV HIV/HCV 
  Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Inhibition errors 
performance (%) 
    
 50msc 86.25 (17.33) 78.46 (24.01) 90.0 (15.37) 84.61 (28.90) 
 150msc 65.0 (25.67) 63.07 (31.72) 79.16 (17.56) 64.23 (32.45) 
 250msc 50.75 (29.30) 43.46 (30.37) 63.75 (19.32) 50.76 (27.52) 
  350msec 40.83 (32.32) 36.15 (24.76) 36.25 (21.43) 33.07 (22.03) 
 
Card sort Prospective Memory task 
See Table 9 for summary of Card sort task performance.  
Regarding the on-going decision-making control deck, repeated measures 
ANOVA indicated no significant differences between groups on RT, F(1, 23) = 2.40, p 
= .135. A significant effect of time was found, F(1, 23) = 14.64, p = .001, which 
indicated a faster RT at week 12. No difference was found in relation to accuracy. The 
interaction time x group was not significant, F(1, 23) = 3.59, p = .071.  
Decision-making card sort under PM condition: The results indicated a 
significant effect of time, F(1, 23) = 124.79, p < .001. No significant differences were 
found between groups on RT performance, F(1, 23) = 2.67, p = .116. The interaction 
time and group was no significant, F(1, 23) = 2.90, p = .102.   
Cost of carrying a PM intention: The analysis for PM cost showed that there 
was a significant effect of time, F(1, 23) = 27.92, p < .001, indicating a significant 
decrease in PM cost from baseline to week 12 in both groups. The difference between 
groups was not significant, F(1, 23) = 0.01 p = .914. However, the interaction time x 
group was significant, F(1, 23) = 8.95, p =.007, showing that the decrease from baseline 
to week 12 was higher in the co-infected group.  
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Table 9. Card sort task performance at baseline and week 12  
  Baseline Week 12 
  HIV HIV/HCV HIV HIV/HCV 
  Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Decision making  Reaction Time 497.82 (8.16) 497.92 (8.59) 484.56 (11.20) 493.44 (8.92) 
 Accuracy 25.50 (0.67) 25.23 (0.75) 25.43 (0.65) 25.23 (0.72) 
Decision making 
card sort under PM 
condition 
Reaction Time 741.75 (9.86) 748.54 (7.15) 721.83 (5.85) 721.46 (5.14) 
 PM cost  243.33 (10.80) 252.61 (8.90) 236.52 (14.44) 228.01 (10.95) 
 
Stroop Task 
 Table 10 shows the summary of Stroop Task performance. The results of 
ANOVA showed no significant differences between groups in incongruent condition 
across time, F(1, 21) = .071, p = .792, and between groups, F(1, 21) = 2.12, p = .159. 
The interaction group x time was not significant, F(1, 21) = .869, p = .362. 
In  neutral condition there were no significant differences across time, F(1, 21) = 
.027, p = .872; or between groups F(1, 21) = .989, p = .331 . The interaction time x 
group was not significant F(1, 21) = 2.70, p = .115.  
There was no significant difference in Stroop interference across time, F(1, 21) 
= .003, p = .957, or between groups, F(1, 21) = 0.11, p = .745. The interaction group x 
time was not significant, F(1, 21) = 1.11, p = .305. 
Although participants made fewer errors in all conditions over time, they were 
not significantly different at baseline and week 12, F(3, 19) = 3.08, p = .052. No 
significant effect in interaction time x group was found, F(3, 19) = 0.35, p = .791. 
 
Table 10. Stroop Task Performance at baseline and week 12 
 Baseline Week 12 
 HIV HIV/HCV HIV HIV/HCV 
Condition Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Incongruent 880.21 (178.29) 893.052(203.50) 852.65 (200.01) 864.04 (106.83) 
Neutral  765.80 (127.65) 868.21 (201.98) 835.29 (171.04) 811.24 (155.82) 
Interference  5.94 (18.94) 16.87 (82.17) 35.55. (48.65) 4.33 (84.48) 
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RNG task  
The summary of RNG task performance, measured by RNG index and the time 
to perform the task, measured in seconds, is described in table 11. Repeated measures 
ANOVA showed no significant differences were found between groups, F(1, 23) = 
1.09, p = .308. The interaction time x group was not statistically significant, F(1, 23) = 
0.80, p = .381.  The effect of time on the RNG index was not significant during 
treatment, F(1,23) = 0.50, p = .622. 
Regarding the time of execution the task, there were no differences between the 
study groups, F(1, 23) = 0.93, p = .346. Similarly, the interaction time x group was not 
significant, F(1, 23) = 0.15, p = .700. The effect of time was statistically significant, 
F(1, 23) = 47.36, p < .001, indicating that both groups took more time to perform the 
task at week 12. 
 
Table 11. Performance on RNG task (RNG index) and time to performance the task 
(seconds) at baseline and week 12  
 Baseline Week 12 
 HIV HIV/HCV HIV HIV/HCV 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
RNG index 0.10 (0.05) 0.14 (0.06) 0.16 (0.08) 0.16 (0.07) 
RNG time (seconds) 40.83 (8.63) 42.00(5.02) 50.58 (5.28) 53.93 (3.82) 
 
 
TMT task 
The performance on TMT task is presented in Table 12. In relation to TMT A, 
the ANOVA showed that the effect of time was not significant, F(1, 23) = 0.09, p = 
.766. There was a significant effect of group, F(1, 23) = 5.69, p = .026, which indicated 
that HIV/HCV co-infected patients performed significantly worse of TMT A than HIV 
mono-infected patients. The interaction time x group was not significant, F(1, 23) = 
3.51, p = .073.  
The results of the composite TMT B-A indicated no differences over time, F(1, 
23) = 0.001, p = .981. Similarly, no significant effects were found for group, F(1, 23) = 
0.84, p = .369, and interaction time x group, F(1, 23) = 0.55, p = .467.  
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Table 12. Performance on TMT A/B task at baseline and week 12.  
 Baseline Week 12 
 HIV HIV/HCV HIV HIV/HCV 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
TMT A 46.33 (13.96) 53.77 (15.96) 40.17 (11.65) 58.23 (17.84) 
TMT B-A 73.25 (76.31) 84.69 (79.52) 62.58 (47.08) 94.69 (67.00) 
TMT B 119.33 (78.41) 138.46 (89.49) 102.75 (56.22) 149.85 (82.59) 
 
Discussion 
It is well established that HCV INF- α based treatment potentially induces mood 
and cognitive changes (Miller et al., 2016; Udina et al., 2014, 2015). The cognitive 
profile most observed in HCV infection includes EF impairment (Kenelly, 2013; 
Monaco et al., 2015). The same cognitive deficits have been reported in HIV infection 
(Thames et al., 2012; Woods et al., 2009), suggesting that the HIV/HCV co-infected 
population may present a higher risk for EF decline (Garvey et al., 2012; Winston et al., 
2010), in particular when exposed to INF- α treatment (Cattie et al., 2014). Therefore, 
the aim of this study was to assess the effect of HCV treatment on EF performance in a 
sample of HCV acute HIV co-infected patients undergoing DAAs treatment with IFN- 
based therapy. The main findings indicate that during treatment, the co-infected group 
showed a significant increase on prospective memory (PM) cost analysis from baseline 
to week 4. Significant results in speed components on RNG task, and TMT part A task, 
were also observed, indicating processing speed deficits between baseline and week 4. 
The processing speed impairment was confirmed on between groups analysis, measured 
by TMT part A, with the co-infected group being more impaired than the HIV group. 
Both groups presented significant increased reaction time at week 12. Differences 
between groups were found on PM cost analysis with a decrease from baseline to week 
12, higher in the co-infected group.  
The co-infected group showed deficits in PM cost analysis at week 4 of 
treatment indicating that there is a negative effect of DAAs including IFN- based 
treatment on decision making carrying a PM intention. Our results are in accordance 
with recent reports that considered that inhibition impairment might predispose to 
difficulties in executing ongoing tasks with prospective intention in a sample of 
inflammatory chronic condition (Dagenais et al., 2016). It has been suggested that PM 
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impairment is associated with deficits in sustain and retrieve information (Cona et al., 
2015; Kliegel et al., 2002) as part of decision-making processes (Carey et al., 2006; 
Martin et al., 2007; Woods et al., 2008; 2009). Inhibition has been described as the 
ability to maintain and manage goals (Friedman & Miyake, 2016) so it seems that when 
carrying a PM intention in an ongoing decision making task, equivalent of loading 
prospective memory factors (PM intention), that will cause a cognitive challenge within 
the co-infected group. The clinical impact of inhibition impairment, measured by PM 
cost analysis, is related with daily activities that requires processing information to goal 
directed tasks (taking medication); control of complex cognition (remembering different 
appointments, diet and controlling side effects of treatment) and non-routine behaviour 
(Banich, 2009). Our results are pilot data and suggests that DAAS with IFN- therapy 
affects cognition . As previously reported exposure to INF-  alone (Cohen et al., 2011; 
Udina et al., 2015) might justify these outcomes and also active HCV replication was 
still present at week 4.  Nevertheless, does this PM deficit represent an effect of IFN-  
at week 4 of treatment? Or indicate a pattern of deficit that might be present in the 
course of HIV infection that is not dissociable from the presence of active HCV virus 
replication? Or is it a combination of both? Clearly, the changes that were observed here 
on the PM component on the card-sort task indicate an impact on attentional and 
executive function resources but more research is needed.  
Within group analysis of the HIV/HCV co-infected group confirmed the 
disadvantage on the speed processing components of EF performance during HCV 
treatment, with significant effect between baseline and week 4. Acute HCV in HIV 
infection has been associated with significant reduction in certain cerebral metabolites 
(RBG mI/Cr ratio) suggesting effects of HCV on the central nervous system (CNS) with 
negative impact on neurocognition (Winston et al., 2010). Acute HCV in HIV-infected 
patients was independently associated with EF performance impairment (Garvey et al., 
2012). These results indicate that a neurological compromise involves prefrontal cortex 
and fronto-striatal regions even in samples without HCV treatment. It is reasonable to 
hypothesize that in the presence of DAAs with IFN- the co-infected group presents 
cognitive deficits. A recent study suggested that IFN- at week 4 causes changes in 
striatal molecular structure (Dowell et al., 2015). In addition, it was reported that after 
peripheral IFN- administration the whole brain presented functional network changes, 
translated by a reduction in mean number of network connections that were 
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significantly associated with mood and cognitive impairments (Dipasquale et al., 2016). 
It seems that the presence of IFN- causes changes in the brain that would explain the 
decline on information processing speed level of EF performance and the preference of 
IFN-α acting in brain areas that affect motor behaviour as described above (Monchi et 
al., 2001).  
The frontal lobe hypothesis was often linked to executive function deterioration, 
information processing speed impairment being significantly associated with structural 
changes in the prefrontal cortex (Kerchner et al., 2012). However, recent studies found 
that EF are not exclusively based on prefrontal contributions resulting in a complex 
interplay of frontal-parietal brain areas (Bettcher et al., 2016; Miyake & Friedman, 
2014; Niendam et al., 2012). Factor analysis using a two factor model considering 
shifting/inhibition and updating/working memory provided evidence that cortical grey 
matter was significantly associated with updating performance and cortical grey matter 
and corpus callosum contribute to shifting/inhibition performance (Bettcher et al., 
2016). Another report demonstrated that updating tasks were associated with activation 
on anterior and posterior brain areas, while shifting performance activated parietal lobe 
and inhibition performance was associated with right orbitofrontal gyrus areas (Collette 
et al., 2005). It is clear that a broad network of brain structures are involved in EF 
performance.  
The data indicated an improvement in PM cost in both groups between baseline 
and week 12, however that improvement was higher in the co-infected group. As 
previously reported being co-infected is a risk factor for cognitive impairment, with 
studies reporting a significant decline on EF status (Garvey et al., 2012; Winston et al., 
2010). A study aimed to clarify the effect of HCV on cognitive dysfunction. The cross-
sectional study enrolled 53 participants, 19 HCV mono infected, 14 HIV mono infected, 
17 co infected with HIV/HCV, and 28 controls. All participants were free of substance 
abuse, without clinical depression, and had undetectable HIV viral load. 
Neuropsychological assessment covered seven cognitive domains. The co-infected HIV 
HCV group performed more poorly on attention, executive function, fine motor 
function and visual and verbal learning/memory tests compared with a HCV mono 
infected group (Sun et al., 2013). This research group pointed out that co infection with 
HIV and HCV significantly increases the risk of cognitive impairment in subjects with 
controlled HIV viral loads (Sun et al., 2013). Therefore, our results are not surprising, 
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because at week 12 the co-infected group was clear for HCV virus, which means that 
when treated for HCV an improvement on cognition was expected. Nevertheless, our 
results must be interpreted carefully due to the nature of our sample, acute HCV 
infection in HIV MSM group, and the type of treatment, DAAs. There is a research gap 
on evidence of neuropsychiatric side effects of DAAs and our sample size is small 
leading us to look at our data as potential arguments that need to be replicated. 
Additionally, variability in the literature could be accounted for, by inconsistency in 
neuropsychological batteries and methodologies.  
Both groups presented higher reaction time on the RNG task at week 12, 
however with no disadvantage on updating performance, measured by RNG index. 
Recently, changes in the striatum after 4 weeks peripheral administration of IFN-α in 
HCV mono-infection was observed, that has been significantly associated with fatigue 
(Dowell et al., 2015). The higher reaction time on RNG task, as observed in both 
groups, could be explained by fatigue. In the co-infection group it is reasonable to 
associate fatigue with residual effects of IFN-α but it remains unclear why the same 
effect was found in the HIV group. Another hypothesis could be related to the effect of 
HIV itself on the information processing speed component. Although due to HIV 
therapy efficacy the severity of HIV associated neurocognitive disorders reduced the 
less severe forms of HIV-associated cognitive impairment is reported (Heaton et al., 
2011). The reasons for high rates of minor and mild HIV-associated cognitive disorders 
are unclear, but several hypotheses have been suggested; such as incomplete HIV viral 
suppression in the CNS, drug resistance, prolonged exposure to inflammatory responses 
and cART neurotoxicity (Heaton et al., 2011). 
We found significant differences between groups on TMT part A indicating that 
the co-infected group performed worse than the mono-infected group. The TMT part A 
has been linked with pure motor skills that was significantly associated with mental 
processing speed (Misdraji & Gass, 2010). These findings highlight that the co-infected 
group performance was consistent with information processing speed impairment 
probably because of the influence of IFN-α on motor control mechanism of EF. EF 
relies heavily on prefrontal cortex (PFC) recruiting several neural substrates (Collette et 
al., 2005). Neuroimaging studies reported that updating and inhibition were more 
associated with anterior prefrontal areas than shifting (Wager & Smith, 2003). 
However, it seems that IFN-α affects brain areas, which primarily influence motor 
behaviour (Monchi et al., 2001). It is noteworthy to clarify that at week 12 the co-
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infected group was seronegative for HCV RNA being less likely to have HCV 
replication in the CNS. We must interpret our results very carefully considering that 
processing information impairment in co-infection might be associated with a 
cumulative effect of IFN-α, or the influence of HIV itself or both. 
 
Strengths and limitations 
Our results were not consistent across the cognitive tasks as previously 
described with evidence of EF impairment during IFN-α based treatment (Hilsabeck et 
al., 2005; Lieb et al., 2006) and other studies failing to find those changes (Fontana et 
al., 2007; Majer et al., 2008). Potential explanations are associated with the time and 
dose of IFN-α (Fontana et al., 2007), suggesting that short period of exposure, as 12 
weeks, will not affect EF performance. Another explanation might be related with the 
characteristics of our total sample with undetectable HIV viral load, acute HCV 
infection, no history of injection drug use (IDU) and no major depressive disorder 
(MDD), matched by age and education. It is worth highlighting that our total sample 
presented HIV viral load suppression and CD4 counts > 500, suggestive of cART 
efficacy, as previous reported (Letendre et al., 2008) that has greatly contributed to 
reduce severity cognitive impairment (Ferrando et al., 2003; Letendre et al., 2004; 
Sacktor et al., 1999). It is also important to note that the sample of this study was not 
depressed as measured by SCID-I in all sessions. Major depressive disorder and EF 
appear to share similar neurological networks. MDD is associated with changes in 
prefrontal cortex (PFC) function (Levin et al., 2007) as has been posited in EF 
(Davidson et al., 2002). Meta-analytic data suggested that increased severity of 
depression was significantly associated with EF impairment (Marazzitti et al., 2010; 
McDermott et al., 2009; Snyder et al., 2012). It is therefore not surprising that in a non-
depressed cohort there were no EF performance impairment differences on all tasks 
between groups. Nevertheless, reports on cognitive impairment in HIV/HCV co-
infection are limited and more research is needed in order to clarify in what way both 
viruses actually affect the CNS, with and without HCV treatment exposure. Regarding 
treatment with interferon-based therapies, acute infection is strongly associated with 
high rates of SVR, with studies reporting a 98% rate of cure (Jaeckel et al., 2001; 
Mangia et al., 2013). DAAs have been associated with significant improvement in SVR 
(Bansal et al., 2015). In our study, participants were acute HCV infected and presented 
a high rate of SVR with DAAs regimens being HCV seronegative at week 12, which 
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represents an absence of HCV RNA on the CNS and consequently no significant impact 
on cognitive status measured by EF tasks performance.  
Our data shows that EF tasks present a variability, which may be due to task 
impurity and individual differences, as previously described in the literature (Friedman 
& Miyake, 2016; Miyake & Friedman, 2012). Nevertheless, the strengths of this study 
include the use of multiple measures of EF to obtain a purer outcome of EF 
performance during hepatitis C treatment and use of a prospective design.  
This study is not without limitations. These limitations include the small sample 
size, which emphasize that our findings need to be interpreted carefully. We could also 
have included the HCV mono-infection group or an untreated HIV HCV group to 
analyse the HCV EF associated impairment. Another limitation is the absence of a time 
point of assessment after treatment ended; this would be relevant to explore the residual 
effects of treatment on cognition. Nevertheless, we controlled bias factors, such as 
depression and chronic HCV stage (in our sample all the patients were acute HCV), 
which have been identified as risk factors for cognitive impairment.  
 
Conclusions and Future directions 
 Overall in acute HCV and HIV MSM co-infected patients undergoing DAAs 
with IFN- based therapy the between and withinsubject-analysis confirmed that in EF 
composite there is a cost to processing information speed. This outcome has 
implications in terms of ability to adhere to complex treatment regimes, such as HCV 
and HIV therapy and it might be a cognitive marker for progression of neurocognitive 
infection diseases that needs to be routinely included in psychological assessment 
routine. In this study, nine participants were HCV-reinfected. The rate of HCV 
reinfection in positive HIV MSM is increasing and the costs associated with repeated 
treatments are worth taking into account (Ingiliz et al., 2016; Martin et al., 2013). For 
future research a careful assessment of EF should be performed in co-infected patients 
with HCV reinfection receiving HCV treatment and exploration of wether reinfection is 
a consequence of EF impairment.  
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Infection with Hepatitis C virus has a devastating impact with about 20% to 85% 
of the infected patients progressing to HCV chronic condition mainly due to 
unawareness of their infection (Mah'moud, 2016). Historically, the treatment of HCV in 
HIV/HCV coinfection has been more complex when compared with HCV mono-
infection due to longer treatment and less response to treatment (Bidell et al., 2016). 
When sexual transmission of HCV emerged as the main cause of the HCV epidemic in 
MSM at the turn of the century (Browne et al., 2004) the importance of routine HCV 
testing became a priority, especially in HIV infected individuals (Platt et al., 2016). 
A solid body of research showed that HIV/HCV co-infection group is more likely 
to present with psychiatric disorders than HCV or HIV mono-infection (Baillargeon et 
al., 2008; Hilsabeck et al., 2005; Operskalski & Kovacs, 2011). In addition, there is a 
higher risk of HCV reinfection in HIV positive MSM (Martin et al., 2013; Simons et al., 
2016), and these individuals are also more at risk of developing neuropsychiatric side 
effects during HCV IFN- based treatment (Laguno et al., 2004; Landau et al., 2001; 
Myers et al., 2004; Moreno et al., 2004; Rockstroh et al., 2002).  
The model of inflammation induced psychiatric disorders comes from evidence of 
cytokine immune therapy and has included studies of patients with chronic HCV 
infection (Capuron et al, 2002, 2004, 2006, 2007; Eccles et al, 2012; Schaefer et al., 
2012; Udina et al, 2014; Whale et al, 2015). Powerful empirical data supports an IFN-  
induced neuropsychiatric syndrome in hepatitis C treatment (Capuron & Castanon, 
2017; Harrison, 2017) via an inflammatory response that has been associated with a 
complex relationship between the immune system and the brain, mediated by cytokines 
(Dantzer et al., 2008; Hoyo-Becerra et 2014; Miller, 2010; Raison & Miller, 2006; 
Swardfager et al., 2016). The IFN- based behavioral syndrome is characterized by a 
combination of mood depression and cognitive changes (Barbosa et al., 2014; Capuron 
& Miller, 2004; Dowell et al., 2015; Fialho et al., 2017; Goldsmith et al., 2016; Miller 
& Raison, 2016, Whale et al., 2015). 
The neuropsychiatric side effects of hepatitis C interferon based therapy had been 
significantly associated with emergence of MDD and cognitive impairment with 
implications on achieving sustained virological response due to high rates of 
withdrawing from treatment and non remittance of neuropsychiatric symptoms (Udina 
et al., 2012; Udina et al., 2015; Cattie et al., 2014). Potential inflammatory mechanisms 
boosted by HCV infection itself (Forton et al., 2008) and the effect of HCV interferon 
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based therapy (Whale et al., 2015) might explain these behavioural outcomes. 
Inflammation may play a role in the pathogenesis of psychiatric disorders and 
therapeutic options are needed to reduce neuropsychiatric symptoms   
The lack of studies of HIV HCV co-infection was clear, which lead me initially 
to synthesise empirical questions about differences in neuropsychiatric syndromes 
between co-infection and HIV and HCV mono-infection groups. Furthermore, it was 
crucial to understand what type of depression-like behaviour is associated with HCV 
treatment, with the aim of reducing the risk of treatment attrition by optimising the 
screening and treatment of this specific depressive disorder.  
Cognitive impairment had been broadly described as a side effect of HCV 
treatment but the literature was not consistent. The need was identified to assess the 
nature of this cognitive impairment profile and explore to what extend it may  have an 
impact on treatment outcome such as adherence or dropout from therapy.  
The research gap in HIV/HCV co-infection was clear, which led me initially to 
synthesise empirical evidence on neuropsychiatric syndromes, such as depression and 
cognitive impairment. Meta-analyses in this thesis more conclusively showed that the 
co-infected group had higher rates of depression symptoms and were more globally 
cognitively impaired when compared with HIV or HCV mono-infection respectively 
(Fialho et al., 2016; Fialho et al., 2017).  
There are several possible explanations for why the co-infected group was more 
likely to report depressive symptoms when compared with HIV or HCV mono-infected 
groups. One possible explanation is related with the baseline characteristics of the 
participants, who had high rates of historical injecting drug use (Backus et al., 2005; 
Clifford et al., 2005) as confirmed by a meta-analysis that the prevalence of co-infection 
in HIV was 82% in people who injected drugs (Platt et al., 2016). The influence of well 
described psychosocial factors, such as stress, hopelessness, social disadvantage that 
have been significantly associated with this population (Pantalone et al., 2012; Pereira 
et al., 2014) might also contribute to a higher risk profile for the emergence of 
depression. In patients undergoing HCV treatment the side effects could also increase 
the risk of depression (Laguno et al., 2004; Landau et al., 2001; Myers et al., 2004; 
Rockstroch et al., 2002). My results add weight to the evidence that a high rate of 
depression is associated with co-infection. However, I also showed that data on HCV 
treatment in co-infection is suboptimal, with studies that were not recent, small in 
sample size and co-infected HIV MSM were understudied.  
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In the systematic review and meta-analysis on cognitive aspect in HIV/HCV co-
infection, the co-infected group had a significantly higher global deficit score and 
information processing speed impairment than the HIV mono-infected patients. The 
greater cognitive impairment among co-infection appears associated with HCV 
replication in the brain (Sun et al., 2013) monocyte activation (Rempel et al., 2013), 
plasma inflammatory cytokine levels (Cohen et al., 2011), and the combination of HIV 
and HCV replication on specific brain sites (Hilsabeck et al., 2005). The greater 
neurotoxicity as a result of infection by both viruses may explain the global cognitive 
deficit and in particular the information processing speed impairment. No significant 
differences in cognition between co-infection and HCV mono-infected group were 
reported, which may be related to HCV specific mechanisms that are not yet 
established. Methodological issues might also explain this lack of difference between 
co-infection and HCV mono-infection, in particular heterogeneity on cognitive 
measures and samples characteristics. Furthermore, in the included studies sufficient 
explanations regarding the specific aspects of cognition in coinfection patients 
undergoing hepatitis C treatment was not provided. Nevertheless, the relevance of the 
findings is an association with the patient’s difficulties in overall functioning, including 
adherence to treatment.  
The systematic review and meta-analyses chapter demonstrated that the co-
infected injected drug use (IDU) group is more at risk of developing depression and 
cognitive impairment, but most importantly reveals that the co-infected group is an 
understudied population, in particular during HCV interferon based treatment.  
As stated above HCV is a major health burden, with increasing cases of HCV 
infection in HIV infected patients that has been associated with poorer treatment 
response (Weber et al., 2006) than in HCV monoinfected populations. Therefore, I 
designed several prospective studies within clinical populations, aiming to explore 
potential behavioral and clinical markers of the effect of HCV treatment, including 
direct acting antivirals (DAAs) therapy. 
 
Is interferon-induced depression a sub-type of major depressive disorder in 
hepatitis C treatment? 
 
Data showed a high rate of major depressive disorder (MDD) during HCV 
interferon based therapy in a sample of HCV infected patients, including HIV/HCV co-
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infection. Both groups had significantly increased depressive symptoms at the 
beginning of the treatment in comparison to pretreatment and showed remittance of 
depressive symptoms after treatment ended as previously reported (Fialho et al., 2014, 
2015; Huckans et al., 2015; Whale et al., 2015; Udina et al., 2014, 2015). This suggests 
that IFN- is directly associated with depressive like behavior (Capuron et al., 2001, 
2003; Cattie et al., 2014; Loftis, 2013). However, in contrast with established literature 
(Laguno et al., 2004; Landau et al., 2001; Moreno et al., 2004; Myers et al., 2004; 
Rockstroh et al., 2002) my findings indicated that the HCV group is most vulnerable to 
develop depression when compared with the co-infected group. Potential explanations 
may be associated with the sample characteristics however; the HCV group were more 
likely to present risk factors to develop MDD, such as previous history of mental health 
and past history of drug abuse (Boscarino et al., 2015; Carta et al., 2012; Hilsabeck et 
al., 2005; Udina et al., 2015). 
The HCV mono-infected group was more likely to present with MDD at the 
beginning of treatment and presented with significantly more neurovegetative 
depressive symptoms than the HIV/HCV co-infected group. Several studies on hepatitis 
C treatment reported that interferon activates different mechanisms that are significantly 
associated with different behavioral syndromes (Capuron et al., 2002, 2003; Eccles et 
al., 2012; Loftis 2013). In particular, the diversion of tryptophan metabolism (Capuron 
et al., 2003; Reus et al., 2015) has been significantly associated with the emergence of 
neurovegetative symptoms such as fatigue (Dowell et al., 2015), impaired activity 
(Whale et al., 2015) and sleep alterations (Raison et al., 2010). This result is particularly 
relevant for interferon induced depression treatment because as previously reported a 
neurovegetative syndrome has been described as more resistant to anti-depressant 
treatment (Capuron et al., 2004).  
Overall it seems that there is a subtype of MDD that emerges at the beginning of 
IFN- treatment and tends to present a neurovegetative symptom profile, as previously 
reported (Whale et al., 2015). These symptoms appeared more prevalent within the 
mono-infection group than the co-infected group, possibly because the HCV group had 
a higher rate of past psychiatric history and IDU.  
 
Does gender play a role in the emergence of interferon-induced depression? 
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 The neuropsychiatric syndrome induced by inflammation is well studied, 
however the described results must be interpreted carefully because not all MDD cases 
are inflammation based. MDD can occur without increased inflammatory cytokine 
activation (Marques-Deak et al., 2007) and equally patients can have increased 
inflammatory markers but do not present MDD symptoms (Lotrich et al., 2007). The 
lack of overall consensus regarding the inflammatory model of depression suggests 
need for clarification of a specific type of inflammatory induced depression behavior.  
In the non-iatrogenic model of depression, being female is a well-established 
vulnerability factor (Azorin et al., 2014; Parker et al., 2014) for the development of 
depression. In the inflammatory model of depression, however, female gender as a 
vulnerability marker was not confirmed (Whale et al., 2015; Udina et al., 2012). I aimed 
to examine the prevalence of MDD and explore differences between genders in a mono-
infected HCV sample undergoing hepatitis C DAAs with interferon based treatment. 
The findings confirmed the depressogenic nature of interferon with a significant 
increase in MDD at the beginning of treatment and a significant decrease in MDD at the 
end of treatment. It seems that interferon induced depression causes a severe depressive 
reaction that should be treated to avoid HCV treatment disruption (Fialho et al., 2016; 
Whale et al., 2015). Women were more likely to experience MDD at the end of 
treatment when compared with men. These results could be explained by a cumulative 
effect of symptoms that was confirmed by the high rate of neurovegetative and mood-
cognitive syndromes as measured by the Hamilton Depression Rating Scale (HAMD), 
or could be associated with residual symptoms and risk factors such as past drug use 
and previous history of psychiatric disorders. 
I failed to replicate the biphasic depression paradigm with both of the syndromes 
(neurovegetative and mood-cognitive) being significant at the beginning of the 
treatment and that could be associated with as yet unidentified mechanisms induced by 
protease inhibitor (DAAs). HCV triple therapy, composed of IFN-; ribavirin and a 
protease inhibitor (telaprevir) appears to reduce the likelihood of MDD in women only. 
Adding a protease inhibitor, the rates of sustained virological response (SVR) are high 
and the time of treatment can be reduced (Hullegie et al., 2015), but if it inhibits 
depression emergence, then the mechanisms involved require further exploration. 
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Does the immune response act to prevent interferon-induced depression in co-
infection? 
 
Another route to explore interferon-induced depression was to examine the role of 
the immune system. IFN-, tryptophan metabolism and CD4 cells count are part of a 
complex immune inflammatory network that has been associated with depression like 
behaviour (Capuron et al., 2001; Maes et al., 2001). An association between high rates 
of depression and a poor immune response during interferon treatment was expected. I 
confirmed a significant increase of depressive symptoms at an early stage of treatment 
but no significant association with immune response, as measured by CD4 cell count. 
Although a significant decrease of CD4 cell count was observed at the beginning of 
treatment there was no significant association with depression score. My findings can be 
justified by the high baseline CD4 cell count (>500 cells/mm3) before the start of 
treatment and well controlled HIV as represented by HIV RNA below the level of 
detectability (<40c/ml). Chronic inflammatory conditions are risk factors for the 
development and/or exacerbation of depression conditions. Thus, these inflammatory 
states may contribute to neuroimmune changes that underlie depressive like behavior 
(Wohleb et al., 2016). Interestingly, neuroendocrine activation can promote a beneficial 
immune response. In particular, recent evidence found that CD4 cells might induce 
resistance to depression by reducing inflammation (Kim et al., 2016; Loveau et al., 
2015). The mechanisms involved in the role of the immune system fighting the 
emergence of depression have not be explored in this study, but our findings seem to 
indicate that a high CD4 cells count is associated with a reduced likelihood of 
presenting depression symptoms. Clearly more research is needed to clarify the specific 
mechanism activated by CD4 cells and how they influence depression, however it has 
been suggested that CD4 cells have anti-inflammatory effects that may actually 
contribute to the treatment of depression (Felger et al., 2015; Miller, 2010). 
 
Does interferon-based treatment with DAAs confer a specific cognitive profile in 
co-infected samples? 
 
Neuropsychiatric side effects of HCV INF- α based treatment are composed of 
depression and cognitive impairment (Sarkar et al., 2014; Cattie et al., 2014). Interferon 
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induced cognitive impairment has been commonly described but poorly explored in the 
literature. Subjective memory complaints, attention deficits and executive function 
impairment have been reported (Hilsabeck et al., 2005; Lieb et al., 2006; Pawelczyk et 
al., 2008; Monaco et al., 2015; Wilson, Finch, & Cohen, 2002). In particular, executive 
function impairment has been frequently reported in chronic viral conditions (Monaco 
et al., 2015; Thames et al., 2012).  Main cognitive findings indicated that during DAAs 
interferon based treatment, in acute HCV in an HIV men who have sex with men 
(MSM) sample there was a cost to processing speed information. A significant increase 
on prospective memory cost analysis was observed from baseline to week 4. These 
cognitive outcomes where observed at the time of treatment were there was a clear 
effect of interferon (at week 4), indicating that there is an influence of an inflammatory 
condition on processing speed performance. Data indicated that in acute HIV/HCV co-
infection there is a possible effect on cognition that, as in depression, seems to remit 
after treatment ended (week 12). The between group analysis confirmed a disadvantage 
on the speed components in the con-infected group when compared with the HIV group. 
Overall, there was an effect of DAAs IFN- based therapy on executive function 
performance, with a disadvantage on information processing speed components with 
potential influence on attentional prospective memory layers. The implications of my 
findings are relevant for HIV/HCV co-infected patients due to impact on daily tasks 
such as medication adherence (Banich, 2009). At the best of our knowledge we are the 
first research group looking at the cognitive side effects of DAAs in HIV/HCV co-
infection, nevertheless, our sample size is small and we interpret our results as an 
indicator of potential cognitive changes in the new era of HCV therapy.  
HCV treatment has dramatically changed with the advent of interferon free 
therapy in recent years (Mah’moud, 2016). Recent clinical trials have demonstrated 
high efficacy of these treatments in HCV infected patients but the utility and efficacy in 
co-infected groups is unclear due to poorly representative samples (Ingiliz et al., 2016), 
HCV reinfection in HIV patients, drug interactions, and the effect of short term 
treatment on the efficacy of DAA treatment in co-infection (Hesamizadeh et al., 2016; 
Majumdar et al., 2016; Sulkowski, 2016). It appears that the DAAs reduce the 
prevalence of advanced liver disease but their high cost may constitute a barrier to their 
use worldwide (Chayama et al., 2015). It is likely that therapies including interferon 
will need to continue to be a treatment option therefore in the foreseeable future. 
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My findings have an important clinical impact. Firstly, recognition of the distinct 
profile of neuropsychiatric side effects of HCV in co-infection and HCV mono-
infection will allow for the screening and treatment of these conditions accordingly, 
increasing the overall HCV therapy efficacy. Secondly, the co-infected population 
studied was mainly HIV MSM. According to recent reports there is an increasing HCV 
epidemic in HIV MSM in the UK (Martin et al., 2016). HCV has been considered as a 
sexually transmitted infection (STI) due to an outbreak of acute HCV infection among 
the HIV MSM population (Browne et al., 2004; Page & Nelson, 2016). Additionally, 
MSM with moderate to low levels of depression appear more at risk to engage in risky 
sexual behavior (O’Cleirigh et al., 2013), increasing the likelihood of HCV infections. 
The study sample was not severely depressed, indicating that they may be more likely to 
be at risk of HCV (re) infections. My findings highlight that regular screening and 
treatment of lower to moderate depression symptoms and assessment of sexual health 
should be risk-reducing strategies for the acute HCV HIV MSM population.  
The effect of HCV treatment on cognitive status appears to be a specific impact 
on processing speed that remits when treatment ends, as confirmed by meta-analysis in 
populations without HCV treatment (Fialho et al., 2016). The clinical impact is based 
on the nature of this specific cognitive outcome, which has been considered a cognitive 
marker for developing severe HIV associated neurocognitive disorders (Becker & 
Salthouse, 1999). Although I present pilot data, it appears that the co-infected group 
have a disadvantage in information processing speed. These patients could therefore 
benefit from cognitive assessment before, during and after treatment to monitor and 
identify impairments with the aim of reducing impact on overall functioning, including 
ability to adhere to treatment (Arentsen et al., 2016; Huerta et al., 2016).  
The limitations of my studies are detailed in each report, however during the 
research process what stood out, as a main barrier was the constant need to translate the 
research outcomes into real clinical benefits. It was a challenge to manage some factors 
that are out of the scope of this thesis but they are worthy of mention. Tasks such as 
recruitment, testing and providing feedback for a non academic audience were the main 
difficulties.  
 There is evidence suggesting that clinical practices improved when based on 
clinical research outcomes (Doyle et al., 2016; Ishida et al., 2016). My perspective is 
that optimal assessment and clarification of neuropsychiatric symptoms, including 
depressive disorders and cognitive functioning, at baseline is essential to enable early 
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detection versus late detection of neuropsychiatric interferon induced syndromes. 
However, from my experience the impact of conducting clinical studies in this clinically 
complex population is challenging.  
The nature of this research was focused on clinical benefit to patients, on a 
dynamic platform between School of Psychology (UoS), Sussex Partnership Foundation 
Trust (SPT) and Brighton and Sussex University Hospitals (BSUH). BSUH was 
selected as a National Hepatitis Treatment Centre, which allowed me to work closely 
with this population and apply research outcomes to inform improved clinical care. My 
findings replicated the depressogenic nature of interferon treatment and identified a sub-
type of depression composed of neurovegetative symptoms. I also clarified a specific 
cognitive impairment profile, specifically of processing speed in acute HCV HIV MSM 
population during DAA treatment. Regarding vulnerability factors, it appears that being 
female does not confer specific risk for developing depression and we were unable to 
identify an association with mood disorders and the biological marker CD4 cell count.  
For future research it is important to explore how cytokine induced depressive disorder 
differs from non-iatrogenic depressive disorder. Also, it is crucial to flag the reinfection 
group and explore what are the particular risk factors associated with it. Taking into 
account my findings, hypothetically the information processing speed impairment and 
mild depression symptoms may boost decision-making deficits and contribute to the 
(re)infection behavior. Further exploration of IFN- free regimes and associated 
neuropsychiatric side effects it still needed.. My findings suggest that somatic features 
are predominant in interferon-induced depression. The identification of an 
inflammatory influence on mood disorder may be further explored in HIV alone, 
particularly examining association between inflammatory markers and  somatic 
depressive features.  
As previously reported there is poverty of studies exploring  the co-infected HIV 
HCV group. Interestingly this clinical group appears to have a high rate of HCV 
reinfection following treatment (Martin et al., 2013) that has been associated with 
sexual risk behaviours and depressive disorder (O’Cleirigh et al., 2013). It would be 
valuable to  develop an epidemiologic analysis of reinfection patterns and associations 
with risk behaviour. Additionally the findings of this thesis suggest that information 
processing speed is impaired in the co-infected group. This processing change may be a 
factor which contributes to reduced adherence to medication, for example difficulties in 
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remembering times to take medication and dietary requirements  (Huerta et al., 2016). 
Future research in the post interferon era would validly focus on how to reduce 
reinfection, which may be achieved through interventions to improve cognition and 
reduce depressive symptoms. This may include more proactive screening and specific 
cognitive interventions for those with identified changes. A Cognitive Behavioural 
Therapy integrative model using cognitive restructuring, behavioural activation 
techniques and proactive depression treatment would validly be explored in a feasibility 
study to explore effect on reinfection rates. 
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